UCB   [ADDRESS_1172498] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 1 of 152 PROTOCOL EP0091  AMENDMENT 2  
ARISE: pAdsevonil in drug -ResIStant Epi[INVESTIGATOR_002]  
A RANDOMIZED, DOUBLE -BLIND, PLACEBO -CONT ROLLED, 
DOSE FINDING STUDY  TO EVALUATE THE EFF ICACY AND 
SAFETY OF PADSEVONIL  AS ADJUNCTIVE TREAT MENT OF 
FOCAL -ONSET SEIZURES IN AD ULT SUBJECTS WITH 
DRUG -RESISTANT EPI[INVESTIGATOR_843706] [ADDRESS_1172499] Number: 2017 -003200 -48 
IND number: 135622  
Sponsor:  
UCB Biopharma SPRL  
Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
Protocol/Amendment number  Date  Type of 
amendment  
Final Protocol  [ADDRESS_1172500] 2018  Substantial  
Confidential Material  
Confidential  
This document  is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172501] INFORMATION  
Sponsor  
UCB Biopharma SPRL  
Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
Sponsor Study Physician  
Name:  , MD PhD  
Address:  UCB Biosciences GmbH  
Alfred Nobel Strasse, 10  
[ZIP_CODE] Monheim am Rhein,  
[LOCATION_013]  
Phone:   
Clinical Project Manager  
Name:   
[CONTACT_2761]:  UCB Biosciences GmbH  
Alfred Nobel Strasse, 10  
[ZIP_CODE] Monheim am Rhein,  
[LOCATION_013]  
Phone:   
Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  UCB Pharma Ltd  
[ADDRESS_1172502]  
Berkshire SL 13WE Slough,  
[LOCATION_006] 
Phone:   
EDACTED COPY 
This document cannot be used to supp ny mark g authorization application and any extensions or variations thereof. 

UCB   [ADDRESS_1172503] Research Organization  
Name:  [CONTACT_352338] (IRL) Limited  
Address:  70 Sir John Rogerson’s Quay  
Dublin 2  
Ireland  
Phone:  [PHONE_12055]  
Fax: [PHONE_17567]  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172504] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 4 of 152 SERIOUS ADVERSE EVENT REPORTING  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World: [PHONE_301] 21  
[LOCATION_003]: +[PHONE_299]  
 or +[PHONE_300]  
Email  Global: [EMAIL_311]  or DSICT. -@ucb.com  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172505] OF ABBREVIATION S ................................ ................................ ................................ .. 11 
1 SUMMARY  ................................ ................................ ................................ .....................  14 
2 INTRODUCTION  ................................ ................................ ................................ ...........  15 
2.1 Drug -resistant epi[INVESTIGATOR_002]  ................................ ................................ ................................  15 
2.2 Padsevonil mechanism of action  ................................ ................................ ..................  16 
2.3 Clinical studies  ................................ ................................ ................................ .............  16 
2.3.1  Adverse event profile  ................................ ................................ ...........................  18 
2.4 Rationale for this study  ................................ ................................ ................................  19 
3 STUDY OBJECTIVES  ................................ ................................ ................................ .... 19 
3.1 Primary objective  ................................ ................................ ................................ .........  19 
3.2 Secondary objective  ................................ ................................ ................................ ..... 19 
3.3 Other objectives  ................................ ................................ ................................ ...........  20 
3.3.1  Efficacy objectives  ................................ ................................ ...............................  20 
3.3.2  Pharmacokinetic objectives  ................................ ................................ .................  20 
3.3.3  Exploratory nonhereditary pharmacogenomics and pharmacogenetics  ..............  20 
4 STUDY VARIABLES  ................................ ................................ ................................ ..... 20 
4.1 Effica cy variables ................................ ................................ ................................ .........  20 
4.1.1  Primary efficacy variable  ................................ ................................ .....................  20 
[IP_ADDRESS]  Primary efficacy variable for the US FDA, PMDA, and other regulatory 
authorities not specified in Section [IP_ADDRESS]  ................................ ...............  20 
[IP_ADDRESS]  Primary efficacy variable for EMA and regulatory authorities who 
reference EMA  ................................ ................................ ..........................  20 
4.1.2  Secondary efficacy variables  ................................ ................................ ...............  20 
[IP_ADDRESS]  Secondary efficacy variables for the US FDA, PMDA, and other 
regulatory authorities not specified in Section [IP_ADDRESS]  ..............................  20 
[IP_ADDRESS]  Secondary efficacy variables for EMA and regulatory authorities who 
reference EMA  ................................ ................................ ..........................  21 
4.1.3  Other efficacy variables (This list applies for all regulatory authorities)  ............  [ADDRESS_1172506] compliance  ................................ ............................  52 
7.8 Concomitant medications/treatments  ................................ ................................ ...........  52 
7.8.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  ..........................  52 
7.8.2  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])  .........................  53 
7.8.3  Rescue medication  ................................ ................................ ...............................  53 
7.9 Blinding ................................ ................................ ................................ ........................  53 
7.9.1  Procedures for maintaining and breaking the treatment blind  .............................  53 
[IP_ADDRESS]  Maintenance of study treatment blind  ................................ .......................  53 
[IP_ADDRESS]  Breaking the treatment blind in an emergency situation  ...........................  54 
7.10  Randomization and numbering of subjects  ................................ ................................ .. 54 
8 STUDY PROCEDURES BY [CONTACT_16990]  ................................ ................................ ...............  54 
8.1 Baseline Period (4  weeks)  ................................ ................................ ............................  [ADDRESS_1172507] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 7 of 152 8.1.1  Visit  1 (Week  -4) ................................ ................................ ................................ . 54 
8.2 Treatment Period (16 weeks ±1  week from Visit  2) ................................ ....................  56 
8.2.1  Titration Period (3 weeks ±1 week from Visit  2) ................................ ................  56 
[IP_ADDRESS]  Visit  2, Baseline (Day 1, 4 to 5 weeks after Visit  1) ................................ . 56 
[IP_ADDRESS]  Telephone call (Week  1 ±3 days) ................................ ..............................  57 
[IP_ADDRESS]  Visit  3 (Week  2 ±1 week)  ................................ ................................ ..........  57 
8.2.2  Stabilization Period (1  week ±3 days)  ................................ ................................ . 57 
[IP_ADDRESS]  Telephone call (Week  3) ................................ ................................ ...........  57 
8.2.3  Maintenance Period (12 weeks ± 1  week)  ................................ ...........................  57 
[IP_ADDRESS]  Visit  4 (Week  4 ±1 week)  ................................ ................................ ..........  57 
[IP_ADDRESS]  Visit  5 (Week  8 ±1 week) and Visit  6 (Week  12 ±1 week)  ......................  58 
[IP_ADDRESS]  Visit  7 (Week  16±1  week for End -of-Treatment or earl ier for 
Early  Discontinuation Visit)  ................................ ................................ ...... 59 
8.3 Taper/Conversion Period (3 to 4 weeks ±1  week)  ................................ .......................  60 
8.3.1  Telephone call (after 1 or 2 weeks in tapering/converting, as needed)  ...............  60 
8.3.2  Visit  8 (Week  19/20 ±1 week, end of Taper/Conversion)  ................................ ... 60 
8.4 Safety Follow -Up (Visit  9 [Week [ADDRESS_1172508] IMP intake])  ................................ ................................ ................................ ..........  61 
8.5 Unscheduled Visit/Telephone call  ................................ ................................ ...............  62 
8.6 Open -label extension study (EP0093)  ................................ ................................ .........  62 
9 ASSESSMENT OF EFFICA CY ................................ ................................ ......................  62 
9.1 Seizure frequency ................................ ................................ ................................ .........  62 
9.2 Seizure Severity Global Item  ................................ ................................ .......................  63 
9.3 Quality of Life Inventory in Epi[INVESTIGATOR_002] -31-P ................................ ................................ . 63 
9.4 Hospi[INVESTIGATOR_5620]  ................................ ................................ ....... 63 
9.5 Health -related outcomes and healthcare resource utilization  ................................ ...... 63 
9.6 Entry and exit personal outcomes interview  ................................ ................................  64 
9.7 Caregiver survey  ................................ ................................ ................................ ..........  64 
10 ASSESSMENT OF PHARMA COKINETIC AND EXPLOR ATORY VARIABLES  ... 65 
10.1  Pharmacokinetic variables  ................................ ................................ ...........................  65 
10.1.1  PK sampling procedures  ................................ ................................ ......................  65 
[IP_ADDRESS]  PSL assay  ................................ ................................ ................................ .. 65 
[IP_ADDRESS]  Concomitant AED and exploratory pharmacokinetic evaluation  ..............  65 
10.2  Exploratory variables  ................................ ................................ ................................ ... 66 
11 ASSESSMENT OF SAFETY  ................................ ................................ ..........................  66 
11.1  Adverse events  ................................ ................................ ................................ .............  66 
11.1.1  Definitions  ................................ ................................ ................................ ...........  66 
[IP_ADDRESS]  Adverse events  ................................ ................................ ..........................  66 
[IP_ADDRESS]  Serious adverse events  ................................ ................................ ...............  [ADDRESS_1172509] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 8 of 152 11.1.2  Procedures for reporting and recording adverse events  ................................ ....... 68 
[IP_ADDRESS]  Description of adverse events  ................................ ................................ .... 68 
[IP_ADDRESS]  Rule for repetition of an adverse event ................................ ......................  68 
[IP_ADDRESS]  Additional procedures for reporting serious adverse events  .....................  [ADDRESS_1172510]  ................................ ...................  70 
11.1.7  Safety signal detection  ................................ ................................ .........................  70 
11.2  Laboratory measurements  ................................ ................................ ............................  71 
11.2.1  Evaluation of PDILI  ................................ ................................ ............................  73 
[IP_ADDRESS]  Consultation with Medical Monitor and local hepatologist  ......................  76 
[IP_ADDRESS]  Immediate action: determination of IMP discontinuatio n .........................  76 
[IP_ADDRESS]  Testing: identification/exclusion of alternative etiology  ...........................  77 
[IP_ADDRESS]  Follow -up evaluation  ................................ ................................ .................  [ADDRESS_1172511] Screening and Enrollment log/Subject Identification Code list ..............  [ADDRESS_1172512] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 9 of 152 13.1  Definition of analysis sets  ................................ ................................ ............................  85 
13.1.1  Enrolled Set  ................................ ................................ ................................ .........  85 
13.1.2  Randomized Set  ................................ ................................ ................................ ... 85 
13.1.3  Safety Set  ................................ ................................ ................................ .............  85 
13.1.4  Full Analysis Set  ................................ ................................ ................................ .. 85 
13.1.5 Per-Protocol Set  ................................ ................................ ................................ ... 86 
13.1.6  Pharmacokinetic/Pharmacodynamic Set  ................................ .............................  86 
13.2  General statistical considerations  ................................ ................................ .................  86 
13.3  Planned efficacy analyses  ................................ ................................ ............................  86 
13.3.1  Analysis of the primary efficacy variable  ................................ ............................  86 
[IP_ADDRESS]  Analysis of the primary efficacy variable for the US FDA, PMDA, and  
other regulatory authorities not specified in Section [IP_ADDRESS]  .....................  86 
[IP_ADDRESS]  Analysis of the primary efficacy variable for EMA and r egulatory 
authorities who reference EMA ................................ ................................ . 87 
13.3.2  Secondary efficacy analysis  ................................ ................................ .................  87 
[IP_ADDRESS]  Secondary efficacy variables for the US FDA, PMDA, and other 
regulatory authorities not specified in Section [IP_ADDRESS]  ..............................  87 
[IP_ADDRESS]  Secondary efficacy variables for EMA and regulatory authorities who 
reference EMA  ................................ ................................ ..........................  [ADDRESS_1172513] OF TABLES  
Table  5-1: Schedule of assessments  ................................ ................................ ..................  28 
Table  6-1: Valvular abnormality grading criteria  ................................ ..............................  47 
Table  7-1: Titration Period dosing  ................................ ................................ ....................  49 
Table  7-2: Dosing during fallback option  ................................ ................................ .........  49 
Table  7-3: Taper Period dosing  ................................ ................................ .........................  50 
Table  7-4: Conversion Period dosing  ................................ ................................ ................  51 
Table  11‒1:  Anticipated SAEs for the epi[INVESTIGATOR_67513]  ................................ .................  67 
Table  11‒2:  Laboratory measurements  ................................ ................................ ................  72 
Table  11-3: Required investigations and follow up for PDILI ................................ ............  74 
Table  11‒4:  PDILI laboratory measurements  ................................ ................................ ...... 77 
Table  11‒5:  PDILI information to be collected  ................................ ................................ ... [ADDRESS_1172514] OF FIGURES  
Figure  5‒1:  Study design  ................................ ................................ ................................ ..... [ADDRESS_1172515] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 12 of 152 HADS  Hospi[INVESTIGATOR_843707] -resistant epi[INVESTIGATOR_843708]’s Brochure  
ICF Informed Consent form  
ICH International Council  for Harmonisation  
IEC Independent Ethics Committee  
ILAE  International League Against Epi[INVESTIGATOR_843709] -label extension  
PD pharmacodynamics  
PDILI  potential drug -induced liver injury  
PET positron -emission tomography  
PK pharmacokinetics  
PMDA  Pharmaceuticals and Medical Devices Agency  
PPS Per-Protocol Set  
PRN  (pro re nata) as needed  
PS Patient Safety  
PSL padsevonil  
QOLIE -31-P Quality of Life Inventory in Epi[INVESTIGATOR_002] -31-P 
QTcB  QT interval corrected for heart rate using Bazett’s formula  
QTcF  QT interval corrected for heart rate using Fridericia’s formula  
RNA  ribonucleic acid  
RS Randomized Set  
SAE  serious adverse event  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172516] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 14 of 152 1 SUMMARY  
Padsevonil (PSL) is a novel chemical entity that has selective affinity for both presynaptic 
synaptic vesicle 2 (SV2) proteins and postsynaptic central benzodiazepi[INVESTIGATOR_32538] (cBZR) sites 
on the gamma -aminobutyric acid -A (GABA -A) receptor. Specifically synthesized and designed 
for an increased anticonvulsant activity, PSL has the potential to benefit an underserved 
population with high unmet medical need , namely those with drug -resistant epi[INVESTIGATOR_843710] -onset seizures that constitute substantial threats to their health and well -being.  
EP0091 is a multicenter, randomized, double -blind, placebo -controlled, parallel -group, 
dose-finding study in adults (≥18  years of age) with drug -resistant epi[INVESTIGATOR_843711] -onset seizures despi[INVESTIGATOR_843712]  4 tolerated, appropriately chosen 
and used prior antiepi[INVESTIGATOR_006] (AEDs),  including current AEDs (Kwan et al , 2010).  
The primary objectives of this study are to characterize the dose -response relationship with 
respect to efficacy of PSL administered concomitantly with up to 3 AEDs for treatment of 
observable focal -onset seizures in subjects with drug -resistant e pi[INVESTIGATOR_843713] 4 selected dose regimens of PSL compared with placebo. The secondary objective 
is to assess the safety and tolerability of all doses of PSL in relation to placebo.  
The study is comprised of the following periods:  a 4-week Baseline Period; a 16 -week Treatment 
Period consisting of a 3 -week Titration Period followed by a 1 -week Stabilization Period and a 
12-week Maintenance Period; a 3 -week Conversion Period for all subjects who choose to enroll 
in the open -label ext ension (OLE) study, EP0093, at the end of the Maintenance Period; or a 
4-week Taper Period, in case the subjects discontinue or do not enroll in EP0093. During the 
Titration Period, the investigational medicinal product (IMP) will be increased approximatel y 
every [ADDRESS_1172517] of 1  Safety Follow -up (SFU) Visit [ADDRESS_1172518] IMP intake (including an 
echocardiogram) and a 6 -month follow -up echocardiogram, depending on the duration of 
exposure to IMP.  
The assessment of efficacy is based on seizure frequency. For the US Food and Drug 
Administration (F DA), Pharmaceuticals and Medical Devices Agency (PMDA), and other 
regulatory authorities not specified in Section  [IP_ADDRESS] , the primary efficacy varia ble is the change 
from Baseline in log -transformed observable focal -onset seizure frequency (for the purpose of 
this protocol defined as Types IA1, IB, and IC, according to the International League Against 
Epi[INVESTIGATOR_002] [ILAE] classification [ILAE  Classificatio n of Epi[INVESTIGATOR_843714],  1981]) over the 
12-week Maintenance Period. For the European Medicines Agency (EMA) and regulatory 
authorities who reference EMA, the primary efficacy variable is the 75% responder rate, where a 
responder is a subject experiencing a ≥75% reduction in observable focal -onset seizure 
frequency from Baseline, over the [ADDRESS_1172519] of PSL on 
seizure frequency during the entire Treatment Per iod, seizure severity, quality of life, Hospi[INVESTIGATOR_70505] (HADS) score, health -related outcomes, and healthcare resource 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172520] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 15 of 152 utilization (HRU). Safety will be evaluated based on the occurrence of adverse events (AEs) 
reported by [CONTACT_127205]/or caregiver; subject withdrawals or premature tapering due to AEs; 
the results of periodic clinical laboratory, electrocardiogram (ECG), echocardiogram, withdrawal 
symptom monitoring, vital sign monitoring; and physical and neurological examinations.  
The total duration of study per subject will be up to 27  weeks with a maximum of 19  weeks 
exposure to PSL. It is estimated that approximately 500  subjects will be included at 
approximately 200  sites worldwide; [ADDRESS_1172521] the option of providing additional informed consent for 
exploratory deoxyribonucleic acid (DNA), ribonucleic acid (RNA),  and 
lipi[INVESTIGATOR_1800]/proteomics/additional blood biomarker analyses to understand the cause, progre ssion, 
and appropriate treatment of drug -resistant epi[INVESTIGATOR_002]. Participation in this additional portion of the 
study is optional and does not preclude participation in the main study. The additional genomic 
samples must not be collected if the subject has no t consented to participate in this exploratory 
genomic substudy.  
A Data Monitoring Committee (DMC) will be established for the study.  
2 INTRODUCTION  
2.1 Drug -resistant epi[INVESTIGATOR_843715] 2 tolerated and appropriately 
chosen AEDs either as monotherapy or in combination to achieve sustained seizure freedom 
(Kwan et al, 2010). In the US, there are 3  million adults with active epi[INVESTIGATOR_002] 
(Zack  and Kobau,  2017). Assuming epi[INVESTIGATOR_843716] -onset seizures in 60%  of patients and 
resistance to AEDs in 20% to 40% of patients, approximately 360,000 to 720,000  patients suffer 
from drug -resistant epi[INVESTIGATOR_002] (Semah,  et al, 1998; Kwan  and Sander,  2004; Giussani  et al, 2016). 
It is this drug -resistant epi[INVESTIGATOR_843717], physicians, and the healthcare system. A treatment that provides a significant 
reduction in seizure frequency will reduce mortality and significantly improve quality of life.  
In patients with dr ug-resistant epi[INVESTIGATOR_002], seizures have a negative impact on mortality, 
psychosocial functioning, and quality of life across multiple domains. Patients with resistant, 
focal epi[INVESTIGATOR_002], and complex partial or tonic -clonic seizures have a 5 to 10 times higher mo rtality 
rate ( Fazel  et al, 2013; Hesdorffer and Tomson, 2013; Holst  et al, 2013; Sperling,  2004 ), 
including a risk of sudden unexpected death in epi[INVESTIGATOR_002] (SUDEP)  (Devinsky,  2011 ) when 
compared with the general population. An estimated 1% of patients diagno sed with 
drug-resistant epi[INVESTIGATOR_843718] ( Jehi, 2016 ). Moreover, resistant, focal epi[INVESTIGATOR_843719] a progressive disease in which ongoing seizures result in an 
increased risk of further seizures. These patients are pr one to falls and injuries; cannot drive; can 
rarely live independently; feel isolated and stigmatized; have difficulty finding and keepi[INVESTIGATOR_007] a 
job; and often depend on disability benefits ( Azuma  and Akechi,  2014; Taylor  et al, 2001; 
Baker  et al, 1997 ). It is  well known that even with the development of several AEDs in the recent 
past, the proportion of patients with epi[INVESTIGATOR_843720], from 64% to 68% ( Brodie  et al, 2012 ). 
Moreover,  it is important to highlight that there is a continuum of drug resistance within the 
population classified as drug -resistant according to ILAE criteria. The likelihood of achieving 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172522] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 16 of 152 complete seizure control diminishes as the number of failed AED regimens i ncreases. When a 
patient with drug -resistant epi[INVESTIGATOR_843721], he or she has a 10% chance of achieving complete seizure control with subsequent 
AED regimens ( Steinhoff  et al, 2014; Beyenburg  et al, 2012; Chung  et al, 2010a; 
Schiller  and Najjar,  2008; Mohanraj  and Brodie,  2006 ).  
Although effective pharmacologic treatment options are limited for this patient population, some 
patients may benefit from surgical options. Resective surgery may provide lon g-term (up to 
5 years) seizure freedom in up to 52% of patients ( de Tisi  et al, 2011 ). Surgery is associated with 
several risks, both those inherent to surgery (infection, bleeding) and those specific to resective 
epi[INVESTIGATOR_58741] (loss of function after r emoval of brain tissue). The ILAE recommends that 
patients with focal epi[INVESTIGATOR_843722]; however, in most European and North American countries patients are 
referred for s urgery only after failing multiple AED regimens ( Engel,  2013 ). Due to various 
factors (limited number of epi[INVESTIGATOR_843723], inability to localize the seizure focus, 
surgical contraindications, etc) only a small percentage of patients meeting ILAE 
recommendations are evaluated for surgery (Engel, 2013). Therefore, the vast majority of 
patients with drug -resistant, focal epi[INVESTIGATOR_843724] – pharmacological or 
surgical – that can provide complete seizure control or a clinically meaningf ul reduction in the 
number of seizures.  
A treatment that provides a significant reduction in seizure frequency will reduce mortality 
(Laxer  et al, 2014) and significantly improve quality of life (Choi  et al, 2014; Baker  et al, 1997) 
by [CONTACT_654022]’  ability to attain basic safety, freedom from the risk of falls and injuries, 
and reach the milestones that most people take for granted: a feeling of belonging and social 
integration; the ability to form intimate relationships and a family; and having a p roductive and 
rewarding profession; or other means of self -realization.  
2.2 Padsevonil mechanism of action  
Padsevonil is a novel chemical entity that has selective affinity both for presynaptic SV2 proteins 
and for postsynaptic cBZR sites on the GABA -A recepto r. At presynaptic sites, PSL binds with 
high affinity to all 3 subtypes of the human synaptic vesicle 2 protein (ie,  SV2A, SV2B, and 
SV2C), and at postsynaptic sites acts as a partial agonist, binding with moderate affinity to the 
cBZR sites. Whereas SV2A ligands are characterized by [CONTACT_843796] -spectrum anticonvulsant activity, 
GABA -A receptors mediate inhibitory neurotransmission, and their allosteric modulation by 
[CONTACT_843797]. The synergistic anticonvulsive effect 
observ ed when combining levetiracetam (LEV) with benzodiazepi[INVESTIGATOR_1651] (BZDs) in preclinical 
models (Kaminski  et al, 2009) was the motivation that led to the design of PSL.  
In nonclinical studies, PSL has shown higher potency than LEV combined with a BZD 
(diazepam) at matching in  vivo occupancies of SV2A and cBZR, respectively. This suggests that 
PSL’s preclinical potency is not only due to the combination of these 2 preceden ted mechanisms 
of action, but that a unique interaction of PSL with SV2 proteins may also play a role.  
Preclinical experience with PSL is described extensively in the Investigator’s Brochure (IB).  
2.3 Clinical studies  
To date, PSL has been administered in the  following 9 completed human pharmacology studies:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172523] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 17 of 152  N01360 —a single, ascending dose safety, pharmacokinetic (PK), and pharmacodynamic 
(PD) study  
 N01386 —a multiple, ascending dose safety, PK, and PD study  
 UP0010 —a single -dose absorption, distribution, meta bolism, and elimination study  
 UP0001 —a single - and multiple -dose comparative PK and food effect study  
 UP0013 —a multiple -dose, 2 -part drug -drug interaction (DDI) study  
 N01383 —a positron -emission tomography (PET) study evaluating the brain GABA -A 
receptor  occupancy following multiple dosing of PSL  
 UP0002 —a multiple -dose study in subjects with epi[INVESTIGATOR_843725], safety, and tolerability of PSL in the presence 
of concomitant AEDs  
 UP0036 —an adaptive, open -label, single -dose PET study evaluating SV2A occupancy  
 UP0039 — a single - and multiple -dose safety and PK study in healthy Japanese and 
Caucasian subjects  
In addition, the following Phase [ADDRESS_1172524] been performed: EP0069 and EP0073 (on going). 
EP0069 was a multi -center, randomized, double -blind placebo -controlled parallel group study; 
and EP0073 is a multicenter, OLE to evaluate the long -term safety, tolerability, and efficacy of 
PSL when used as adjunctive therapy for partial -onset seiz ures in adult subjects with highly 
drug-resistant focal epi[INVESTIGATOR_002]. The study subjects who enrolled in the Phase  2 study, EP0069, and 
OLE study, EP0073, had highly drug -resistant epi[INVESTIGATOR_002] (HDRE) which was defined in these 
studies as subjects who had ≥4 focal  seizures with or without secondary generalization per week 
and who had failed to achieve seizure control with ≥4  AED regimens of adequate dose and 
duration. Patients with HDRE are considered to be a subset of the drug -resistant epi[INVESTIGATOR_353242], the pr oposed patient population for the registration program including, EP0091 and 
EP0093.  
In the Phase 2 proof of concept study, EP0069, a total of 55 subjects were randomized to receive 
placebo or PSL titrated up to 400mg twice daily  (bid) for a [ADDRESS_1172525]’s current and stable AED regimen. In the placebo arm, the 
2-week inpatient placebo treatment was followed by [CONTACT_25764] -titration to 400mg bid PSL in Week  3. 
All subjects continued on PSL in an [ADDRESS_1172526]’s current, stable AED regimen. Adjunctive therapy with PSL 
was associated with clinically meani ngful improvements in seizure frequency in adult patients 
with highly drug -resistant focal epi[INVESTIGATOR_843726]. 
Three  subjects (n=3/27) (11.1%) in the placebo/PSL treatment group and 8  subjects (n=8/26) 
(30.8%) in the PSL/P SL treatment group had a ≥75% reduction from the Baseline Period in 
focal  seizure frequency during the 2 -week Inpatient Period. The 75% responder rate approached 
statistical significance (p=0.0679) and was clinically meaningful. The median percent reductio n 
in weekly focal seizure frequency from Baseline to the 2 -week Inpatient Period in the PSL/PSL 
treatment group (53.68%) was greater than in the placebo/PSL treatment group (12.50%). The 
median difference vs placebo for the PSL treatment group was 34.0% (9 5% confidence interval 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172527] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 18 of 152 [CI]:  3.0, 67.5). Secondary analyses demonstrated the maintenance of effect during the 
Outpatient Period, last [ADDRESS_1172528] frequently 
reported treatment -emergent advers e events (TEAEs) for subjects overall were somnolence, 
dizziness, headache, fatigue, and irritability. Overall, the most frequently reported TEAEs 
considered drug -related by [CONTACT_843798], dizziness, and fatigue. 
Four  serious TEAEs were reported for 2 subjects ([ADDRESS_1172529] had serious TEAEs of impaired judgment, delirium, and dysphoria) 
during the On -PSL Overall Period. There were no deaths reported during the study. During the 
On-PSL O verall Period, in the [ADDRESS_1172530] on laboratory parameters, vital signs, weight, ECG evaluations, physical 
examinations, or neurological examinations in the overall population. Based on the study results, 
treatment with PSL was generally well tolerated, with an accep table tolerability and safety 
profile pointing to an overall positive benefit/risk balance.  
No study subjects have completed the OLE study (EP0073). At the time of the interim analysis 
(Dec  2016), maintenance of the effect of PSL on seizure control appears  to be supported through 
Month  3. As of the 07  Mar 2017 data cut for safety for the April  2017 DMC, 5  subjects (11.9%) 
had discontinued; [ADDRESS_1172531] (2.4%) due to an AE, 2  subjects (4.8%) due to lack of efficacy, 
[ADDRESS_1172532] (2.4%) due to consent withdrawn, an d [ADDRESS_1172533] (2.4%) for other (negative benefit/risk).  
In summary,  in the Phase 1 program  129 healthy subjects and 20 patients with epi[INVESTIGATOR_002] (male 
and female) have been exposed to PSL at single doses up to 490mg (26 healthy volunteers) and 
repeated doses up  to 400mg bid for up to 12 days (103 healthy subjects and 20  patients) in 
completed studies. In the Phase  2 proof of concept study (EP0069), [ADDRESS_1172534] their PSL dose.  
The psychiatric findings currently reported are consistent with the AE profile of other AEDs, 
including other SV2A ligands. Acute psychiatric effects occurred in  3 subjects administered PSL 
(2 in Phase  1 and 1 in Phase  2a). The events were transient, acute, and required admission to 
psychiatric care and antipsychotics. No definite dose relationship could be determined, and the 
events occurred after variable period s of time after the first administration of the IMP. The 
occurrence of these behavioral AEs highlights the need to consider the possibility of significant 
AEs and to maintain vigilance for them.  
With regard to cardiovascular effects, minor, transient, red uctions in blood pressure (BP) were 
observed in the Phase 1 and Phase 2 studies; however, these were not clinically meaningful and 
resolved without intervention. The degrees of reduction seen in both systolic and diastolic BP are 
consistent with the GABA -A-targeted mechanism of action of PSL and do not appear likely to 
have a clinically significant effect in therapeutic use (Jones  et al, 1979). In regard to ECG results, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172535] consultant whose opi[INVESTIGATOR_843727] “overall, there is no clear evidence that 
PSL is associated with any increase in incidence of ectopy, change in QTc interval, or 
clinically -significant arrhythmia in clinical trials to date. Echoc ardiographic screening of study 
subjects at Baseline (to exclude study subjects with valvulopathies) and ongoing 
echocardiographic monitoring during treatment and posttreatment has been implemented in the 
Phase  2 studies. No  major findings were observed in  EP0069 and in the ongoing OLE, EP0073. 
Cardiac monitoring (eg, ECGs, vital signs, echocardiograms) is planned throughout the duration 
of the development program in order to better understand and mitigate any risks.  
In general, the safety profile has been consistent with the pharmacological properties of the drug 
and consistent with studies of AEDs in regards to the type and severity of nervous system and 
psychiatric AEs reported, with most AEs reported as mild or moderate. The overall safety profile 
during  the clinical program to date can be found in the IB.  
2.4 Rationale for this study  
With over approximately 25 AEDs approved ([ADDRESS_1172536] 15 years), the majority of patients 
with epi[INVESTIGATOR_843728] -onset or focal to bilateral tonic -clonic (previously called “secondary 
generalized”) seizures have options for effective monotherapy and/or combination therapi[INVESTIGATOR_843729]; however, none of the options differentiate by [CONTACT_843799]. 
Seizure control only has changed marginally even with th e latest new AED treatments 
(Brodie  et al, 2012 ) and for the majority of severely affected and drug -resistant patients, there are 
few, if any, treatment options remaining.  
Padsevonil is an AED with a dual mechanism of action, specifically synthesized and designed 
for an increased anticonvulsant activity and hence for the treatment of seizures in patients with 
epi[INVESTIGATOR_843730]. Based on the evidence of unprecedented 
superiority of seizure control compared with other m arketed AEDs across several preclinical 
models of epi[INVESTIGATOR_843731], EP0069, treatment with PSL has 
the potential to benefit an underserved epi[INVESTIGATOR_843732], 
namely those who have drug -resistant epi[INVESTIGATOR_843733] -onset seizures 
constitute a substantial threat to their health and well -being. The current study, EP0091, will 
characterize the dose -response relationship with respect to efficacy and safety of PSL 
administered con comitantly with up to [ADDRESS_1172537] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 20 of 152 3.3 Other objectives  
3.3.1  Efficacy objectives  
The other efficacy objective is to:  
 Assess the HRU and quality of life  
3.3.2  Pharmacokinetic objectives  
The PK objectives are to:  
 Evaluate  the steady -state PK profiles of PSL and the exposure -response relationship  
 Evaluate the impact of enzyme -inducing concomitant AEDs on PSL exposure  
 Evaluate concomitant AED (and/or relevant metabolites) plasma levels  
3.3.3  Exploratory nonhereditary pharmacogeno mics and 
pharmacogenetics  
The other nonhereditary pharmacogenomics and pharmacogenetics objectives are to:  
 Identify genetic polymorphisms, gene expression patterns, plasma proteins, plasma 
metabolites, plasma lipi[INVESTIGATOR_805], or other plasma and serum substances th at predict or are 
associated with disease etiology, drug response, or tolerability  
4 STUDY VARIABLES  
4.1 Efficacy variables  
Seizure frequency refers to 28 -day adjusted frequency. Observable focal -onset seizures refer to 
Type  IA1, IB, and IC (ILAE Classification of Epi[INVESTIGATOR_207161],  1981). Focal -onset seizures 
include all Type I seizures. Seizure -free status and seizure -free days include all (Types  I, II, and 
III) seizure types.  
4.1.1  Primary efficacy variable  
[IP_ADDRESS]  Primary efficacy variable for the US FDA, PMDA, and other  regulatory 
authorities not specified in Section [IP_ADDRESS]  
The primary efficacy variable is the change in log -transformed observable focal -onset seizure 
frequency from Baseline, over the 12 -week Maintenance Period.  
[IP_ADDRESS]  Primary efficacy variable for EMA and regul atory authorities who 
reference EMA  
The primary efficacy variable is  the 75% responder rate, where a responder is a subject 
experiencing a ≥75% reduction in observable focal -onset seizure frequency from Baseline, over 
the 12 -week Maintenance Period.  
4.1.2  Second ary efficacy variables  
[IP_ADDRESS]  Secondary efficacy variables for the US FDA, PMDA, and other 
regulatory authorities not specified in Section [IP_ADDRESS]  
The secondary efficacy variables are as follows:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172538] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 21 of 152  The 75% responder rate, where a responder is a subject experiencing a ≥75% reduction in 
observable focal -onset seizure frequency from Baseline, over the 12 -week Maintenance 
Period  
 The 50% responder rate, where a responder is a subject experiencing a ≥50% reduction in 
observable focal -onset seizure frequency fr om Baseline, over the 12 -week Maintenance 
Period  
 Percent reduction in observable focal -onset seizure frequency from Baseline, over the 
12-week Maintenance Period  
[IP_ADDRESS]  Secondary efficacy variables for EMA and regulatory authorities who 
reference EMA  
The seconda ry efficacy variables are as follows:  
 The change in log -transformed observable focal -onset seizure frequency from Baseline, over 
the 12 -week Maintenance Period  
 The 50% responder rate, where a responder is a subject experiencing a ≥50% reduction in 
observa ble focal -onset seizure frequency from Baseline, over the 12 -week Maintenance 
Period  
 Percent reduction in observable focal -onset seizure frequency from Baseline, over the 
12-week Maintenance Period  
4.1.3  Other efficacy variables (This list applies for all regul atory 
authorities)  
The other efficacy variables are as follows:  
 Change from Baseline in log -transformed observable focal -onset seizure frequency over the 
first [ADDRESS_1172539] 4 weeks of the 12 -week Maintenance Period  
 Change from Baseline in log -transformed observable focal -onset seizure frequency over the 
16-week Treatment Period  
 The 50% responder rate, where a responder is a subject experiencing a ≥50% reduction in 
observable focal -onset seizure frequency from Baseline, over the 16-week Treatment Period  
 The 75% responder rate, where a responder is a subject experiencing a ≥75% reduction in 
observable focal -onset seizure frequency from Baseline, over the 16 -week Treatment Period  
 The 90% responder rate, where a responder is a subje ct experiencing a ≥90% reduction in 
observable focal -onset seizure frequency from Baseline, over the 12 -week Maintenance 
Period  
 Percent reduction in observable focal -onset seizure frequency from Baseline, over the 
16-week Treatment Period  
 Change from Basel ine in log -transformed focal -onset (Type I) seizure frequency over the 
12-week Maintenance Period  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172540] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 22 of 152  The 50% responder rate, where a responder is a subject experiencing a ≥50% reduction in 
focal -onset (Type I) seizure frequency from Baseline, over the 12 -week  Maintenance Period  
 The 75% responder rate, where a responder is a subject experiencing as a ≥75% reduction in 
focal -onset (Type I) seizure frequency from Baseline, over the 12 -week Maintenance Period  
 The 90% responder rate, where a responder is a subject experiencing a ≥90% reduction in 
focal -onset (Type I) seizure frequency from Baseline, over the 12 -week Maintenance Period  
 Percent reduction in focal -onset (Type I) seizure frequency from Baseline, over the 12 -week 
Maintenance Period and the 16 -week Treatm ent Period  
 Seizure -freedom status (yes/no) during the 12 -week Maintenance and the 16 -week Treatment 
Period  
 Percentage of seizure -free days during the 12 -week Maintenance Period and the 16 -week 
Treatment Period  
 Cumulative responder rate during the 16 -week T reatment Period  
 Change in the Seizure Severity Global Item (SSG) scores from Baseline to Week  4 during 
the Maintenance Period (Visit  4) and the end of the 16 -week Treatment Period (Visit  7) 
 Change in Quality of Life Inventory in Epi[INVESTIGATOR_002] -31-P (QOLIE -31-P) scores from Baseline to 
Week  4 during the Maintenance Period (Visit  4) and the end of the 16 -week Treatment 
Period (Visit  7) 
 Change in HADS scores from Baseline to Week 4 during the Maintenance Period (Visit  4) 
and to the end of the 16 -week Treatment Perio d (Visit  7) 
 Time to return to baseline 28-day observable focal -onset seizure count  during the 12 -week 
Maintenance Period  
 Use of health -related outcomes and HRU, including healthcare provider consultations not 
foreseen by [CONTACT_990], caregiver support, concurrent medical procedures, concomitant 
medications and hospi[INVESTIGATOR_602]  
4.2 Safety variables  
4.2.1  Primary safety variables  
The safety variables are as follows:  
 Incidence of TEAEs reported by [CONTACT_3184]/or caregiver or observed by [CONTACT_843800] e entire study  
 Incidence of TEAEs leading to study withdrawal  
 Incidence of treatment -emergent serious adverse events (SAEs) during the entire  study  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172541] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 23 of 152 4.2.2  Other safety variables  
Other safety variables are as follows:  
 Incidence of TEAEs reported by [CONTACT_3184] /or caregiver or observed by [CONTACT_843801]: 16 -week Treatment Period, 12 -week Maintenance Period, 
4-week Titration/Stabilization Period, and 3 -week Taper Period  
 Number of and reason for subjects requiring premature tapering due to TEAEs  
 Number of and reason for subjects requiring a dose reduction during the Stabilization Period 
due to TEAEs  
 Incidence of treatment -emergent SAEs during the following periods: 16 -week Treatment 
Period, 12 -week Maintenance Period, 4 -week Titration /Stabilization Period  
 Changes in clinical laboratory test parameters (including hematology, blood chemistry, and 
urinalysis)  
 Changes in vital sign parameters (including pulse rate, systolic BP, diastolic BP, and 
respi[INVESTIGATOR_697])  
 Changes in 12 -lead ECG par ameters  
 Physical examination (including body weight) and neurological examination findings  
 Changes in Psychiatric and Mental Status  
 Occurrence of valvular abnormalities or pericardial effusion changes or other significant 
abnormalities as identified by 2 -dimensional Doppler echocardiogram at each assessment by 
[CONTACT_39582]  
 Changes in withdrawal symptoms using Clinical Institute With drawal 
Assessment -Benzodiazepi[INVESTIGATOR_1651] (CIWA -B) from the End of Treatment Visit (Visit  7) to end of 
the Taper Period (Visit  8) and end of the SFU Period (Visit  9 [[ADDRESS_1172542] IMP 
intake]).  
4.3 Other variables  
4.3.1  Pharmacokinetic variables  
Blood concentration s of PSL and metabolites will be determined from samples obtained in the 
study during the Titration and Maintenance Periods in order to investigate the following 
variables:  
 The exposure -response relationship for PSL and active metabolite  
 The population PK profiles of PSL and active metabolite  
Blood concentrations of PSL  and active (  metabolite will be used to derive 
PK-population parameters (using population -PK analysis). Subjects will be asked to provide 
these samples whenever possible.  
Blood concentrations of concomitantly administered AEDs will also be evaluated for evidence of 
DDI with PSL at steady state.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 

UCB   [ADDRESS_1172543] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 24 of 152 4.3.2  Exploratory nonhereditary pharmacogenomics variables  
Where local regulations permit, blood samples will be collected at time points speci fied in 
Table  5-1 and stored for up to 20 years to allow for potential exploratory analyses of RNA, 
proteins, lipi[INVESTIGATOR_805], and metabolites biomarkers. Candi date serum biomarkers may also be explored.  
These samples will be used to support biomarker strategies related to epi[INVESTIGATOR_843734] 
(including safety, efficacy, and tolerability of PSL and concomitant therapi[INVESTIGATOR_014]).  
4.3.3  Exploratory pharmacogenetic variab les  
Additional blood samples will be collected at specific time points ( Table  5-1) from subjects who 
consent to participate in the pharmacogenetic subs tudy to measure DNA biomarkers in order to 
assess:  
 Pharmacogenetic variants associated with drug -resistant epi[INVESTIGATOR_843735] -resistant epi[INVESTIGATOR_002], 
AED  resistan ce, and PK. The samples will be stored up to 20 years for the research purposes 
stated in this protocol.  
4.3.4  Exploratory pharmacokinetic evaluation  
Comparison will be made of blood concentration data of PSL and  metabolite derived 
from either convent ional venous sampling or from the volumetric absorptive microsampling 
(VAMS) MITRA® technology.  
Additionally, evaluation of PSL and major metabolites in plasma will be undertaken from trough 
samples. The collection of plasma samples for this comparison may  cease during the course of 
the study based on periodic review of the data.  
5 STUDY DESIGN  
5.1 Study description  
EP0091 is a multicenter, randomized, double -blind, placebo -controlled, parallel -group 
dose-finding study in adults (≥18 years of age) with drug -resistant epi[INVESTIGATOR_843711] -onset seizures despi[INVESTIGATOR_843712] 4 tolerated, appropriately chosen 
and used prior AEDs,  including current AEDs (Kwan et al, 2010). All eligible subjects will have 
an epi[INVESTIGATOR_843736] [ADDRESS_1172544] 1  to 3 AEDs with or without neurostimulation devices.  
Subjects shou ld be educated to complete their diary entries accurately as per instruction.  
The study is composed of 4 periods (see Figure  5‒1 for a schematic diagr am): 
Baseline Period (4 weeks)  
During the Screening Visit (Visit  1, Week -4), subjects will sign a written Informed Consent 
form (ICF) prior to the conduct of any study -related procedure or pre -treatment assessments, and 
the subject’s eligibility will be d etermined on the basis of the inclusion/exclusion criteria. 
Subject eligibility related to seizure frequency will be evaluated based on Investigator 
assessment of the subject report on historical seizure count during the 8 weeks prior to the 
Screening Visi t (Visit  1) for the retrospective seizure baseline. Eligible subjects will be given a 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 

UCB   [ADDRESS_1172545] been on a stable dose of their present 
AEDs during the 8 -week period prior to the Screening Visit (Visit  1). For the neurostimulation 
device (if applicable), the settings should be stable for 12  weeks prior to Screening Visit 
(Visit  1). Both should be stable throughout the  study until the end of Treatment Period.  The 
Investigator will be asked to send documentation of video -electroencephalogram (EEG) report as 
per instruction to the UCB Study Physician or representative for confirmation of eligibility 
before randomization o f the subject.  
Treatment Period  (16 weeks)  
The 16 -week Treatment Period includes a 3 -week Titration Period followed by a 1 -week 
Stabilization Period and a 12 -week Maintenance Period. Four weeks after the Screening Visit 
(Visit  1), subjects will return to t he clinic for the Baseline Visit (Visit  2, Day  1). Subjects who 
continue to fulfill the inclusion and exclusion criteria will be randomized to 1 of the 5  treatment 
arms in a 1:1:1:1:1 ratio (random permuted blocks) to ensure the balance to 1 of the 5  treatment 
arms. Randomization will be stratified by [CONTACT_843802]2A proteins 
(LEV or brivaracetam) and by [CONTACT_11338] ( North America, Europe, and Asia) at the time of 
randomization.  
After the Baseline Visit (Visit  2), subjects will return t o the clinic for regular visits for the 
remainder of the Titration Phase. Investigational medicinal product will be increased 
approximately every 3  to 7 days depending on treatment arms (refer to Table  7-1 for details) . 
Subjects will be instructed to take the IMP in [ADDRESS_1172546] remain stable. The dose of IMP should remain stable during the 
Maintenance Period.  
Subjects who cannot tolerate IMP prior to Week 3 will be withdrawn from the study. For 
subjects with tolera bility issues experienced at their target dose, one fallback option to a 
predefined dose based on the randomized dose (see Table  7-2) will be allowed du ring the 
Stabilization Period and at least 2  days prior to start of maintenance (Visit  4). The Study 
Physician or delegate should be consulted prior to use of the fallback option and the date as well 
as the reason for fallback will be recorded in the sourc e documents and in the electronic Case 
Report form (eCRF).  
Fallback may be managed via an unscheduled visit. Fallback IMP packs will be allocated via the 
Interactive Response Technology (IRT). After fallback, the dose will be kept stable for the rest 
of the Maintenance Period. Further dose changes (ie, titration) are not allowed. Subjects, who are 
not able to tolerate the IMP during titration and after the fallback, will be tapered off IMP in a 
blinded fashion and will be withdrawn from the study.  
At Visit  4 (at the end of the Stabilization Period), subjects will enter a 12 -week Maintenance 
Period during which they will receive their target dose (or their fallback dose, if applicable). 
During the entire 12 -week Maintenance Period, the dose of IMP (target dos e or fallback dose) 
and concomitant AEDs must remain stable. Subjects must return to the clinic for scheduled visits 
as outlined in Table  5-1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172547] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 26 of 152 Subjects who complete the Maintenance Period will return for an End of Treatment Visit. 
Subjects who discontinue early from the study will return for an Early Discontinuation Visit 
(EDV). Su bjects completing the Maintenance Period will have the opportunity to enroll into the 
OLE study, EP0093. They will be converted to the entry dose of the EP0093 study, 400mg/day. 
Subjects withdrawing from the study or deciding not to participate in the OLE study (EP0093) 
will be progressively tapered off the IMP.  
For subjects discontinuing the study:  
Taper Period  (4 weeks)  
The 4 -week Taper Period will be required for subjects who choose not to enroll in the OLE study 
or who discontinue prior to the end of the Maintenance Period. Subjects participating in the 
4-week Taper Period should be gradually tapered off the IMP over a 3 -week period ( Table  7-3) 
followed by 1 -week drug -free period. A faster or slower taper schedule than the suggested 
3 weeks may be implemented, if medically necessary, as per the Investigator's medical 
judgement. Subjects will start their taper at the EDV/End -of-Treatment (Visit  7) and  will return 
[ADDRESS_1172548] intake of IMP for the End -of-Taper Visit at Visit  8. Changes to concomitant 
AED(s) are not allowed during the taper of PSL  unless they are medically necessary as per the 
Investigator’s medical judgement to treat rebound seizu res. 
Safety Follow -Up Period  
Safety follow up for subjects not entering the OLE will consist of [ADDRESS_1172549] IMP intake (Week  23 or sooner in case of early discontinuation) including an 
echocardiogram. An additional follow -up ec hocardiogram will be performed at 6 months 
(±1 month) after the last IMP intake only for subjects exposed to IMP for more than 3  weeks.  
For subjects continuing to the OLE study:  
Conversion Period  (3 weeks)  
The 3 -week Conversion Period will be required for subjects who choose to enroll in the OLE 
study at the end of the Maintenance Period. Doses for subjects participating in the 3 -week 
Conversion Period will be gradually adapted (increased or decreased) in a blinded way to reach 
the entry dose for the OLE. S ubjects who took placebo during the maintenance phase will 
progressively receive PSL.  
5.1.[ADDRESS_1172550] the option of providing additional informed consent for 
exploratory DNA, RNA, and lipi[INVESTIGATOR_1800]/proteomics/additional blood biomarker analyses. 
Participation in this additional portion of the study is optional and does not preclude participation 
in the main study. The additional pharmacogenetic sample must not be collected if the subject 
has not consented to participate i n this exploratory genetic substudy. A volume of 6mL of whole 
blood samples will be collected at Baseline (Visit  2). 
Any exploratory pharmacogenetic analysis will only be related to the exploration of the 
underlying causes of drug -resistant epi[INVESTIGATOR_002], AED r esistance, and drug response.  
Justification for additional genomic analyses is detailed in Section  5.4.[ADDRESS_1172551] will be up to 27 weeks with a maximum of 19  weeks 
exposure to PSL. An additional follow -up ec hocardiogram will be performed at 6  months 
(±1 month) after the last IMP intake only for subjects exposed to IMP for more than [ADDRESS_1172552] SFU Visit ([ADDRESS_1172553] IMP 
intake) of the last subject in the study. Additionally, the reporting of SAEs will continue until the 
6-month follow -up echocardiogram.  
5.1.3  Planned number of subjects and sites  
It is estimated that approximately 500 subjects w ill be included at approximately 200  sites 
worldwide; [ADDRESS_1172554] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 28 of 152 Table  5-1: Schedule of assessments  
 BL 
Period  
(4 Wk)  Treatment Period (16 Wk ±1 week from Visit  2) Taper/Conversion  
Period  
(3 to 4 Wk  
±1 week) a SFU  
(30 days 
after 
IMP 
intake)  
Unsch 
Visit b
 Titration Period  
(3 Wk ±1 week)  
(±3 days per week)  Stab  
(1 Wk 
±3 days)  Maintenance Period  
(12 Wk ±1 week )  
(±3 days per week)  
 Visits  V1 V2 
BL TC V3 TC V4 V5 V6 V7  
(EDV/EOT
) TC V8 V9 
 
Assessments  Start of  
Week x  Wk -4 D 1 Wk 1  Wk 2  Wk 3  Wk 4  Wk 8  Wk 12  Wk 16   Wk 19/[ADDRESS_1172555]  X             
Demographic data  X             
Verification of 
inclusion/exclusion criteria  X X            
Verification of withdrawal 
criteria   X X X  X X X X     
General 
medical/procedures history  X             
Epi[INVESTIGATOR_843737], diagnosis, 
surgery, and seizure history  X             
Documentation of MRI 
(within 10 years)  X             
Documentation of 
video -EEG  X             
AED history  X             
Habits and lifestyle  X             
Randomization (IRT)   X            
C-SSRS Baseline c X             
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172556] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 29 of 152 Table  5-1: Schedule of assessments  
 BL 
Period  
(4 Wk)  Treatment Period (16 Wk ±1 week from Visit  2) Taper/Conversion  
Period  
(3 to 4 Wk  
±1 week) a SFU  
(30 days 
after 
IMP 
intake)  
Unsch 
Visit b
 Titration Period  
(3 Wk ±1 week)  
(±3 days per week)  Stab  
(1 Wk 
±3 days)  Maintenance Period  
(12 Wk ±1 week )  
(±3 days per week)  
 Visits  V1 V2 
BL TC V3 TC V4 V5 V6 V7  
(EDV/EOT
) TC V8 V9 
 
Assessments  Start of  
Week x  Wk -4 D 1 Wk 1  Wk 2  Wk 3  Wk 4  Wk 8  Wk 12  Wk 16   Wk 19/[ADDRESS_1172557] visit  c d  X  X  X X X X  X X  
HADS  c  X    X   X   X  
SSG  c  X    X   X   X  
QOLIE -31-P  c   X    X   X   X  
CIWA -B c         X  X X  
Vital signs e X X  X  X X X X  X X  
Body weight and height f X X    X X X X  X X  
Physical examination g  
(XF = Full – XB =  Brief)  XF XB    XB   XF  XF XB  
Neurological examination h 
(XF = Full – XB = Brief)  XF XB    XB   XF  XF XB  
Psychiatric and Mental 
Status   X  X  X X X X  X X  
12-lead ECG i X X  X  X X  X  X X  
Echocardiogram j X       X    X k  
Blood/urine sample for 
clinical laboratory analyses  X X    X  X X  X X  
Blood sample for 
concomitant AED assay l m X X      X X     
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172558] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 30 of 152 Table  5-1: Schedule of assessments  
 BL 
Period  
(4 Wk)  Treatment Period (16 Wk ±1 week from Visit  2) Taper/Conversion  
Period  
(3 to 4 Wk  
±1 week) a SFU  
(30 days 
after 
IMP 
intake)  
Unsch 
Visit b
 Titration Period  
(3 Wk ±1 week)  
(±3 days per week)  Stab  
(1 Wk 
±3 days)  Maintenance Period  
(12 Wk ±1 week )  
(±3 days per week)  
 Visits  V1 V2 
BL TC V3 TC V4 V5 V6 V7  
(EDV/EOT
) TC V8 V9 
 
Assessments  Start of  
Week x  Wk -4 D 1 Wk 1  Wk 2  Wk 3  Wk 4  Wk 8  Wk 12  Wk 16   Wk 19/20  Wk 23   
Blood sample for PSL PK 
analysis n m    X  X X X X     
Blood sample for DNA   X            
Blood sample for RNA   X    X   X     
Blood sample for 
proteins/lipi[INVESTIGATOR_805]/metabolites   X    X   X     
Pregnancy test o X X  X  X X X X  X X  
Seizure evaluation  
(count & type) p  X X X X X X X X X X X  
Concomitant medications 
(AEDs and non -AEDs) and 
procedures  X X X X X X X X X X X X  
Recording of adverse 
events  X X X X X X X X X X X X  
Health -related outcomes 
and HRU  X X  X  X X X X  X X  
IMP dispensing (IRT)   X  X  X X X X     
IMP accountability and 
return q    X  X X X X  X   
Entry and exit personal 
outcome interview r X      X     
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172559] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 31 of 152 Table  5-1: Schedule of assessments  
 BL 
Period  
(4 Wk)  Treatment Period (16 Wk ±1 week from Visit  2) Taper/Conversion  
Period  
(3 to 4 Wk  
±1 week) a SFU  
(30 days 
after 
IMP 
intake)  
Unsch 
Visit b
 Titration Period  
(3 Wk ±1 week)  
(±3 days per week)  Stab  
(1 Wk 
±3 days)  Maintenance Period  
(12 Wk ±1 week )  
(±3 days per week)  
 Visits  V1 V2 
BL TC V3 TC V4 V5 V6 V7  
(EDV/EOT
) TC V8 V9 
 
Assessments  Start of  
Week x  Wk -4 D 1 Wk 1  Wk 2  Wk 3  Wk 4  Wk 8  Wk 12  Wk 16   Wk 19/20  Wk 23   
Study termination            X X s  
AED=antiepi[INVESTIGATOR_32551]; BL=Baseline; BP=blood pressure; CIWA -B=Clinical Institute Withdrawal Assessment -Benzodiazepi[INVESTIGATOR_1651]; C -SSRS=Columbia -
Suicide Severity Rating Scale; DNA=deoxyribonucleic acid; ECG=electrocardiogram; EDV=Early discontinuation Visit; EEG=electroencephalogram; 
EOT=End of Treatment; HADS=Hospi[INVESTIGATOR_5620]; HRU=healthcare resource utilization; IMP=investigative medi cinal product; 
IRT=interactive response technolog y; MRI=magnetic resonance imaging; OLE=open -label extension; PK=pharmacokinetic; PSL=padsevonil; QOLIE -31-
P=Quality of Life Inventory in Epi[INVESTIGATOR_002] -31-P; RNA= ribonucleic acid; SFU=Safety Follow -Up; SSG=Seizure Severity Global Item; Stab=Stabilization 
Period ; TC=telephone call; Unsch=unscheduled; V=visit; Wk=Week  
 a Taper Period, for subjects who choose to not enter OLE study EP0093, will last for [ADDRESS_1172560] and/or legal re presentative deem it necessary. Appropriate 
assessments will be conducted in relation to the reason for the visit.  
 c Questionnaires to be completed by [CONTACT_843803] , when possible . 
 d If an unscheduled visit is conducted due to safety or efficacy reasons, a C -SSRS assessment will be performed with the subject during the visit. If an 
unsche duled visit is conducted for reasons other than safety or efficacy concerns (eg, replacement of lost medication, repeated col lection of a laboratory 
specimen due to collection, or analysis issues), a C -SSRS will not be required at these visits.  
 e Vital signs measured in supi[INVESTIGATOR_55848] [ADDRESS_1172561] include pulse rate, respi[INVESTIGATOR_697], systolic BP, and diasto lic BP.  
f Height  will only be measured at Visit  1. 
 g Full physical examinations will assess cardiac and respi[INVESTIGATOR_843738]: general appearance; ear, 
nose, and throat; eyes; hair and skin; respi[INVESTIGATOR_696]; cardiovascular; gastrointestinal; musculoskeletal; hepatic; neurological; and mental status. Brief physical 
examinations will include a review of the following body systems: general appearance (including m ental status); skin; respi[INVESTIGATOR_696]; cardiovascular; 
gastrointestinal; and hepatic.  
 h Brief neurological examination will include a general assessment and evaluation of reflexes, muscle strength an d coordination, and cerebellar function. 
Full neurological examinations will include in addition, evaluation of cranial nerves, motor system (general muscle strength and t one), sensations in 
upper/lower extremities.  
 i Baseline ECG has to be scheduled and results received before Visit  2. An ECG at the SFU Visit will be performed only if abnormal at end of treatment or 
premature discontinuation visit. All ECG recordings will be performed with the s ubject resting in the supi[INVESTIGATOR_21683] [ADDRESS_1172562] IMP intake at the SFU Visit (except if performed at Visit  6). A repeat echocardiogram will be performed for 
subjects with a new finding, Grade  2 (moderate severity), or Grade 3 (severe  severity).  
k An echocardiogram will also be performed [ADDRESS_1172563] IMP intake for subjects exposed to >3 weeks to IMP and discontin uing the study (but not for 
subjects with <3 weeks expo sure).  
l AED samples will ideally be taken immediately prior to dose of concomitant medication on each occasion. If this is not possib le, then the sample may be taken 
at any time after dose and t he timing of sample in relation to dose should be kept the same ( ±1 hour) on each occasion for each subject. Therefore, the timing of 
visits for each subject when AED samples are collected should be scheduled approximately at the same time whenever possibl e. Assay of parent PSL and 
metabolites may be included in the AED panel of tests at Visits 6 and 7.  
m On Visits 6 and 7, unless the concomitant AED sample is within ±[ADDRESS_1172564] IMP intake and the time of 
sample collectio n. On Visits 4 and 7, blood samples for measurement of sparse PK profiles will be collected as follows: immediately before IM P intake 
(maximum 15  minute s before intake) and then 3 times after (between 30 minutes and 3 hours after IMP intake), taken at leas t [ADDRESS_1172565] at Visits  1 and 7 (in case t he subject enters into the OLE study) and where applicable. Urine pregnancy test will 
be used at other visits for female subjects of childbearing potential.  
 p Seizure counts are collected on the  subject’s daily record card on a daily basis.  
 q At each visit following an IMP dispensation, IMP should be presented to check for compliance.  
r Subject entry interview will be performed on a voluntary basis either at Visit  [ADDRESS_1172566]/caregiver exit interview/survey will be performed on a 
voluntary basis either at Visit  [ADDRESS_1172567] 2018  
Clinical Study Protocol  Padsevonil   EP0091  
   
Confidential  Page 33 of 152 5.3 Schematic diagram  
A schematic diagram is provided in Figure  5‒1. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172568] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 34 of 152 Figure  5‒1: Study design  
 
OLE=open -label extension, TC=telephone call; V=visit, WK=week  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172569] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 35 of 152 5.4 Rationale for study design and selection of dose  
5.4.1  Choice of study design and endpoints  
The target indication for PSL is as adjunctive therapy in the treatment of focal -onset seizures in 
adult patients with drug -resistant epi[INVESTIGATOR_002]. The key inclusion criteria are aimed at selecting a 
sample of study subjects from this target population. The cr iterion for drug resistance or failure 
to achieve control of seizures, with ≥[ADDRESS_1172570] not been able to 
control their seizures de spi[INVESTIGATOR_12847] 4 or more AED regimens, the likelihood of 
achieving complete seizure control with another AED regimen is further reduced to 1% to 4% 
(Schiller  and Najjar,  2008; Mohanraj and Brodie, 2006). Study subjects also will be required to 
have o n average at least 4 spontaneous and observable focal -onset seizures (IA1, IB, or IC) per 
28 days during each 4 -week interval of the 8 -week retrospective Baseline Period prior to entry 
and during the 4 -week Baseline Period. This minimum seizure frequency w as selected to provide 
assurance that a meaningful change in percent reduction in seizure frequency over 28  days and 
50%, 75%, and 90% responder rates could be demonstrated during the [ADDRESS_1172571] diagnosis of epi[INVESTIGATOR_002], that the 
disease is relatively stable, that there are no drugs/treatments which could confound analyses or 
present a safety issue as a result of DDI or efficacy against seizures, that there is no evidence of 
previous safety issues with other drugs that share PSL’s mechanisms of action, and to mitigate 
risks or potential risks study subjects from this target population.  
The decision to use the continuous variable, log change in seizure frequency, as opposed to a 
binary variable, responder rate, as the primary outcome was based on the reduction in power 
consequent to the loss of information when a dichotomous variable is used compared to when a 
continuous variable is used ( Altman and Royston, 2006 ). 
UCB regards the  12-week duration for the Maintenance Period as adequate to distinguish 
long-term from short -term efficacy. Moreover, 12 weeks is consistent with registration studies 
for recently approved AEDs as adjunctive therapy for focal -onset seizures (Moseley  et al, 2016; 
Chung  et al, 2010b; Elger  et al, 2009) and conforms to the guidance documents by [CONTACT_1556],  Guidance for Industry,  1981 and European Medicines Agency 
(CHMP/EWP/566/98  Rev.2/Corr,  2010). Given the increased risk of SUDEP in patients with 
uncontrolled s eizures (Jehi,  2016) and in those randomized to placebo in clinical trials 
(Ryvlin  et al, 2011), UCB considers that requiring patients to remain on placebo longer or for all 
enrolled patients to exclude dose adjustments is not acceptable. Because of the in creased 
incidence of SUDEP, subjects should be monitored closely and, depending on the Investigator’s 
judgment, withdrawn from the study in the event of seizure worsening, particularly subjects 
experiencing an increase in secondarily generalized seizures. Additionally, a [ADDRESS_1172572] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 36 of 152 5.4.2  Rationale for dose selection  
Dose selection for EP0091 was informed by [CONTACT_843804]:  
1. UP0036: PET -derived human SV2A receptor occupancy vs exposure relationship  
2. N01383: PET -derived human GABA -A receptor occupancy  
3. The maximum tolerated dose (MTD) of 400mg bid in Phase 1  
4. EP0069: efficacy -exposure analysis  
5. Preclinical pharmacological exposure -response data  
Four dose levels of PSL (equally spaced on the logarithmic scale), 100mg/day, 200mg/day, 
400mg/day, and 800mg/day, administered bid have been selected to fully explore the 
dose-response curve for PSL in patients with drug -resistant epi[INVESTIGATOR_002].  
Two PET studies, UP0036: PET -derived human SV2A receptor occupancy and 
N01383:  PET-derived h uman GABA -A receptor occupancy, were performed to inform dose 
selection for the clinical studies. Using population -PK modeling of the PK and PET data with a 
SV2A ligand in UP0036, simulations projected SV2A receptor occupancy in human brain 
regions to be g reater than 90% over the whole dosing interval for 90% of a population treated 
with the 400 and 300mg bid dosing, and greater than 90% for 75% of a population at 100mg bid 
dosing. In N01383, modeling of the receptor occupancy of PSL at brain GABA -A recepto rs 
measured using the PET ligand, flumazenil, demonstrated that subjects treated with PSL 200mg 
bid had maximal GABA -A receptor occupancy ranging from lower limit quantification (5%) to 
9.7%. Subjects treated with PSL 400mg bid had maximal GABA -A receptor occupancy ranging 
from 7.6% to 16.8%.  
The rationale for the selection of the maximum dose, 400mg bid (800mg/day), is based on the 
MTD seen in Phase 1 single dose and multiple dose clinical studies, and is in line with receptor 
occupancy at the SV2A recepto r and the nonclinical data described above. Furthermore, 
800mg/day has demonstrated clinically meaningful efficacy (EP0069 primary outcome analysis) 
with acceptable tolerability. The maximum dose is supported further by [CONTACT_843805]2A receptor occupancy are required for efficacy in the primary 
model of resistant epi[INVESTIGATOR_002] (amygdala kindling, mean effective dose [ED 50]=95%). Conversely, 
receptor occupancy at the GABA site associated with efficacy was relatively low (ED 50=9%). 
Therefore, it is reasonable to conclude that the high dose level should be associated with 
occupancy consistent with these levels observed at SV2A and GABA -A receptors and 
maintained for SV2A.  
However, for brivaracetam, an AED with SV2A mode of action, a dose with demonstrated 
therapeutic efficacy (200mg), had an observed SV2A receptor occupancy below 90% 
(UCB  internal data, EP0074). In this context, the lowest dose for PSL in EP0091 has been set at 
100mg/day (50mg bid) based on preliminary simul ations that indicate that a dose around 
50mg  bid will have an SV2A occupancy roughly equivalent to that associated with a therapeutic 
dose of brivaracetam. Of note, data from N01383 indicates that, at this lower dose level, 
GABA -A receptor occupancy may be  below quantifiable levels, but even very low levels of 
occupancy may provide some synergy with SV2 mechanisms.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172573] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 37 of 152 Finally, the 2 intermediate doses were selected based on equal spacing between the high and low 
doses on log -scale and SV2A and GABA -A receptor occupancy:  
 100mg bid (200mg/day) which represent an SV2A receptor occupancy >90% with no 
quantifiable GABA -A occupancy  
 200mg bid (400mg/day) which represent an SV2A receptor occupancy >90% with 
quantifiable GABA -A occupancy  
Subjects completing the Maintena nce Period in EP0091 will be offered the option to enter the 
OLE study EP0093 with open -label treatment with PSL. This will be achieved through a 
Conversion Period to ensure blinding of the parent study. All subjects who choose to transition to 
EP0093 will  enter the study after the 3 -week Conversion Period at an intermediate dose of 
400mg/day PSL before further individual dose adjustment can be made. This dose level was 
selected considering the benefit/risk balance and is based on clinical pharmacology and PET data 
in healthy human subjects suggesting that it will provide full occupancy at the SV2A binding site 
while maintaining some minimal binding to the GABA -A binding site. For subjects previously 
on placebo in EP0091, a full SV2A occupancy is desirable t o obtain a meaningful anticonvulsive 
effect while minimal BZD binding will result in fewer GABA -related CNS AEs. On the other 
hand, for subjects exposed to high doses of PSL in EP0091 maintenance (800mg/day), the target 
transition dose of 400mg/day will li kely maintain the full SV2A -related effect while not entirely 
eliminating GABA -binding related effects. Once subjects enter EP0093, further individual dose 
adjustments can be made, as needed as per the OLE protocol.  
5.4.3  Justification for genomic and biomarker strategy  
The biomarker samples will be collected to understand the molecular characteristics of epi[INVESTIGATOR_843739] (including safety, efficacy, and tolerability of PSL and concomitant therapi[INVESTIGATOR_014]), 
which may enable potential molecular stratification in future clinical studies. A broad range of 
molecular data may be generated from each individual sample. The exact format of these 
analyses will be specified at a later time. The samples will be stored at -80°C at the Central 
Laboratory facilities for up to [ADDRESS_1172574] be met:  
General  
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
ICF is signed and dated by [CONTACT_261490](s) or by [CONTACT_80518], 
where applicable. The ICF or a specific Assent form, where required, will be signed and 
dated by [CONTACT_122256], according to country -specific regulations. A separate ICF should be signed 
and dated by [CONTACT_843806], RNA, and 
lipi[INVESTIGATOR_1800]/proteomics/additional blood biomarker samples.  
2. Subject/legal representative/ caregiver  (where legally permitted)  is considered reliable and 
capable of adhering to the protocol (eg, able to understand and complete diaries), visit 
schedule, or medication intake according to the judgment of the Investigator.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172575] is an adult (18 ye ars of age or more).  
4. Subject is of normal weight of at least 40kg (for males and females).  
Epi[INVESTIGATOR_002]  
5. Subject fulfills diagnostic criteria for epi[INVESTIGATOR_843740] -onset (IA1, IB, and 
IC) seizures for at least 3 years at the time of enrolment ( according to the 
ILAE  Classification  of Epi[INVESTIGATOR_843714],  1981):  
 Epi[INVESTIGATOR_843741] -EEG recordings or ictal -EEG 
(+/- simultaneous video) in the past (description or report is available). The Investigator 
must consult  with the UCB Study Physician or representative for confirmation of 
eligibility as per instructions in the Study  Manual.  
If no video -EEG report is available and, in the opi[INVESTIGATOR_689], epi[INVESTIGATOR_843742] (ie,  eye-witnessed seizure  report, home video documentation of 
habitual events, or other proof), the Investigator must consult with the UCB Study 
Physician or representative for a case review  
 A brain magnetic resonance imaging (MRI) to be performed before randomization, if no 
such scan was performed in the last [ADDRESS_1172576] 3 years before randomization will suffice.  
6. Subjects having on average ≥4 spontaneous and observable focal -onset seizures per 28  days 
(based on Investigator assessment of subject report) with at least [ADDRESS_1172577] experience ≥4 spontaneous and observable focal -onset seizures per 28  days 
(based on Investigator assessment of subject report) during the [ADDRESS_1172578] has failed to achieve seizure control with ≥[ADDRESS_1172579] and ongoing treatment, that were individually optimized for adequate 
dose and duration. Prior discontinued AED treatment would need to b e assessed by [CONTACT_843807]/or caregiver interview. 
"Prior AED" is defined as all past and ongoing AED treatments with a start date before the 
Screening Visit (Visit  1). 
Concomitant epi[INVESTIGATOR_843743] 
8. Subject is currently treated with an individually optimized and stable dose of at least 1 and up 
to 3 AEDs for the 8  weeks prior to the Screening Visit (Visit  1) with or without additional 
concurrent vagus nerve stimulation (VNS) or other neurostimulat ion treatments. The latter 
will not be counted as AEDs for the purpose of eligibility.  
Laboratory parameter  
9. Subject has clinical laboratory test results within the reference ranges of the laboratory or 
isolated test results that are outside the specified r anges and that are deemed as not clinically 
significant by [CONTACT_737].  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172580] at the 
Screening Visit (Visit  1), which is confirmed to be negative by [CONTACT_843808]  1 (Visit  2) and prior to further dispensing at each study visit thereafter. 
Subjects will be withdrawn from the study as soon as pregnancy is known.  
Female subjects will use an efficient form of contraception fo r the duration of the study 
for a period of [ADDRESS_1172581] intake of IMP. Hormonal contraception may be 
susceptible to an interaction with the IMP, which may reduce the efficacy of the 
contraception method. The potential for reduced efficacy of any hormonal contraception 
method requires that a barrier method (preferably male condom) also be used.  
Birth control methods considered as an efficient form of contraception:  
 Combined (estrogen - and progesterone -containing) hormonal contraception (oral, 
implant, injectable) associated with inhibition of ovulation, (which must be stable for at 
least 1  full month prior to Screening [Visit  1], and should remain stable during the study) 
in combination with a barrier method (preferably a condom).  
 Progesterone -only hormonal contraceptives (oral, implant, injectable) associated with 
inhibition of ovulation (which must be stable for at least 1 full month prior to Screening 
[Visit  1], and should remain stable during the study) in combination with a barrier 
method ( preferably a condom).  
 Progesterone -releasing intrauterine systems or the TCu 380A intrauterine device in 
combination with a barrier method (preferably a condom).  
 Progestogen -only oral hormonal contraception, where inhibition of ovulation is not the 
primary  mode of action, in combination with a barrier method (preferably a male 
condom)  
 Male or female condom with spermicide (ie, double -barrier)  
 Cap, diaphragm or sponge with spermicide (ie, double -barrier)  
 Bilateral tubal ligation  
 Vasectomized partner (provided sole partner, and partner has medical proof of surgical 
success)  
 True heterosexual sexual abstinence is an acceptable form of contraception when this is 
in line with the preferred and usual lifestyle of the person. Periodic abstinence 
(eg, calend ar, ovulation, symptothermal, post -ovulation methods), declaration of 
abstinence for the duration of the study, and withdrawal are not acceptable methods of 
contraception.  
 Women not agreeing to use birth control must be abstinent (as described in the prece ding 
bullet) or be of nonchildbearing potential, defined as being postmenopausal (for at least 2 
years before the Screening Visit [Visit  1]), verified by [CONTACT_843809] >40mIU/mL at the Screening Visit (Visit  1), or permanently st erilized (eg, bilateral 
tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656]), or congenitally sterile.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172582] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 40 of 152  Both male and female subjects must use the above mentioned contraception during the 
study.  
 To ensure a proper birth control, females who use hormonal contraception should use an 
efficient barrier contraceptive in the [ADDRESS_1172583] intake of IMP.  
6.2 Exclusion criteria  
Subjects are not permitted to enroll in the study if any of the following criteria is met:  
General  
1. Subject has previously been ra ndomized in this study or a study of the medication under 
investigation in this study.  Re-screening of a subject may be permitted but requires prior 
medical monitor approval, and is not permitted in case of screen failure due to seizure count.  
2. Subject has participated in another study of an investigational medication (or a medical 
device) within the last 30 days or 5 half -lives (whichever is longer) or is currently 
participating in another study of an investigational medication (or a medical device).  
Labora tory parameter  
3. Subject has either:  
 >2.0x upper limit of normal (ULN) of any of the following:  
◦ alanine aminotransferase (ALT)  
◦ aspartate aminotransferase (AST)  
◦ alkaline phosphatase (ALP)  
-OR- 
 >ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert ’s syndrome).  
If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, 
fractionate bilirubin to identify possible undiagnosed Gilbert’s syndrome (ie, direct 
bilirubin <35%).  
For randomized subjects with a baseline result >ULN for ALT,  AST, ALP, or total 
bilirubin, a baseline diagnosis and/or the cause of any clinically meaningful elevation 
must be understood and recorded.  
If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at 
screening, repeat the tests, if pos sible, prior to dosing to ensure there is no further 
ongoing clinically relevant increase. In case of a clinically relevant increase, inclusion 
of the subject must be discussed with the Medical Monitor.  
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be 
repeated once for confirmation before Baseline (Visit  2).  
Medical condition  
4. Subject has a history or current medical condition that, in the opi[INVESTIGATOR_689], 
could  jeopardize or would compromise the subject’s ability to participate in this study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172584] 12  months which, in 
the opi[INVESTIGATOR_689], could compromise his/her safety or ability to  participate in 
this study including but not limited to schizophrenia, schizoaffective disorder, bipolar 
disorder, severe unipolar depression, dementia, or irreversible severe or progressive 
encephalopathy.  
6. Subject has a lifetime history of suicide attempt  (including an actual attempt, interrupted 
attempt, or aborted attempt), or has suicidal ideation in the past 6  months as indicated by a 
positive response (“Yes”) to either question 4 or question 5 of the “Screening/Baseline” 
version of the Columbia -Suicid e Severity Rating Scale (C -SSRS) at screening.  
7. Subject has a history of chronic alcohol or drug abuse within the last [ADDRESS_1172585] has presen ce of any sign (clinical or imaging techniques) suggesting rapi[INVESTIGATOR_180856] (ie, not expected to stay stable during study participation) brain disorder or brain 
tumor. Stable lesions such as arteriovenous malformations, meningiomas, or other benign 
tumo rs are acceptable if no surgical removal is planned or likely for the duration of the study.  
10. Subject has any clinical condition (eg, bone marrow depression, chronic hepatic disease, 
and/or severe renal impairment) that could impair reliable participation i n the study or 
necessitate the use of medication not allowed by [CONTACT_990].  
11. Subject has presence of a terminal illness.  
12. Subject has presence of a serious infection.  
13. Subject has a clinically significant abnormality on ECG that, in the opi[INVESTIGATOR_388321], increases the risks associated with participating in the study. In addition, any 
subject with any of the following findings will be excluded:  
 QT interval corrected for heart rate using Bazett’s formula (QTcB) or QT interval 
corrected for heart rate u sing Fridericia’s formula (QTcF) interval >450ms  
 Bundle branch blocks and other conduction abnormalities that are clinically significant 
according to the Investigator and/or with a PR interval ≥220ms, irregular rhythms other 
than sinus arrhythmia or occasi onal, rare supraventricular or rare ventricular ectopic beats 
in the judgment of the Investigator, or T -wave configurations are not of sufficient quality 
for assessing QT interval duration  
 Subject has a history of unexplained syncope or a family history of  sudden death due to 
long QT syndrome.  
14. Subject has an abnormality on echocardiogram at Screening Visit (Visit  1) as assessed by 
[CONTACT_843810] (eg, shortness of breath, palpi[INVESTIGATOR_814], 
and murmur) or a ≥Grade  2*/moderate severity abnormality or a history of rheumatic heart 
disease or other known valvular abnormalities (*according to the ASE Guidelines, 
Zoghbi  et al, 2017).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172586] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 42 of 152 Subjects whose echocardiograms are not interpretable at Screening Visit (Visit  1) by 
[CONTACT_462612] (TTE), eg, due to technical difficulties or position of the heart 
will be excluded from the study.  
Epi[INVESTIGATOR_002]  
15. Subject has a history of or signs of generalized (formerly referred to as ‘idiopathic 
generalized’) or combined gene ralized and focal (formerly referred to as ‘symptomatic 
generalized’) epi[INVESTIGATOR_002] (Scheffer IE et al, 2017).  
16. Subject has a history of status epi[INVESTIGATOR_843744] 6 -month period prior to Screening  Visit 
(Visit  1). 
17. Subject has seizures on a regular basis that  are uncountable eg due to clustering (ie,  an 
epi[INVESTIGATOR_843745] 30  minutes in which several seizures occur with such frequency that 
the initiation and completion of each individual seizure cannot be distinguished) during the 
8-week retrospective Ba seline and during the [ADDRESS_1172587] has isolated auras only (ie, focal -onset seizures which involve subjective sensory or 
psychic phenomena only, without impairment of consciousness or awareness, [formerly 
referred to as simple partial s eizures without observable component]).  
19. Subject has a current diagnosis of pseudo - or nonepi[INVESTIGATOR_122174], or other nonepi[INVESTIGATOR_843746].  
20. Subject had resective surgery for epi[INVESTIGATOR_843747] [ADDRESS_1172588] had an epi[INVESTIGATOR_843748] <3 months prior to Screening Visit (Visit  1). 
22. Subject has VNS, deep brain stimulation, Responsive Neurostimulator System, or other 
neurostimulation for epi[INVESTIGATOR_843749]  
 implanted and activated <1 year prior to enrollment, or  
 with stimulation parameters that have been stable for <3 months, or  
 with bat tery life of unit not anticipated to extend for duration of trial.  
23. Subject is currently treated with carbamazepi[INVESTIGATOR_050], phenytoin, primidone, or phenobarbital or 
any other drug known as a strong inducer of cytochrome P450 (CYP) 3A4  liver enzymes.  
24. Subjects prev iously had serious side -effects with drugs having SV2A and GABA -ergic 
mechanisms of action.  
Medical treatment  
25. Subject has a known hypersensitivity to any components of PSL formulation or a history of 
drug or other allergy that, in the opi[INVESTIGATOR_843750], contraindicates her/his participation.  
26. Subject has taken or is taking any prescription, nonprescription, dietary (eg,  grapefruit or 
passion fruit), or herbal products (eg, St. John's wort) that are strong inducer s or strong 
inhibitors of the CYP3A4 or 2C19 pathway for 2 weeks (or 5  half-lives, whichever is longer) 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172589] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 43 of 152 prior to the Baseline Visit (Visit  2). Subjects taking sensitive substrates of CYP2C19 are 
similarly excluded.  Please also note the prohibited concomit ant medications listed in 
Section  7.8.[ADDRESS_1172590] associated with 1 of the following 2  conditions:  
 there was a change from a visual field test done at some point while the subject was 
taking vigabatrin, or  
 there was a change fro m a visual field test done within weeks after stoppi[INVESTIGATOR_843751].  
30. Subject has been taking felbamate for less than 12 months and/or has no appropriate 
laboratory tests showing no indication of aplastic anemia or hepatic failure.  
31. Subject taki ng retigabine for less than [ADDRESS_1172591] currently taking retigabine 
or having been exposed to retigabine with no documentation (at least every [ADDRESS_1172592] exposure) of normal/stable visual acuity, slit -lamp examination , dilated 
fundus photography and macular Optical Coherence Tomography imaging.  
32. Subject is taking GABA -A-ergic drugs regularly (agonists [ie, barbiturates] or receptor 
positive allosteric modulators [ie, BZDs or non -BZDs]), excluding as needed (PRN) intake  of 
GABA -A-ergic AEDs <[ADDRESS_1172593] who plans to become pregnant or is breastfeeding.  
6.3 Withdrawal criteria  
Subjects are free to withdraw from the study at any time, without prejudice to their continued 
care.  
Subjects should be withdrawn from the study if any of the following events occur:  
1. Subject withdraws his/her consent.  
2. The Sponsor or a regulatory agency requests withdrawal of the subject.  
3. Subject is noncompliant with the study procedures or medications in the  opi[INVESTIGATOR_684].  
4. Subject takes prohibited concomitant medications, prescribed or over -the-counter as defined 
in this protocol.  
5. Subject develops an illness that would interfere with his/her continued participation.  
6. A prolongation or worsening of overall seizure duration, frequency, type, or pattern 
considered by [CONTACT_843811].  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172594] with an echocardiogram showing a Grade  2 finding (moderate regurgitation/stenosis) 
if accompanied w ith moderate to severe signs/symptoms or a Grade 3 finding (severe 
regurgitation/stenosis) will be discontinued from the study regardless of accompanying 
clinical symptoms, and should begin discontinuation of the IMP. Additionally, a jump of 
2 grades, from  Grade  0 to Grade  2 (moderate regurgitation/stenosis) accompanied with 
moderate to severe symptoms or from Grade  1 to Grade 3 (severe regurgitation/stenosis) will 
result in subject discontinuation (see Section  6.3.2 ). 
8. Changes in the ECG that are regarded as clinically significant and/or that worsen over time.  
 An ECG shows an absolute value for QTcB or QTcF ≥500ms or ≥60ms above Baseline.  
 Subject devel ops second - or third -degree atrioventricular block or another clinically 
relevant change in ECG as determined by [CONTACT_737].  
9. Subject has active suicidal ideation without specific plan as indicated by a positive response 
(“Yes”) to question 4 of the “ Since Last Visit” version of the C -SSRS. The subject should be 
referred immediately to a mental healthcare professional and may be withdrawn from the 
study based upon the Investigator’s judgment of benefit/risk of continuing the subject in the 
study/on IMP . 
Subject has active suicidal ideation with a specific plan as indicated by a positive 
response (“Yes”) to question 5 of the “Since Last Visit” version of the C -SSRS. The 
subject should be referred immediately to a mental healthcare professional and must b e 
withdrawn from the study.  
10. For subjects developi[INVESTIGATOR_843752]/mood/behavioral signs or disturbances (see examples in 
list below) that are clinically concerning or that worsen over time, the subject should be 
referred immediately to a mental healthcare pr ofessional and must be withdrawn from the 
study.  
 Auditory or visual hallucinations  
 Delusions/paranoia/grandeur  
 Disorganized thought process  
 Agitation/aggression/apathy  
 Dysphoria/depression/mood lability/euphoria  
 Disinhibition  
 Cognitive changes/memory impai rment/delirium  
 Aberrant motor behavior  
11. Subject is suspected of having a serious multiorgan hypersensitivity reaction. Serious 
suspected multiorgan hypersensitivity cases may be identified and reported to the Sponsor by 
[CONTACT_843812]:  
 An AE or laboratory value (as defined below) suggestive of internal organ involvement 
including but not limited to hepatitis, nephritis, pneumonitis, carditis, colitis, encephalitis, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172595] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 45 of 152 pancreatitis, myositis, arthritis, or hematologic system invo lvement) combined with 
at least 1 of the following: fever, rash, lymphadenopathy, or eosinophilia  
 Treatment -emergent abnormal laboratory value criteria suggestive of internal organ 
involvement or eosinophilia:  
 Eosinophils percentage ≥10%  
 Eosinophils absolu te ≥0.5G/L  
 Neutrophils absolute <1.5G/L  
 Platelets absolute ≤100G/L  
12. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test. 
Investigators should attempt to obtain information on subjects in the case of withdrawal or  
discontinuation. For subjects considered as lost to follow up, the Investigator should make an 
effort (at least [ADDRESS_1172596]), and document his/her effort 
(date and summary of the phone call and copy of the written mes sage in the source documents), 
to complete the final evaluation. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the subject, must be recorded in the source 
documents. The eCRF must doc ument the primary reason for withdrawal or discontinuation.  
Investigators should contact [CONTACT_1689], whenever possible, to discuss the withdrawal 
of a subject in advance.  
6.3.1  Potential drug -induced liver injury IMP discontinuation criteria  
Subjects with potential drug -induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued.  
The PDILI cr iteria below require immediate and permanent discontinuation of IMP:  
 Subjects with either of the following:  
 ALT or AST ≥5x ULN  
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
The PDILI criterion below requires immediate discontinuation of IMP:  
 Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).  
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
Investigator:  
 Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN,  total bilirubin 
<2xULN, and no eosin ophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis 
(eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172597] be discontinued immediately.  
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinu ation and subject withdrawal (if 
applicable), must be recorded in the source documents. The eCRF must document the primary 
reason for IMP discontinuation.  
6.3.2  Echocardiogram valvular abnormalities assessments  
Table  6-1 shows the grading of valvular abnormalities defined by a 0 to 3 Grade scale (according 
to the ASE  Guidelines,  2017; Zoghbi  et al, 2017) as well as the respective severity descriptions 
of absent , mild, moderate, and severe. Potential cardiovascular signs/symptoms that may 
accompany valvular abnormalities are included in the table as potential indicators of new or 
increasing severity of valvular changes and will be identified through routine physi cal 
examinations and AE/symptom reporting. However, symptom reporting often occurs only at an 
advanced stage of the disease (Iung  and Vahanian,  2011), suggesting that valvular disease may 
or may not have accompanying clinical symptoms.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172598] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 47 of 152 Table  6-1: Valvular abnormality grading criteria  
Echocardiogram 
Valvular 
Abnormality  Severity / Description  Potential 
Cardiovascular 
Signs/Symptoms  Action  
Grade  0 Absent: no regurgitation, 
no stenosis  None reported  None  
Grade  1 Mild: trace or barely 
detected 
regurgitation/stenosis  Minimal to none  None; continued observation  
Grade  2 Moderate: 
regurgitation/stenosis 
with intermediate values  Symptomsa: 
Shortness of breath on 
exertion or at rest; 
palpi[INVESTIGATOR_332]; syncope; 
anginal or pericarditic 
chest pain; fatigue or 
weakness  
 
Signs:  
Pulmonary arterial 
pressure >40mm Hg and 
rise of >10mmHg; 
pulmonary edema; 
peripheral edema or 
ascites; atrial fibrillation 
or malignant arrhythmia; 
hypotension  For a Grade  2/moderate severity, a 
decision to discontinue is based on 
severity of clinical si gns/symptoms; 
if accompanied with moderate to 
severe signs/symptoms this results 
in subject discontinuation.  
Grade 3  Severe: 
regurgitation/stenosis in 
the extreme range, often 
accompanied by [CONTACT_190218] 
(eg, pulmonary 
congestion)  Discontinuation of subject.  
For a Grade [ADDRESS_1172599] 
should be discontinued regardless of 
accompanying clinical symptoms.  
Grade increase by 
2 levels  Increasing from:  
Grade  0 to 2 or  
Grade  1 to 3  Rapid onset of above 
signs/symptoms  A jump of 2 grades to 
Grade  2/mod erate accompanied with 
moderate to severe signs/symptoms 
results in subject discontinuation.  
A jump of 2 grades to 
Grade  3/severe (with/without 
symptoms) will result in subject 
discontinuation.  
a [LOCATION_001] Heart Association Classification of symptoms; for other echocardiogram measurements, see the 
Echocardiogram Manual.  
Echocardiograms will be obtained every 3 months and will be repeated sooner if new or 
worsening abnormalities are present (detail ed below). Echocardiograms will be examined at the 
site by [CONTACT_843813] a cardiologist. When local reads 
warrant, central reads will be  expedited. An expedited review of an echocardiogram should be 
performed if the following conditions are met: (1) a Grade  2 finding of moderate severity, 
accompanied by [CONTACT_843814]/symptoms; (2) a Grade 3 finding of severe severity 
(with or wi thout accompanying symptoms; or (3) an increase (or jump) in 2 grades (0 to 2 or 1 to 
3) between echocardiograms. When any of these findings are observed, the Investigator/site 
should initiate an expedited review from the central reader.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172600] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 48 of 152 Subjects with Grad e 0 or 1 (absent or mild symptoms) will not undergo any additional 
procedures, other than continued monitoring for any symptomatic clinical events (as listed in 
Table  6-1). 
Subjects with an echocardiogram showing a Grade  2 finding (moderate regurgitation/stenosis) 
will undergo a repeat echocardiogram within 1 month (unscheduled visit) to confirm the finding. 
For a Grade  2 echocardiogram of moderate severity, a decision to discontinue will be based on 
the severity of clinical signs/symptoms; if accompanied with moderate to severe signs/symptoms 
this would result in subject discontinuation. Investigators may contact [CONTACT_843815]’s clinical signs/symptoms.  
Subjects with an echocardiogram showing a Grade 3 finding (severe regurgitation/stenosis) will 
undergo a repeat echocardiogram within 2 weeks (unscheduled visit) to confirm the finding. For 
a Grade  [ADDRESS_1172601] should be discontinued from the 
study regardless of accompanying clinical signs/symptoms and should begin discontinuation of 
the IMP.  
Any subject that shows an increase in 2 grades levels (Grade  0 to 2 or Grade  1 to 3) will undergo 
a repeat echocardiogram within 2 weeks (unscheduled visit) to confirm the finding. A jump of 
2 grades to Grade  2 (moderate) accompanied with moderate to severe symptoms will result in 
subject discontinuation. Investigators may contact [CONTACT_843816]’s clinical signs/symptoms. If the clinical symptoms are mild, the subject is not 
required to discontinue. However, a jump of 2 grades, to Grade 3 (severe), will result in subject 
discontinuation with/wit hout and signs/symptoms.  
Regulatory authorities will be notified of any subject who is discontinued due to an abnormal 
echocardiogram.  
7 STUDY TREATMENTS  
7.1 Description of investigational medicinal products  
Padsevonil will be supplied by [CONTACT_658257] 25mg, 100mg, and  200mg film -coated tablets of different 
sizes and appearance (ie, shape and color). Placebo will be provided as tablets of matching size 
and aspect to PSL tablets allowing a double -blind packaging.  
7.2 Treatments to be administered  
All IMP will be administered  in a double -blind manner.  
All subjects will be instructed to take 5 or 6 tablets containing either PSL or placebo bid, 
approximately 12h apart. The IMP should be dosed within 30  minutes after food when 
practically feasible.  
Subjects will be allocated to 1  of the following 5  treatment arms using the IRT system at the 
Randomization Visit (Visit  2): 
 Padsevonil 100mg/day (or 50mg bid)  
 Padsevonil 200mg/day (or 100mg bid)  
 Padsevonil 400mg/day (or 200mg bid)  
 Padsevonil 800mg/day (or 400mg bid)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172602] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 49 of 152  Placebo  
7.2.1  Titration Period  
Titration to PSL maintenance doses will occur over the course of 3 weeks as presented in 
Table  7-1. 
Table  7-1: Titration Period dosing  
Dose Arm  Dose in mg per intake (morning -evening) during titration  
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
Week  Week  1 Week  2 Week  3 
PSL 800mg/day  
50-50 100-100 150-150 200-200 300-300a 
PSL 400mg/day  200-200 
PSL 200mg/day  100-100 
PSL 100mg/day  50-50 
Placebo  1-1 
PSL=padsevonil  
a On Day 22, the target dose will be administered.  
A variation of ±1 day is allowed for each period of 3 or 4 days and a variation of ±3  days by 
[CONTACT_843817], but the overall Titration Period variance in length should not exceed 
±[ADDRESS_1172603] 2 days prior to start of maintenance (Visit  4). The UCB Study Physician or delegate 
should be consulted prior to use of the fallback option and the date as well as the reason for 
fallback will be recorded in the source documents and in the eCRF. The dosing during the 
fallback option is presented in Table  7-2. 
Fallback may be managed via an unscheduled visit. Fallback IMP packs will be allocated via the 
IRT system.  
Table  7-2: Dosing during fallback option  
Dose arm  Fallback (mg/day)  
PSL 800mg/day  PSL 600mg/day  
PSL 400mg/day  PSL 300mg/day  
PSL 200mg/day  PSL 150mg/day  
PSL 100mg/day  PSL 50mg/day  
Placebo  Placebo  
PSL=padsevonil  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172604] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 50 of 152 After fallback, the dose will be kept stable for the duration of the Maintenance Period. Further 
titration is not allowed.  
7.2.2  Taper Period  
The Taper Period, in case of withdrawal or completion of the study, will comprise 3  weeks as 
presented in Table  7-3. A faster or slower tap er schedule than the suggested 3  weeks may be 
implemented if medically necessary, as per the Investigator’s medical judgment. During the 
Taper Period, the dose of PSL must always be administered as bid morning and evening doses, 
approximately 12 hours apar t. Concomitant AED dosages should be kept stable throughout the 
entire study including the Taper Period.  
Subjects should be monitored during the Taper Period for withdrawal symptoms, including 
behavioral changes, withdrawal -related AEs or rebound seizures as well as the severity of the 
CIWA -B withdrawal scores. Withdrawal symptoms may require medical treatment for 
management of severe withdrawal symptoms. Additional AEDs (excluding prohibited 
medications) may be added and/or changes to dose regimens of conc omitant AEDs are permitted 
if medically necessary as per Investigator's medical judgement to manage rebound seizures.  
Table  7-3: Taper Period dosing  
Dose Arm  Dose in mg per intake (morning -evening) during tapera 
Week  Week  16 Week  17 Week  18 
PSL 800mg/day  
300-300 200-200 
150-150 100-100 50-50 PSL 600mg/day  
PSL 400mg/day  200-200 
PSL 300mg/day  150-150 
100-100 
50-50 PSL 200mg/day  100-100 
PSL 150mg/day  75-75 
PSL 100mg/day  50-50 
PSL 50mg/day  25-25 
Placebo  1-1 
PSL=padsevonil  
a Taper Period for subjects who choose an early discontinuation may occur before Week 16.  
Note: Taper steps may vary in length by ±[ADDRESS_1172605] to reach the single -entry dose into the OLE study (PSL 400mg/day) 
as presented in Table  7-4. During the Conversion Period, the dose of IMP must always be 
administered as bid morning and evening doses, approximately [ADDRESS_1172606] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 51 of 152 Table  7-4: Conversion Period dosing  
Dose Arm  Dose per day (morning -evening) during conversion  
Week:  Week  16 Week  17 Week  18 
PSL 800mg/day  
300-300 200-200 
PSL 600mg/day  
PSL 400mg/day  
200-200 
PSL 300mg/day  
PSL 200mg/day  
100-100 150-150 200-200 
PSL 150mg/day  
PSL 100mg/day  
50-50 100-100 150-150 PSL 50mg/day  
Placebo  
OLE= -open -label extension; PSL=padsevonil  
After completion of Week 18, the dose will be 200 -200, the entry dose in the OLE study, EP0093.  
Note: Dose adjustments steps may vary in length by ±3 days per week while overall Conversion Period length 
should not change by [CONTACT_726] 1 week.  
7.3 Packaging  
Padsevonil tablets are manufactured, packaged, and labeled according to Good Manufacturing 
Practice (GMP) guidelines and applicable laws or regulations.  
The IMP will be provided in blister -packed treatment cards, each providing 3, 4, or 7  days’ 
treatment of active or placebo (plus some reserve tablets in case of unexpected event).  
7.4 Labeling  
Clinical drug supplies will be labeled in accordance with the current International Council on 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and Good Ma nufacturing 
Practice and will include any locally required statements. If necessary, labels will be translated 
into the local language.  
7.5 Handling and storage requirements  
The Investigator (or designee) is responsible for the safe and proper storage of IMP a t the site. 
Investigational medicinal product stored by [CONTACT_58951] a secured area with 
limited access according to the storage conditions mentioned on the label.  
Appropriate storage conditions must be ensured either by [CONTACT_843818] e temperature (eg, room, 
refrigeration unit) or by [CONTACT_37142] a temperature log in accordance with local requirements 
on a weekly basis, including the capture of minimum and maximum temperatures reached over 
the time interval.  
In case an out -of-range t emperature is noted, it must be immediately reported as per instruction 
contained in the IMP Handling Manual.  
The Investigator (or designee) will instruct the subject to store the IMP following the instructions 
on the label.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172607], damaged (due to breakage or wastage), not used, partially use d, disposed of at the 
study site, or returned to the Sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to review.  
The Investigator ( or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.  
The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
site to an appropriate pharmaci st/designee.  
The Investigator must ensure that the IMP is used only in accordance with the protocol.  
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers) or partially used, unused, damaged, and exp ired IMP must be reconciled and either 
destroyed at site according to local laws, regulations, and UCB SOPs or returned to UCB (or 
designee). Investigational medicinal product intended for the study cannot be used for any other 
purpose than that described in this protocol.  
7.[ADDRESS_1172608] compliance  
At each visit after IMP is dispensed and at the end of the Taper/Conversion Period, subjects must 
return all unused IMP and empty IMP containers. Drug accountability must be done in the 
subject ’s presence in order to obtain explanations regarding discrepancies in compliance with the 
dosing regimen. Drug accountability must be recorded on the Drug Accountability form.  
If a subject is found to be persistently noncompliant (defined as less than 75%  or more than 
125% compliant with the dosage schedule), the Sponsor, in conjunction with the Investigator, 
will make a decision as to whether the subject should be withdrawn from the study.  
Timely completion of the subject diary is essential for evaluation  of safety and efficacy. A 
caregiver is allowed to help the subject with the completion of the subject diary. Subject diary 
completion will be reviewed at each visit.  
7.8 Concomitant medications/treatments  
7.8.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  
All subjects should continue to take their Baseline AED regimen (1 to 3 AEDs) unchanged over 
the whole study period. During the Taper Period, the Investigator is allowed to adjust AED 
dosing and/or add additional AED(s), only if medically necess ary, based on his/her medical 
judgement.  
 Drugs with possible CNS effects are allowed if at a stable dose from at least 1  month before 
Visit  1 and during the whole study period.  
 Drugs with no CNS effects, and which are not strong CYP enzyme inducers/inhibitors or 
sensitive CYP2C19 substrates, are allowed. In cases of uncertainty the Study Physician (or 
designee) should be contact[CONTACT_843819][INVESTIGATOR_843753] a medical emergency.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172609] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 53 of 152  Vigabatrin, retigab ine, and felbamate are allowed and count as add -on AEDs  
 if taken for more than 2, 4, and 1 years, respectively, and  
 if requirements mentioned in the Exclusion Criteria ( Section  6.2) were met.  
7.8.2  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])  
The following concomitant medications are prohibited during the study:  
 GABA -A-ergic drugs including agonists (ie, barbiturates) or receptor -positive a llosteric 
modulators (ie, BZDs or non -BZDs like zolpi[INVESTIGATOR_6730]) taken >2  times per week. Regular intake 
of benzodiazepi[INVESTIGATOR_843754]. However, PRN intake of GABA -A drugs <3 times per week is all owed, ie, for 
emergencies.  
 Strong CYP3A4 inhibitors/inducers  
 AEDs including carbamazepi[INVESTIGATOR_050], phenytoin, phenobarbital, primidone  
 Non-AED strong CYP3A4 enzyme inducers/inhibitors (ie, prescription drugs, 
nonprescription drugs, medical cannabis, cannabidiol , dietary [eg, grapefruit or passion 
fruit]. For more details refer to Table  3-2 and Table  3-3 in FDA Drug Development 
Resources, Drug development and drug interactions: Table  of substrates, inhibitor and 
inducers.  
 Strong CYP2C19 sensitive substrates/inhib itors/inducers including S -mephenytoin, 
omeprazole, fluconazole, fluoxetine, fluvoxamine, ticlopi[INVESTIGATOR_5325], rifampin, ritonavir ( for more 
details refer to Table  3-1, Table  3-2, and Table  3-3 in FDA Drug Development Resources, 
Drug development and drug interacti ons: Table  of substrates, inhibitor and inducers).  
7.8.3  Rescue medication  
Benzodiazepi[INVESTIGATOR_1651] (as a rescue medication) are allowed for up to two doses within 7  days.  
Each BZD intake for “as needed” must be listed individually in the eCRF, either on the 
concomitant AED medication page or on the concomitant non -AED medication page, according 
to the indication.  
7.9 Blinding  
This is a study with a double -blind study during all study periods (ie, Titration Period, Treatment 
Period, and Taper/Conversion Period). At the start of the Titration Period, subjects will be 
randomized to 1 of the 5 -treatment arms in a 1:1:1:1:1 ratio (random permuted blocks).  
Randomization will be stratified by [CONTACT_843802]2A proteins (LEV or 
brivaracetam) and region (North A merica, Europe, and Asia) at the time of randomization.  
7.9.1  Procedures for maintaining and breaking the treatment blind  
[IP_ADDRESS]  Maintenance of study treatment blind  
All subject treatment details will be allocated and maintained by [CONTACT_82550]. Details of the 
IRT sy stem will be addressed in a separate randomization schedule specification document.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172610] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 54 of 152 [IP_ADDRESS]  Breaking the treatment blind in an emergency situation  
In the event of an emergency, it will be possible to determine to which treatment arm and dose 
the subject has been a llocated by [CONTACT_352237]. All sites will be provided with details of 
how to contact [CONTACT_58958]. The Medical Monitor or 
equivalent should be consulted prior to unblinding, whenever possible.  
The Clinical Pro ject Manager (CPM) will be informed immediately via the IRT when a code is 
broken, but will remain blinded to specific treatment information. Any unblinding of the IMP 
performed by [CONTACT_352239].  
7.10 Randomization and numbering of subjects  
An IRT will be used for assigning eligible subjects to a treatment regimen (as applicable) based 
on a predetermined production randomization and/or packaging schedule provided by [CONTACT_843820]. The IRT will generate individual assignments for subject kits of IMP, as appropriate, 
according to the visit schedule.  
To enroll a subject (Visit  1), the Investigator or designee will contact [CONTACT_843821] b e enrolled. Each subject will receive a 5 -digit number assigned at 
Screening Visit (Visit  1) that serves as the subject identifier throughout the study. The subject 
number will be required in all communication between the Investigator or designee and the I RT 
regarding a particular subject. Subject numbers and kit numbers will be tracked via the IRT.  
To randomize a subject (Visit  2), the Investigator or designee will contact [CONTACT_843822]. The IRT will a llocate kit numbers to the subject 
based on the subject number during the course of the study. The randomization number must be 
incorporated into the eCRF.  
[ADDRESS_1172611] the time of the visits to 
maintain the overall timeframe of the study or study periods.  
8.1 Baseline Period (4  weeks)  
8.1.1  Visit  1 (Week  -4) 
The following procedures will be performed:  
 Obtain written informed  consent. For subjects willing to participate in the genotypi[INVESTIGATOR_21389], signature [CONTACT_843875]. For subjects/caregivers 
willing to perform the entry and exit personal outcomes interview/survey, signature [CONTACT_843876]. 
 Call IRT to obtain subject number  
 Dispense Subject Trial Card  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172612] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 55 of 152  Collect demographic data, including habits and lifestyle  
 Verify Inclusion and Exclusion criteria (laboratory parameters/ECG/echocardiogram/MRI 
results may not be available at the visit but  assessments need to be performed and evaluated 
before Visit  2) 
 Collect general medical and procedure history  
 Collect epi[INVESTIGATOR_806015], diagnosis, surgery, and seizure history  
 Brain MRI to be performed before Visit  [ADDRESS_1172613] 10  years 
and/or no report is available. If a scan was performed within the last [ADDRESS_1172614] scan, a new scan should be obtained.  
 Obtain the report of past video -EEG  by [CONTACT_843823]  2 
 Collect AED history  
 Obtain Baseline C -SSRS data  
 Measure vital signs (pulse rate, systolic BP, diastolic BP, and respi[INVESTIGATOR_697]), in supi[INVESTIGATOR_268672] [ADDRESS_1172615]  
 Measure body  weight and height  
 Perform full physical examination (refer to Section  11.3.4  for details)  
 Perform full neurological examination (refer to Section  11.3.5  for details)  
 Perform [ADDRESS_1172616] it assessed by [CONTACT_843824]  2 
 Perform echocardiogram and have it assessed by [INVESTIGATOR_24309] r eader before Visit  2 
 Collect blood and urine samples for clinical laboratory analyses  
 Collect blood sample for concomitant AED assay  
 Perform serum pregnancy test (for all female subjects)  
 Record concomitant medication (AEDs and non -AEDs) and procedures  
 Record AEs since the signature [CONTACT_28513]  
 Record health -related outcomes and HRU (refer to Section  9.5 for details)  
 Dispense diary and provide instructions on proper completion  
 Perform entry personal outcomes interview/survey (can be done at Visit  2 instead) if the 
subject consented to take part in this activity  
 Provide appointment to next visit in [ADDRESS_1172617] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 56 of 152 8.2 Treatment Period (16 weeks ±1 week from Visit  2) 
8.2.1  Titration Period (3 weeks ±1 week from Visit  2) 
[IP_ADDRESS]  Visit  2, Baseline (Day 1, 4 to 5 weeks after Visit  1) 
The following procedures will be performed:  
 Obtain C -SSRS data since the last visit  
 Obtain HADS data  
 Obtain SSG data  
 Obtain QOLIE -31-P data  
 Measure vital signs (pulse rate, systolic BP, diastolic BP, and respi[INVESTIGATOR_697]), in supi[INVESTIGATOR_268672] [ADDRESS_1172618]  
 Measure body weight  
 Perform brief physical examination (refer to Section  11.3.4  for details)  
 Perform brief neurological examination (refer to Section  11.3.5  for det ails) 
 Perform Psychiatric and Mental Status assessment  
 Obtain 12 -lead ECG  
 Collect blood and urine samples for clinical laboratory analyses  
 Collect blood sample for concomitant AED assay  
 Obtain blood samples for DNA (to be performed only in adults – mentall y impaired subjects 
will be excluded – having given specific consent for it, where ethically accepted and 
authorized by [CONTACT_17513]), RNA, protein, lipi[INVESTIGATOR_805], and metabolites  
 Perform urine pregnancy test (female subjects of childbearing potential only ) 
 Seizure evaluation (count and type) from subject’s daily record card  
 Record concomitant medication (AEDs and non -AEDs) and procedures  
 Record AEs  
 Verify Inclusion and Exclusion criteria (including results of laboratory samples, ECG, MRI, 
echocardiogram  results performed since Visit  1). In the event one of these results is not 
available, the visit may be delayed by 1 week.  
 Verify withdrawal criteria  
 Randomize subjects using IRT  
 Record health -related outcomes and HRU (refer to Section  9.5 for details), with the 
exception of socio -professional status  
 Perform entry personal outcomes interview (if not done at Visit  1) if the subject consented to 
take par t in this activity  
 Dispense IMP using IRT  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172619] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 57 of 152 [IP_ADDRESS]  Telephone call (Week  1 ±3 days)  
Subject will be interviewed to check his/her health condition including, seizure experience, 
concomitant medications and procedures, and AEs.  
[IP_ADDRESS]  Visit  3 (Week  2 ±1 week)  
The following procedures will be performed:  
 Verification of withdrawal criteria  
 Obtain C -SSRS data since the last visit  
 Vital signs measurement (pulse rate, systolic BP, diastolic BP, and respi[INVESTIGATOR_697]), in supi[INVESTIGATOR_268672] [ADDRESS_1172620]  
 Perform Psychiatric and Mental Status assessment  
 Obtain 12 -lead ECG  
 Obtain blood sample for random PSL levels at any time between IMP intakes and record 
accurately the time of last IMP intake and time of the sample  
 Perform urine pregnancy test (female subjects of childbearing  potential only)  
 Seizure evaluation (count and type) from subject’s daily record card  
 Record concomitant medication (AEDs and non -AEDs) and procedures  
 Record AEs  
 Record health -related outcomes and HRU (refer to Section  9.5 for details), with the 
exception of socio -professional status  
 Dispense IMP using IRT  
 Check IMP accountability  
8.2.2  Stabilization Period (1  week ±3 days)  
[IP_ADDRESS]  Telephone call (Week  3) 
Subject will be interviewed to check his/her health condition including seizure experience, 
concomitant medications and procedures, and AEs. Subject should be informed to call the 
Investigator within 3 days in case of AEs (in order to eventually consider fallback) . 
8.2.3  Maintenance Period (12 weeks ± 1 week)  
[IP_ADDRESS]  Visit  4 (Week  4 ±1 week)  
The following procedures will be performed:  
 Verification of withdrawal criteria  
 Obtain C -SSRS data since the last visit  
 Obtain HADS data  
 Obtain SSG data  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172621] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 58 of 152  Obtain QOLIE -31-P data  
 Measure vital  signs (pulse rate, systolic BP blood, diastolic BP, and respi[INVESTIGATOR_697]), in 
supi[INVESTIGATOR_55848] [ADDRESS_1172622]  
 Measure body weight  
 Perform brief physical examination (refer to Section  11.3.4  for details)  
 Perform brief neurological examination (refer to Section  11.3.5  for details)  
 Perform Psychiatric and Mental Status assessment  
 Obtain 12 -lead ECG  
 Collect blood and urine samples for clinical laboratory analyses  
 Obtain MITRA blood samples immediately befor e IMP intake (maximum 15  minutes before 
IMP intake) and then 3 times after (between 30 minutes and 3 hours after IMP intake) taken 
at least 30  minutes apart  
 Obtain blood samples for RNA, protein, lipi[INVESTIGATOR_805], and metabolites  
 Perform urine pregnancy test (femal e subjects of childbearing potential only)  
 Seizure evaluation (count and type) from subject’s daily record card  
 Record concomitant medication (AEDs and non -AEDs) and procedures  
 Record AEs  
 Record health -related outcomes and HRU (refer to Section  9.5 for details), with the 
exception of socio -professional status  
 Dispense IMP using IRT  
 Check IMP accountability  
[IP_ADDRESS]  Visit  5 (Week  8 ±1 week) and Visit  6 (Week  12 ±1 week)  
The following procedures will be performed:  
 Verification of withdrawal criteria  
 Obtain C -SSRS data since the last visit  
 Measure vital signs (pulse rate, systolic BP blood, diastolic BP, and respi[INVESTIGATOR_697]), in 
supi[INVESTIGATOR_55848] [ADDRESS_1172623]  
 Measure body weight  
 Perform Psychiatric and Mental Status assessment  
 Obtain 12 -lead ECG (only at Visit  5/Week  8)  
 Obtain echocardiogram (only at Visit  6/Week  12) for subjects continuing into the OLE  
 Collect blood and urine samples for clinical laboratory analyses (only at Visit  6/Week  12) 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172624] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 59 of 152  Collect blood samples for concomitant AED assay (only at Visit  6/Week 12) including an 
additional MITRA sample if the AED sample is not within ±5 minutes of 1 of the scheduled 
PSL PK samples  
 Obtain MITRA blood sample for random PSL levels at any time between IMP intakes and 
record accurately the time of last IMP intake and time of the sample.  
 Perform urine pregnancy test (female subjects of childbearing potential only)  
 Seizure evaluation (count and type) from subject’s daily record card  
 Record concomitant medication (AEDs and non -AEDs) and procedures  
 Record AEs  
 Record health -related outcomes and HRU (refer to Section  9.5 for details), with the 
exception of socio -professional status  
 Dispense IMP using IRT  
 Check IMP accountability  
 Perform exit personal outcomes interview/survey (at Visit  6, or can be done at Visit  7) if the 
subject/caregiver consented to ta ke part in this activity  
[IP_ADDRESS]  Visit  7 (Week  16±1 week for End -of-Treatment or earlier for 
Early  Discontinuation Visit)  
The following procedures will be performed:  
 Verification of withdrawal criteria  
 Obtain C -SSRS data since the last visit  
 Obtain HADS data  
 Obtai n SSG data  
 Obtain QOLIE -31-P data  
 Obtain CIWA -B data (only for subjects tapering)  
 Measure vital signs (pulse rate, systolic BP blood, diastolic BP, and respi[INVESTIGATOR_697]), in 
supi[INVESTIGATOR_55848] [ADDRESS_1172625]  
 Measure body weight  
 Perform full physic al examination (refer to Section  11.3.4  for details)  
 Perform full neurological examination (refer to Section  11.3.5  for details)  
 Perform Psychiatric and Mental Status assessment  
 Obtain 12 -lead ECG  
 Collect blood and urine samples for clinical laboratory analyses  
 Collect blood sample for concomitant AED assay including an additional MITRA sample if 
the AED sample is not within ±[ADDRESS_1172626] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 60 of 152  Obtain MITRA blood samples immediately before IMP intake (maximum 15 minutes before 
IMP intake) and then 3 times afte r (between 30 minutes and 3 hours after IMP intake) taken 
at least 30 minutes apart.  
 Obtain blood samples for RNA, protein, lipi[INVESTIGATOR_805], and metabolites  
 Perform urine pregnancy test (for female subjects of childbearing potential discontinuing the 
study only) a nd serum pregnancy test (for female subjects continuing in the OLE study)  
 Seizure evaluation (count and type) from subject’s daily record card  
 Record concomitant medication (AEDs and non -AEDs) and procedures  
 Record AEs  
 Record health -related outcomes and HRU (refer to Section  9.5 for details)  
 Dispense IMP using IRT  
 Check IMP accountability  
 Perform exit personal outc omes interview/survey (if not done at Visit  6) if the 
subject/caregiver consented to take part in this activity  
8.3 Taper/Conversion Period (3 to 4 weeks ±1 week)  
8.3.1  Telephone call (after 1 or 2 weeks in tapering/converting, as needed)  
Subject will be interviewed  to check his/her health condition including seizure experience, 
concomitant medications and procedures, and AEs.  
8.3.2  Visit  8 (Week  19/20 ±1 week, end of Taper/Conversion)  
The following procedures will be performed:  
 Obtain C -SSRS data since the last visit  
 Obta in CIWA -B data only for subjects tapering  
 Measure vital signs (pulse rate, systolic BP, diastolic BP, and respi[INVESTIGATOR_697]), in supi[INVESTIGATOR_268672] [ADDRESS_1172627]  
 Measure body weight  
 Perform full physical examination (refer to Section  11.3.4  for details)  
 Perform full neurological examination (refer to Section  11.3.5  for details)  
 Perform Psychiatric and Mental Status assessment  
 Obtain 12 -lead ECG  
 Collect blood and urine samples for clinical laboratory analyses  
 Perform urine pregnancy test (female subjects of childbearing potential only)  
 Seizure evaluation (count and type) from subject’s daily record card  
 Record concomitant medication (AEDs and non -AEDs) and procedures  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172628] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 61 of 152  Record AEs  
 Record health -related outcomes and HRU (refer to Section  9.5 for details), with the 
exception of socio -professional status  
 Check IMP accountability  
 Study termination (only for subjects enrolling in OLE study, EP0093)  
8.4 Safety Follow -Up (Visit  9 [Week [ADDRESS_1172629] IMP intake])  
The following procedures will be performed:  
 Obtain C -SSRS data since the last visit  
 Obtain HADS data  
 Obtain SSG data  
 Obtain QOLIE -31-P data  
 Obtain CIWA -B data  
 Measure vital signs (pulse  rate, systolic BP, diastolic BP, and respi[INVESTIGATOR_697]), in supi[INVESTIGATOR_268672] [ADDRESS_1172630]  
 Measure body weight  
 Perform brief physical examination (refer to Section  11.3.4  for details)  
 Perform brief neurological examination (refer to Section  11.3.5  for details)  
 Perform Psychiatric and Ment al Status assessment  
 Obtain 12 -lead ECG  
 Obtain echocardiogram for subjects discontinuing the study (except if performed at Visit  6) 
 Collect blood and urine samples for clinical laboratory analyses  
 Perform urine pregnancy test (female subjects of childbeari ng potential only)  
 Seizure evaluation (count and type) from subject’s daily record card  
 Record concomitant medication (AEDs and non -AEDs) and procedures  
 Record AEs  
 Record health -related outcomes and HRU (refer to Section  9.5 for details), with the 
exception of socio -professional status  
 End of diary recording  
 Study termination, only for subjects who do not enter EP0093  
An additional follow -up echocardiogram will be performed at 6 months (±1  month) after the last 
IMP intake only for discontinued subjects exposed to IMP for more than [ADDRESS_1172631] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 62 of 152 8.5 Unscheduled Visit/Telephone call  
At any time, the subject may have an unscheduled study visit/telephone call if the Investigator 
and/or the subject deem it necessary. An unscheduled visit may be conducted due to safety or 
efficacy reasons and appropriate assessments will be conducted in relation to the reason for the 
visit. All information, including reason for visit/telephone call, any information on AEs, etc, 
should be collected in the source documents and recorded in the appropriate section of the eCRF.  
8.6 Open -label extension study (EP0093)  
Subjects from this study, have the  option of taking PSL during an OLE study, EP0093. The 
decision to enter the OLE study must be made by [CONTACT_843825]/or the subject’s caregiver. This decision must take into account the potential risks of 
long-term e xposure to PSL and the potential benefit and risks of other treatment options 
available.  
9 ASSESSMENT OF EFFICA CY 
The efficacy variables are described in detail in Section  4.1. 
9.1 Seizure frequency  
At the Screening Visit (Visit  1), seizure count will be based on Investigator assessment of 
subjects’ reports during the 8 weeks prior to the Screening Visit (Visit  1). The subject should 
report on average a mini mum of [ADDRESS_1172632] should experience a minimum of 4 spontaneous and 
observable focal -onset (based on Investigator assessment of subject report). During the study, 
subjects will keep diaries to record daily seizure activity from the Screening Visit (Visit  1) until 
the end of study participation. Subjects should be reminded t o bring their diaries with them to 
each clinic visit.  
The written information will be discussed with the subjects at each visit in order to ensure 
completeness and accuracy. As a result of the discussion, the Investigator will assess and confirm 
the seizur es according to the ILAE codes and record the seizure types and frequency in the 
eCRF/diary; he/she will also confirm the presence of AEs if applicable.  
Subjects should record all types of seizures that occur in their diary and be educated to complete 
their diary entries after each seizure or at least once a day (eg, when taking evening tablets). A 
caregiver can assist in completing the diary if necessary. If the subject does not complete diary 
entry as per instruction, this may result in subject discontinu ation from the study at any time by 
[CONTACT_29539] ( Section  6.3). 
The following seizure information will be recorded in the diary:  
 Seizure type  
 Seizure frequency  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172633] 4 weeks and/or since the Baseline (in 
EP0091) . The subjects should describe all types of seizures when answering the questions.  
The SSG will be completed according to the tabular schedule of study procedures, Table  5-1. At 
the very beginning of the visit, the SSG will be provided to all subjects. It is preferred that the 
subject complete the questionnaire on his/her own; however, assistance may be provided by 
[CONTACT_843826]. Once completed, the subject will return the 
completed questionnaire to the Investigator or designee, who will verify that all questions have 
been answered. Further details about the SSG will be covered in the Study Manual.  
9.[ADDRESS_1172634] functioning and health -related quality of life.  
The QOLIE -31-P (Cramer  et al, 2003) is an adaptation of the original QOLIE -31 instrument 
(Cramer  et al, 1998) that includes 31 items grouped into 7 multi item  subscales (Seizure Worry 
[5 items], Overall Quality of Life [2 items], Emotional Well -being [5 items], Energy/Fatigue 
[4 items], Cognitive Functioning [6 items], Medication Effects [3 items], and Daily 
Activities/Social Functioning [5 items]) and 1 health  status item.  
In addition to the 31 items of the QOLIE -31, the QOLIE -31-P contains 7 items assessing the 
degree of “distress” associated with the topic of each subscale (ie, distress items) and 1  item 
asking about the relative importance of each subscale t opic (ie, prioritization item).  
The QOLIE -31-P will be completed according to the tabular schedule of study procedures in 
Table  5-1. At the very beginn ing of the visit, the QOLIE -31-P will be provided to all subjects. It 
is preferred that the subject will be asked to complete the questionnaire on his/her own; however, 
assistance may be provided by [CONTACT_843827]. Once completed, t he subject 
will return the completed questionnaire to the Investigator or designee, who will verify that all 
questions have been answered. Further details about the QOLIE -31-P will be covered in the 
Study Manual.  
9.4 Hospi[INVESTIGATOR_843755] H ADS was chosen for its well -established psychometric properties both in general 
population and more recently in patients with epi[INVESTIGATOR_002] (Lin and Pakpour, 2017; 
Wiglusz  et al, 2016; de  Oliviera  et al, 2014). The HADS scores for anxiety and for depression 
range from 0 -21 with higher scores indicating worse state. A score below 8 is considered to be 
normal (Zigmond  and Snaith,  1983). It is preferred that the subject complete the questionnaire on 
his/her own; however, assistance may be provided by [CONTACT_843828].  
9.5 Health -related outcomes and healthcare resource utilization  
Health -related outcomes and HRU will be collected in the eCRF and/or diary during the study 
according to the tabular schedule of study procedures, Table  5-1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172635] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 64 of 152 These assessments will include:  
 Socio -professional status  
 Healthcare provider consultations not foreseen by [CONTACT_843829] 
(general practitioner, specialist physician, nurse), the site of care (office -private, 
office -hospi[INVESTIGATOR_307], home, emergency room) and the reason leading to the consultation  
 Concurrent medical procedures  
 Concomitant medications  
 Hospi[INVESTIGATOR_843756], the admission ward 
transfers and length of stay  
 Caregiver support needs  
 Number of school or working days lost due to the medical condition of the subjects  
9.[ADDRESS_1172636] approximately 30 to 
45 minutes (before treatment starts [Visit  1 or Visit  2]), and in another 30 -minute qualitative 
interview at th e end of the study (Visit  6 or Visit  7). For subjects who choose to participate, the 
interviews will be conducted by a study nurse/study personnel using a semi -structured interview 
guide and will be audio -recorded.  
The aim of the entry interview is to gat her insight into how epi[INVESTIGATOR_843757]’s life 
(beyond seizure count) across various domains (social, relationship, independence, work, 
psychological,  etc), what is most restrictive for the subject, and to understand what would 
constitute a meani ngful change when trying a new therapy and the trade -off across various 
domains.  
The aim of the exit interview is to evaluate if and which aspects (domains) of the subject’s life is 
impacted by [CONTACT_843830] w hat is considered a 
meaningful change by [CONTACT_423]. If a subject leaves the study prematurely, he/she will also be 
invited to participate in an exit interview at this/her final visit (Visit  7). 
9.[ADDRESS_1172637]'s participation in 
the main study. The caregiver optional survey aims to gather their perspective on the impact of 
epi[INVESTIGATOR_843758]’s life and expectations of meaningful change. The caregiver survey will 
also a ssess the impact of caring for a subject with epi[INVESTIGATOR_843759]/her own life across various 
domains (social, relationship, independence, work, etc). This survey will allow UCB to gather 
differences in perspective and expectations from the subject and his/her  caregiver’s point of 
view.  
Refer to Section  13.4.[ADDRESS_1172638] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 65 of 152 10 ASSESSMENT OF PHARMA COKINETIC AND 
EXPLORATORY VARIABLES  
Blood samples for PK and exploratory variables will be obtained at the scheduled time points 
presented in Table  5-1 and details of the collec tion, storage, preparation, and shippi[INVESTIGATOR_843760] a Laboratory Manual.  
10.1 Pharmacokinetic variables  
The PK variables for parent PSL and metabolites are described in detail in Section  4.3.1 . 
Calculations of PK parameters will be made using population PK modeling. Additionally, 
plasma concentration data for concomitantly administered AEDs will be evaluated by [CONTACT_843831]. For details of PK analys es, refer to Section  13.4.2. 
Detailed information on the collection, storage, preparation, and shippi[INVESTIGATOR_843761] a Laboratory Manual.  
10.1.1  PK sampling procedures  
[IP_ADDRESS]  PSL assay  
Subjects are requested to provide blood samples for measurement of PSL and metabolite levels 
whenever possible using the VAMS technology on the MITRA microsampling device. Site 
personnel are requested to discuss the  importance of PK samples to measure blood levels of PSL 
and inform the selection of the safety and efficacy of the doses examined in this study. Site 
personnel should educate subjects regarding the importance of accurately recording the time of 
the last I MP intake and their concomitant AEDs.  
On Visits 3, 5, and 6, site personnel should obtain blood samples for random PSL levels at any 
time between IMP intakes and record accurately the time of last IMP intake and time of the 
sample.  
On Visits 4 and 7, blood  samples for measurement of sparse PK profiles should be collected as 
follows: immediately before IMP intake (maximum 15 minutes before intake) and then 3  times 
after (between 30  minutes and 3  hours after IMP intake) taken at least 30  minutes apart.  
All sa mples may be taken either at home or at the site when possible or partly at home and partly 
at the site.  
[IP_ADDRESS]  Concomitant AED and exploratory pharmacokinetic evaluation  
Subjects are requested to provide blood samples for concomitant AED assay (to evaluate any 
DDI with PSL) at Visits 1, 2, 6, and 7.  
On Visits 6 and 7, if the time point of sampling is not within 5 minutes of 1 of the scheduled 
PSL PK collections, then an additional MITRA sample will be taken alongside (±5  minutes) the 
concomitant AED sample. This process will only be done at some pre -selected sites for a limited 
number of subjects.  
Assay of PSL metabolites may be included in the concomitant AED assay screen.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172639] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 66 of 152 10.2 Exploratory variables  
Detailed information on the collection, storage, preparation, and shi ppi[INVESTIGATOR_843762], 
RNA, lipi[INVESTIGATOR_1800], and proteomics analysis will be presented in a Laboratory Manual.  
Results for the exploratory parameters obtained from DNA, RNA, lipi[INVESTIGATOR_1800], and proteomics 
analysis, and serum biomarkers will be described in a sep arate report.  
11 ASSESSMENT OF SAFETY  
11.1 Adverse events  
11.1.1  Definitions  
[IP_ADDRESS]  Adverse events  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product that does not necessarily have a causal relationship  with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory or echocardiogram finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not r elated to the medicinal 
(investigational) product.  
In order to ensure complete safety data collection, all AEs occurring during the study (ie,  after 
the signing of the ICF until the SFU Visit), including any pretreatment and posttreatment periods 
required by [CONTACT_760], must be reported in the eCRF even if no IMP was taken but specific 
study procedures were conducted. This includes all AEs not present prior to the initial visit and 
all AEs that recurred or worsened after the initial visit.  
Signs or sympto ms of the condition/disease for which the IMP is being studied (ie,  seizures) 
should be recorded as AEs only if their nature changes considerably or their frequency or 
intensity increases in a clinically significant manner as compared with the clinical pro file known 
to the Investigator from the subject’s history or the Baseline Period.  
[IP_ADDRESS]  Serious adverse events  
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following crite ria: 
 Death  
 Life-threatening  
(Life -threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)  
 Significant or persistent disability/incapacity  
 Congenital anomaly/birth defect (including that occurring in a fe tus) 
 Important medical event that, based upon appropriate medical judgment, may jeopardize the 
subject and may require medical or surgical intervention to prevent 1 of the other outcomes 
listed in the definition of serious  
(Important medical events may inc lude, but are not limited to, potential Hy’s Law [see 
Section  [IP_ADDRESS].2  ], allergic bronchospasm requiring intensive treatment in an emergency 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172640] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 67 of 152 room  or at home, blood dyscrasias that do not result in inpatient hospi[INVESTIGATOR_059], or the 
development of drug dependency or drug abuse)  
 Initial inpatient hospi[INVESTIGATOR_318]  
(A patient admitted to a hospi[INVESTIGATOR_307], even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospi[INVESTIGATOR_059]. An emergency room visit that results in 
admission to the hospi[INVESTIGATOR_58912]. 
However, emergency room visits that do not result in admission to the hospi[INVESTIGATOR_352178], instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg,  life-threatening adverse experience, important medical event].  
Hospi[INVESTIGATOR_843763] [eg,  preplanned 
surgery or elective surgery for a pre -existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not qualify for reporting. For example, if  a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospi[INVESTIGATOR_18256], 
since there is no AE upon which to assess the serious criteria. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the event would need to 
be determined.)  
[IP_ADDRESS].[ADDRESS_1172641] does not change the Investigator’s obligation to report all SAEs (including Anticipated 
SAEs) as de tailed in Section  [IP_ADDRESS] . 
Table  11‒1: Anticipated SAEs for  the epi[INVESTIGATOR_843764], poisoning, and procedural complication  Fall a, fracture  a, injury  a 
Nervous system disorders  Cluster seizures, con vulsion, incontinence  a 
memory impairment, status epi[INVESTIGATOR_843765], puerperium, and perinatal disorders  Abortion spontaneous  
Psychiatric disorders  Abnormal behavior, acute psychosis, anxiety, 
cognitive disorder, confusional state, psychotic 
behavior, sleep disorder and disturbances  
Reproductive system and breast disorders  Impotence, menstrual disorder  
MedDRA=Medical Dictionary for Regulatory Activities, Version 19.1; SAE=serious adverse event; SOC=System 
Organ Class  
 a Event are anticipated when occurring in the context of seizure, but not cl assified in MedDRA primary SOC.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172642] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 68 of 152 [IP_ADDRESS].[ADDRESS_1172643]  
Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total bilirubin in 
the absence of ≥2xULN ALP, with no alternative explanation for the biochemical abnormality, 
must A LWAYS be reported to UCB as an AE of special interest (ie, without waiting for any 
additional etiologic investigations to have been concluded). Follow -up information should then 
be reported if an alternative etiology is identified during investigation and monitoring of the 
subject.  
11.1.[ADDRESS_1172644] AEs. For example:  
“Did you notice anything unusual about your health (since your last visit)?”  
In addition, the Investigator should review any self -assessment procedures (eg, diary cards) 
employed in the study.  
[IP_ADDRESS]  Description of adverse events  
When recording an AE, the Investigator should use  the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents should be consistent. Any discrepancies between the subject’s own words 
on his/her own records (eg, dia ry card) and the corresponding medical terminology should be 
clarified in the source documentation.  
Details for completion of the Adverse Event eCRF (including judgment of relationship to IMP) 
are described in the eCRF Completion Guidelines.  
[IP_ADDRESS]  Rule for repet ition of an adverse event  
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:  
 The outcome date of the first AE that is not related to the natural course of the disease being 
the same as the start date of the r epeated AE, and the outcome of “worsening”  
 The AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one  
[IP_ADDRESS]  Additional procedures for reporting serious adverse events  
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information by 
[CONTACT_779] (see contact [CONTACT_58977]). The Investigator must forward to UCB (or its re presentative) a duly 
completed “Investigator SAE Report Form for Development Drug” (SAE report form) provided 
by [CONTACT_18338], even if the data are incomplete, or if it is obvious that more data will be needed in order 
to draw any conclusions. Information recorded on this form will be entered into the global safety 
database.  
An Investigator SAE report form will be provided to the Investigator. The Investigator SAE 
Report form must be completed in English.  
It is important for the Investigator, when completing the SAE  report form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172645] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 69 of 152 from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE r equires reporting to the regulatory authorities in an 
expedited manner.  
Additional information (eg,  autopsy or laboratory reports) received by [CONTACT_18399] [ADDRESS_1172646] and report to UCB (or its representative) any 
SAEs (even if the I nvestigator is certain that they are in no way associated with the IMP), up to 
[ADDRESS_1172647] (ie, until the 6 -month follow -up 
echocardiogram), and to also inform participating subjects of the need to inform the Investigator  
of any SAE within this period. Serious AEs that the Investigator thinks may be associated with 
the IMP must be reported to UCB regardless of the time between the event and the end of the 
study.  
Upon receipt of the SAE report form, UCB will perform an asse ssment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the IB.  
11.1.[ADDRESS_1172648], follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. The follow up will usually be continued for [ADDRESS_1172649] has discontinued his/her IMP.  
Informatio n on SAEs obtained after final clinical database lock will be captured through the 
Patient Safety (PS) database without limitation of time.  
11.1.[ADDRESS_1172650] immediately notify UCB’s PS department by [CONTACT_352255] (for contact [CONTACT_580672]). The subject should be withdrawn from the study as so on as 
pregnancy is known (by [CONTACT_162916]), and the following should be completed:  
 The subject should return for an EDV.  
 The subject should immediately stop the intake of the IMP or be tapered as instructed at the 
EDV.  
 An SFU Visit should  be scheduled [ADDRESS_1172651] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 70 of 152 The pregnancy will be documented on the Pregnancy Rep ort and Outcome form provided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome form in which the Investigator has to 
report on the health of the mother a nd of the child. Every reasonable attempt should be made to 
follow the health of the child for [ADDRESS_1172652] to follow up and/or refuses to give information, written documentation of 
attempts to contact [CONTACT_58970]. 
UCB’s PS department is the primary contact [CONTACT_843832], eventual birth, and follow up.  
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
Investigator or designee is asked to contact [CONTACT_843833]/IEC and should 
be available in the Investigator site file. In case of questions about the consent process, the 
Investigator may contact [CONTACT_58973]/contract research organization (CRO) contract monitor for the 
study. The Investigator will complete the Pregnancy Report and Outcome form and send it to 
UCB’s PS department (for contact [CONTACT_417714]) only after the partner has agreed that additional information can be captured and has 
provided the signed Partner Pregnancy Consent form. UCB’s PS department is also the primary 
contact [CONTACT_58974], eventual birth, 
and follow up.  
A pregnancy becomes a SAE in the following circumstances: miscarriage, abortion (elective or 
spontaneous), unintended pregnancy after hormonal contraceptive failure (if the hormonal 
contraceptive was correctly used), ectopic pregnancy, fetal demise, or any congenital 
anomaly/birth defect of the baby. Those SAEs must be additionally reported using the 
Investigator SAE Report form.  
11.1.[ADDRESS_1172653] should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the CRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion  protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.  
11.1.[ADDRESS_1172654]  
Excessive dosing (beyond that prescribed in the protocol and including overdose) s hould be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of t aking the excess medicine itself 
is an AE or SAE (eg,  suicide attempt).  
11.1.[ADDRESS_1172655] as early as possible any 
safety concern(s) related to the IMP so that Investigators, clini cal study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172656] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 71 of 152 The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations  in collaboration with the PS representative.  
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg,  AEs, 
vital signs, laboratory, ECG, and echo cardiogram results) for which data will be periodically 
reviewed during the course of the study.  
In addition, an unblinded independent DMC will oversee safety data approximately every 6 
months (subject to DMC recommendation) during the course of the study during which the 
safety of PSL will be assessed. The safety variables and the decision rules to be used will be 
specified in the DMC charter. This analysis will inform any decisions regarding changes in study 
conduct and/or study termination. The precise m embership, scope, and responsibilities of the 
DMC are described in the DMC charter.  
11.[ADDRESS_1172657] methods at a central laboratory. The 
central laboratory will provide the Investigator with dedicated, standardized sampling equipment 
(labels, needles, tubes), and a study -specific Laboratory Manual, which will explain how to use 
the equipment and how to ship the samples to the central laboratory. The laboratory parameters 
measured are presented  in Table  11‒2. 
The total blood volume drawn for clinical laboratory assessments per subject will be a maximum 
of 31.6mL by [CONTACT_141420], which includes 2mL  for hematology, 5mL for blood chemistry, 5mL 
and 20µL for AED and PSL plasma level (including back -up samples for AED assay), 6mL for 
genetic substudy, 13.5mL for genomic assessments,  and 80µL for PK measurements.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172658] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 72 of 152 Table  11‒2: Laboratory measurements  
Hematology  Chemistry  Urinalysis  
Basophils  ALP  Glucose  
Eosinophils  ALT  pH 
Hematocrit  AST  RBC  
Hemoglobin  Bilirubin  Total protein  
Lymphocytes  BUN or urea  WBC  
MCH  Calcium  Microscopy (WBC, RBC, casts, 
crystals, bacteria) a 
MCHC  Chloride  Other  
MCV  Creatinine  FSHb 
Monocytes  Glucose   
Neutrophils  HDL   
Platelet count  LDH   
RBC count  LDL   
WBC count  Magnesium   
 Potassium   
 Sodium   
 Total bilirubin   
 Total cholesterol   
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; HDL=high density lipoprotein; FSH=follicle stimulating hormone; LDH=lactate dehydrogenase; 
LDL=low density lipoprotein; MCH=mean corpuscular hemoglobin; MCHC=mean corpuscular hemoglobin 
concentration; MCV=mean corpuscular volume; RBC=red blood cell; WBC=white blood cell  
a Microscopy will be p erformed only in case of abnormalities.  
b Only applicable to postmenopausal women  
Where applicable (ie, for women of childbearing potential), a serum pregnancy test (β -human 
chorionic gonadotropin levels) will be conducted at Visits [ADDRESS_1172659] be abstinent or be of nonchildbearing potential, 
defined as being postmenopausal (for at least 2 years before the Screening Visit [Visit 1]), 
verified by [CONTACT_843834] >40mIU/mL at the Screening Visit (Visit 1), 
or permanently sterilized (eg, bilateral tubal occlusion, hysterectomy, bilateral s alpi[INVESTIGATOR_1656]), 
or congenitally sterile.  
Sampling time and last AED intake should be recorded in the eCRF.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172660] be reported as an AE and reported to the study site and Sponsor within 24  hours of l earning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section  [IP_ADDRESS].2  ), and, if applicable, also reported as 
an SAE (see  Section  [IP_ADDRESS] ). 
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table  11-3 (specific tests dependent on laboratory results a nd corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section  [IP_ADDRESS] ). The local 
hepatologist is the e xpert usually consulted by [CONTACT_58979]. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section  [IP_ADDRESS] ). 
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and Sponsor.  
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat r esult.  
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapi[INVESTIGATOR_58916] a conservative approa ch must be taken if the results from the 
2 laboratory tests are significantly different. Data from the local and central laboratory are to be 
recorded on the applicable eCRF pages.  
When IMP is discontinued, all concomitant medications and herbal supplement s that are not 
medically necessary should also be discontinued. In these cases, the Investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known to  be hepatotoxic to a suitable 
alternative.  
When IMP is stopped due to PDILI (as described in Section  6.3.1 ), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. If a 
subsequent alternative diagnosis fully explains the hepatic findings , and the requirements 
provided in Section  [IP_ADDRESS].[ADDRESS_1172661] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 74 of 152 Table  11-3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptoms a of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN  ≥2xULN b
 NA Hepatology consult. c 
Medical Monitor must 
be notified within 
24 hours (eg,  by 
[CONTACT_58980]) and 
subject discussed with 
Medical Monitor 
ASAP.  Immediate, 
permanent IMP 
discontinuation.  
 Essential: Must 
have repeat liver 
chemistry val ues 
and additional 
testing completed 
ASAP (see 
Section  [IP_ADDRESS] ); 
recommended to 
occur at the site 
with HCP.  Monitoring of liver chemistry 
values at least twice per week 
until values normalize, 
stabilize, or return to within 
Baseline values. d ≥8xULN  NA NA 
≥3xULN  NA Yes Immediate, 
temporary or 
permanent, IMP 
discontinuation.  
≥3xULN 
(and ≥2x 
Baseline) 
and 
<5xULN  <2xULN  No Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.  Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section  [IP_ADDRESS] ). Not required unless 
otherwise 
medically indicated 
(at discretion of 
Investigator).  
≥5xULN 
(and ≥2x 
Baseline)  <2xULN  No Discussion with 
Medical Monitor 
required.  Immediate, 
permanent IMP 
discontinuation.  Essential: Every 
attempt must be 
made to have repeat 
liver chemistry 
values and 
additional testing 
completed within 
48 hours at the site 
with HCP (see 
Section  [IP_ADDRESS] ). Monitoring of liver chemistry 
values at least twice per week 
until values normalize, 
stabilize, or return to within 
Baseline values. d 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible;  AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug -induced liver injury; ULN=upper limit of normal  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172662] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 75 of 152  a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms in clude eosinophilia (>5%), 
rash, and fever (without clear alternative cause).  
 b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi cal Monitor.  
. c Details provided in Section  [IP_ADDRESS] . The local hepatologist is the expert usually consulted by [CONTACT_58981]. This would us ually be a hepatologist, but may be a gastroenterologist.  
 d Unless an alternative monitoring schedule is agreed by [CONTACT_843835]. Determination of stabilizati on is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB Study Physician, as needed.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172663] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 76 of 152 [IP_ADDRESS]  Consultation with Medical Monitor and local hepatologist  
Potential drug -induced liver injury events require n otification of the Medical Monitor within 
24 hours (eg, by [CONTACT_58980]), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepato logist. The 
local hepatologist is the expert usually consulted by [CONTACT_58979]. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discus sion should be followed by a full 
hepatology assessment (see Section  [IP_ADDRESS] ) and SAE report (if applicable).  
[IP_ADDRESS]  Immediate action: determination of IMP  discontinuation  
All PDILI events require immediate action, testing, and monitoring.  
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_843836]) to 
immediate and permanent discontinuation (see Section  6.3.1  and Table  11-3 for details).  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The Investigator should also consider dose 
reduction for med ically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.  
[IP_ADDRESS].1  IMP restart/rechallenge (if applicable)  
Rechallenge with a substance potentially causing drug -induced liver injury is dangerous, may be 
fatal, and must not occur.  
Subjects who are immediately discontinued from IMP due to having met certain criteria for 
PDILI (as described in Section  6.3.1  and Table  11-3), but for whom an alternative diagnosis is 
confirmed, can rarely restart IMP. Rechallenge w ith IMP can occur only if ALL of the following 
requirements are met:  
 The results of additional testing and monitoring described in Section  [IP_ADDRESS]  and 
Section  [IP_ADDRESS]  confirm a nondrug -related cause for the abnormal hepatic labora tory 
parameters and any associated symptoms (ie, a subsequent alternative diagnosis fully 
explains the hepatic findings).  
 No alternative treatment options are available to the subject.  
 The subject has shown clear therapeutic benefit from the IMP.  
 Subject’ s ALT or AST elevations do not exceed ≥3xULN.  
 Subject’s total bilirubin is <1.5xULN.  
 Subject has no signs or symptoms of hypersensitivity.  
 The rechallenge is approved by [CONTACT_352298], DMC, and a hepatologist. 
The hepatologist must be exte rnal to UCB but may be a member of the DMC. It is 
recommended that the hepatologist be a local hepatology expert or the hepatologist treating 
the subject.  
 Subject agrees to the Investigator -recommended monitoring plan.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172664] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 77 of 152 [IP_ADDRESS]  Testing: identification/exclusion of alternative etiology  
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by [CONTACT_67603]  11‒4 (laboratory measurements) and Table  11‒5 (additional information). Results of the 
laboratory measurements and information collected are to be submitted to the Sponsor on the 
corresponding eCRF. If the medical history of the subject indicates a requirement for other 
assessments not included below, these additional assessments should be compl eted and 
submitted, as applicable.  
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.  
The following measurements are to be assessed:  
Table  11‒4: PDILI laboratory measurements  
Virology -
related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain heterophile 
antibody or monospot testing)  
Immunology  Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Eosinophil count  
Urinalysis  Toxicology screen  
Chemistry  Amylase  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin  
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation  
Additional  Prothrombin time/INR a
 
Serum pregnancy test  
PK sample  
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb=hepatitis B core antibody; 
HBsAg=hepatitis  B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; LDH=lactate 
dehydrogenase; PDILI=potential drug -induced liver injury; PK=pharmacokinetic; RNA=ribonucleic acid; 
ULN=upper limit of  normal  
 a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172665] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 78 of 152 The following additional information is to be collected:  
Table  11‒5: PDILI information to be collected  
New or updated information  
Concomitant prescription and over -the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.  
Pertinent medical history, including the following:  
 History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis, or other “fatty liver 
disease”)  
 Adverse reactions to drugs  
 Allergies  
 Relevant family history or inheritable disorders (eg,  Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)  
 Recent travel  
 Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by [CONTACT_5071], should 
not be used as an explanation for significant AST and/or ALT elevations.)  
The appea rance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)  
Recent clinically significant hypotension or hy poxemia with compromised cardiopulmonary function  
Alcohol and illicit drug use  
Results of liver imaging or liver biopsy, if done  
Results of any specialist or hepatology consult, if done  
Any postmortem/pathology reports  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug -induced liver injury  
[IP_ADDRESS]  Follow -up evaluation  
Potential drug -induced liver injury events require follow -up monitoring as described in  
Table  11-3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to Baseline. Determination of stabilization is at the discretion of the Investigator in 
consultation with the hepatologist ( as applicable) and UCB responsible physician, as needed.  
11.[ADDRESS_1172666] 
5 minutes. ECG will be recorded at a speed of 25mm/s and with a calibration of 1cm/mV.  
The Investigator should review all ECG recordings and, determine if there are an y abnormalities 
that are considered clinically significant for a particular subject.  ECGs will also be sent to a 
specified central reader for review as detailed in the ECG Manual . The following ECG 
parameters will be recorded: heart rate, PR -interval, QRS -duration, QT -interval, QTcB or QTcF, 
and Investigator’s conclusion on ECG profile.  
11.3.[ADDRESS_1172667] an echocardiogram performed 30  days (±1  week) after 
the last IMP intake except fo r subjects who have had an echocardiogram performed at Visit  6. 
For subjects discontinuing with more than [ADDRESS_1172668] not entering 
the OLE, an echocardiogram will be performed at 6 months (±1 month) after the last IMP intake.  
Two-dimensional Doppler echocardiography will include the following 
measurements/observations:  
 Epi[INVESTIGATOR_843766]  
 Functional measurements  
 Diastology (ie, Mitral Valve E/A waves, etc.)  
 Systolic (ie, Left Ventricular Ejection Fraction, LVEF, etc. ) 
 Epi[INVESTIGATOR_843767]  
 Amount of effusion  
 Pericardial thickness  
 Valvular Abnormalities  
 Measurement of valve regurgitation/stenosis  
 Measurement of left atrial volume  
Subjects whose echocardiograms are not interpretable by [CONTACT_843837], eg, due to technical 
difficulties or position of the heart, will not be randomized. In the event echocardiograms are not 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172669] for 
review as detailed in the Echocardiogram Manual.  
A repeat echocardiogram will be performed for subjects with a new finding or Grade  2 
(moderate severity) or Grade  3 (severe severity) (see Section  6.3). 
Subjects with an echocardiogram showing an abnormality meeting the withdrawal criteria (see 
Section  6.3) are to be discontinued from the study.  An expedited review of an echocardiogram 
(at the central reader) should be requested if the following conditions are met: (1) a Grade  2 
finding of moderate severity, accompanied by [CONTACT_843814]/symptoms; (2) a Grade  3 
finding of severe severit y (with or without accompanying symptoms); or (3) an increase (or 
jump) in 2  grades (0  to 2 or 1 to 3) between echocardiograms. When any of these conditions are 
met, the Investigator/site should initiate an expedited review from the central reader (see 
Echocardiography Manual ). Regulatory authorities will be notified of any discontinuations.  
In case of discontinuation, the subject should return for an EDV and SFU Visit (Visit  9) 
including an echocardiogram within approximately [ADDRESS_1172670] to follow -up. 
11.3.4  Physical examination  
Physical examinations will be performed at the scheduled time points presented in Table  5-1. 
Findings that are considered clinically significant change s since the physical examination at the 
Baseline Visit will be recorded as AEs.  
A full physical examination will include, cardiac and respi[INVESTIGATOR_843768]: general appearance; ear, nose, and throat;  eyes; hair and 
skin; respi[INVESTIGATOR_696]; cardiovascular; gastrointestinal; musculoskeletal; hepatic; neurological; and 
mental status.  
A brief physical examination will include, review of the following body systems: general 
appearance including mental status; ski n; respi[INVESTIGATOR_696]; cardiovascular; gastrointestinal; and 
hepatic.  
In addition, height will be measured at the Screening Visit (Visit  1) with the subject not wearing 
shoes and the outcome will be rounded to the nearest 0.5cm. Body weight will be measured at 
the scheduled time points presented in Table  5-1. Body weight will be measured with the subject 
in underwear or light clothing and without wearing shoes; the outcome will be rounded to the 
nearest 0.1kg.  
11.3.[ADDRESS_1172671] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 81 of 152 A full neurological examination will include, ge neral assessment; evaluation of reflexes, muscle 
strength and coordination and cerebellar function; evaluation of cranial nerves, motor system 
(general – muscle strength and tone); and sensations in upper/lower extremities.  
A brief neurological examination  will include, general assessment and the evaluation of reflexes, 
muscle strength and coordination and cerebellar function.  
11.3.6  Assessment of suicidality  
The C -SSRS will be completed at the scheduled time points presented in Table  5-1.  
Suicidality will be assessed by [CONTACT_207276] C -SSRS (Posner  et al, 2011). 
This scale will be used for screening as well as to assess suicidal ideation and  behavior that may 
occur during the study. The Investigator’s decision about patient continuation in the study or 
patient withdrawal from the study if the patient has a positive response to the CSSRS Question  4, 
should be based on the benefit/risk balance for continuation or discontinuation of study treatment 
in view of the individual patient circumstances, condition, attained efficacy, causality, alternative 
risk management options, etc.  
If an additional visit (or unscheduled visit) is conducted due to saf ety or efficacy reasons, a 
C-SSRS assessment will be performed with the subject during the visit. If an additional visit 
(or unscheduled visit) is conducted for reasons other than safety or efficacy concerns 
(eg, replacement of lost medication, repeated co llection of a laboratory specimen due to 
collection or analysis issues), a C -SSRS will not be required at these visits.  
Details of the case must be documented by [CONTACT_737] (PI [INVESTIGATOR_843769], not site 
staff conducting the CSSRS) and prov ided to UCB via the SAE reporting process.  
11.3.7  Psychiatric and Mental Status  
The psychiatric and mental status of participating subjects will be closely monitored. Assessment 
of specific domains of psychiatric and cognitive symptoms will be performed by a staf f member 
trained in the identification of psychiatric symptoms. The Psychiatric and Mental Status 
assessment will be performed at Baseline and all scheduled visits ( Table  5-1). The parameters 
that will be evaluated are orientation, attention, memory, mood, calculus, behavior, and thinking 
or feeling. These parameters will be assessed as normal or abnormal and then determined 
whether clinically significant . If present and abnormal, psychiatric symptoms, mental 
impairment, and behavioral problems will be assessed as to whether they are clinically 
significant.  
11.3.8  Withdrawal monitoring  
Any symptoms of withdrawal reactions will be monitored using the CIWA -B questi onnaire at 
the scheduled time points presented in Table  5-1. The CIWA -B questionnaire contains 
22 questions which are selected to distinguish withdrawa l symptoms from other symptoms 
(Busto  et al, 1989).  
Subjects should be monitored during the Taper Period for withdrawal symptoms, including 
withdrawal -related AEs or seizures as well as the severity of the CIWA -B withdrawal scores. 
Withdrawal symptoms may require medical treatment for management of severe withdrawal 
symptoms.  
Further details about this questionnaire will be covered in the Study Manual.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172672] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 82 of 152 12 STUDY MANAGEMENT AND  ADMINISTRATION  
12.1 Adherence to protocol  
The Investigator should not deviate from the pro tocol. In medical emergencies, the Investigator 
may use his/her medical judgment and may remove a study subject from immediate hazard 
before notifying UCB (or its representative) and the IRB/IEC in writing regarding the type of 
emergency and the course of action taken.  
After implementation of such measure, the Investigator must notify the CPM of the Sponsor 
within 24 hours and follow any local regulatory requirements.  
12.2 Monitoring  
UCB (or designee) will monitor the study to meet the Sponsor’s monitoring Stan dard Operating 
Procedures (SOPs), ICH -GCP guideline, and applicable regulatory requirements, and to ensure 
that study initiation, conduct, and closure are adequate. Monitoring of the study may be 
delegated by [CONTACT_18410] a CRO or a contract monitor.  
The Investi gator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to source 
data/documents for study -related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).  
The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
corresponding source documents (eg,  hospi[INVESTIGATOR_843770]). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities regulatio ns, and Investigator’s obligations are being 
fulfilled, and resolve any inconsistencies in the study records.  
12.2.[ADDRESS_1172673] be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made  using some permanent form of recording (ink, typi[INVESTIGATOR_007], printing, 
optical disc). They should not be obscured by [CONTACT_18411] 
(such as removable self -stick notes).  
Source documents are original records in which raw data are f irst recorded. These may include 
hospi[INVESTIGATOR_307]/clinic/general practitioner records, charts, diaries, x -rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, or quality of life 
questionnaires, for example.  Source documents should be kept in a secure, limited access area.  
If they are not included in the clinical dossier/hospi[INVESTIGATOR_122230], the following data may 
be written directly in the eCRF and will therefore be considered as source data  
 Demogr aphic data  
 Childbearing potential and birth control  
 Vital signs  
 Body weight and height  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172674] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 83 of 152  Physical and neurological examinations  
 Healthcare provider consultation not foreseen by [CONTACT_760]  
 Caregiver use  
 Socio -professional data  
 Number of school/working days  lost 
Diaries will be transcribed into the eCRF and will be considered as source documentation.  
Source documents that are computer generated and stored electronically must be printed for 
review by [CONTACT_2037] (eg,  ECG reports). Once printed, these copi[INVESTIGATOR_014] s hould be signed and dated 
by [CONTACT_843838] a permanent part of the subject’s source documents. The 
Investigator will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to  ensure all data are consistent.  
Electronic data records, such as echocardiogram records, must be saved and stored as instructed 
by [CONTACT_18338] (or designee).  
For subjects randomized to investigational product(s), the minimum requirements for source 
documents used  in clinical studies are that they should contain the identity of the subject and 
study -related identifiers (such as randomization/treatment number, or similar), they should 
mention the subject’s participation in the study and identification of that study (study title or 
number), they should record the obtaining of consent (date of consent), the exposure to 
investigational product, the subject’s medical history, the concomitant medication treatments and 
dates (including contraceptive treatment), AEs and SAE s, and the date of the visits. The source 
documents should provide evidence that inclusion/exclusion criteria have been met.  
12.2.[ADDRESS_1172675] to being accurate, complete, and verifiable from 
source documents (eg,  subject files and reports, recordings from automated instruments, tracings 
[ECG], x -ray films, laboratory notes). All data reported on the eCRF sh ould be supported by 
[CONTACT_18412], unless otherwise specified in Section  12.2.[ADDRESS_1172676] be accompanied by a reason for the 
change.  
Corrections made after the Investigator’s review an d approval (by [CONTACT_3553] a 
password/electronic signature) will be reapproved by [CONTACT_737].  
The Investigator should maintain a list of personnel authorized to enter data into the electronic 
eCRF.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172677] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 84 of 152 Detailed instructions will be provided in the eCRF Comp letion Guidelines.  
12.3.2  Database entry and reconciliation  
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in ad dition to manual review to check for discrepancies and to ensure consistency of 
the data. The data are entered into the eCRFs once and are subsequently verified.  
An electronic audit trail system will be maintained within the CDMS to track all data changes in 
the database once the data have been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed.  
12.3.[ADDRESS_1172678] Screening and Enrollment log/Subject Identification Code list  
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
Log. 
The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.  
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.  
12.[ADDRESS_1172679] to quality or quantity.  
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
Investigators/institutions and the regulatory authority(ies) of the termination or suspension and 
the reason(s) for the term ination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by [CONTACT_12942]/institution, as specified by [CONTACT_843839](s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.  
12.[ADDRESS_1172680] elapsed since the 
formal  discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period; however, if required by [CONTACT_8146](s) or by [CONTACT_58993] (CPMP/ICH/135/95, 2002  [Section  4.9.5 ]). The Investiga tor will contact 
[CONTACT_843840]. 
UCB   [ADDRESS_1172681] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 85 of 152 loss or destruction of any study records. The Investigator will also notify UCB should he/she 
relocate or move the study -related files to a l ocation other than that specified in the Sponsor’s 
Study Master File.  
12.[ADDRESS_1172682] been protected, that enrolled subjects (ie,  signing consent and undergoing 
study procedures) are appropriate for the study, and that all data rele vant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the 
protocol, investigational site, and IRB/IEC SOPs, ICH -GCP, and applicable regulatory 
requirements.  
The Investigator will provide direct acc ess to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the Investigator will immediately 
inform UCB (or designee).  
12.7 Good Clinical Practice  
Noncompliance with the protocol, ICH -GCP, or local regu latory requirements by [CONTACT_3786], institution, institution staff, or designees of the Sponsor will lead to prompt action 
by [CONTACT_18418]. Continued noncompliance may result in the termination of the 
site’s involvement in the study.  
13 STATI STICS  
A description of the planned statistical methods is provided in the sections that follow. Full 
details will be provided in the Statistical Analysis Plan (SAP).  
13.1 Definition of analysis sets  
13.1.1  Enrolled Set  
The Enrolled Set consists of all subjects who hav e given informed consent.  
13.1.2  Randomized Set  
The Randomized Set (RS) consists of all subjects randomized into the study.  
13.1.3  Safety Set  
The Safety Set (SS) consists of all subjects who were administered at least 1 dose or a partial 
dose of IMP. The SS will be used  to summarize and analyze all safety variables. In case of 
dosing administration error, summaries and analyses using the SS will be conducted according to 
actual treatment received.  
13.1.4  Full Analysis Set  
The Full Analysis Set (FAS) consists of all subjects in the RS who were administered at least 
[ADDRESS_1172683] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 86 of 152 dose, summaries and anal yses using the FAS will be conducted according to randomized 
treatment. The FAS will be the primary analysis set for all efficacy summaries and analyses.  
13.1.5  Per-Protocol Set  
The Per -Protocol Set (PPS) is a subset of the FAS, consisting of those subjects who had at least 
[ADDRESS_1172684]-Baseline efficacy measurement and who had no major protocol deviation affecting the 
primary efficacy variable, as confirmed during a pre -analysis data review meeting, conducted 
prior to study unblinding.  
13.1.6  Pharmacokinetic/Pharmacodynamic Set 
The Pharmacokinetic/Pharmacodynamic Set is defined as a subset of the FAS, consisting of 
those subjects who provide at least [ADDRESS_1172685]-Baseline PD 
variable.  
13.2 General statistical considerations  
Summary statistics wil l be provided for all efficacy, safety, and Baseline/demographic variables. 
Summary statistics will consist of frequency tables for categorical variables. For continuous 
variables, descriptive statistics (number of available observations, mean, median, sta ndard 
deviation [SD], standard error, minimum, maximum, 25th and 75th percentiles) will be 
tabulated. Unless otherwise mentioned, statistical hypothesis tests will be 2 -sided at the 5% 
significance level.  
13.[ADDRESS_1172686] and is defined as the number of seizures standardized to a 28 -day period. It is 
computed as t he number of seizures recorded over a period, divided by [CONTACT_843841], multiplied by  28. Observable focal -onset seizures refers to Type IA1, IB, and IC 
seizures (according to the ILAE  Classification of Epi[INVESTIGATOR_207161],  1981 ). Focal -onset seizures 
include all Type I seizures. Seizure free status and seizure -free days include all (Type  I, II, and 
III) seizure types.  
13.3.1  Analysis of the primary efficacy variable  
[IP_ADDRESS]  Analysis of the primary efficacy variable for the US FDA, PMDA, and 
other  regulatory authorities not specified in Section [IP_ADDRESS]  
Pairwise comparisons of 400mg, 200mg and 100mg dose groups versus placebo will be carried 
out using the analysis model below. Type 1 error will be controlled by [CONTACT_843842] -up 
procedure within SAS® Proc Multtest. If all the results of the pairwise comparisons are 
statistically significant then the 50mg dose group will be compared to placebo.  
For the US FDA, PMDA, and other regulatory authorities not specified in Section  [IP_ADDRESS] , the 
primary efficacy variable is the change in log -transformed observable focal -onset seizure 
frequency from Baseline, over the [ADDRESS_1172687]-Basel ine (maintenance) seizure frequency will be transformed with the natural logarithm, 
specifically ln(x+1), where x represents the 28 -day seizure frequency. The transformed seizure 
frequency data will be analyzed using analysis of covariance (ANCOVA) with tr eatment group 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172688] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 87 of 152 as the main factor, Baseline log -adjusted seizure frequency as a continuous covariate, and 
Baseline SV2A use and Region as categorical factors. Pairwise contrasts will be constructed to 
compute estimated effects of each dose from placebo.  
All pairwise analyses of the primary efficacy variable will be repeated on the PPS.  
[IP_ADDRESS]  Analysis of the primary efficacy variable for EMA and regulatory 
authorities who reference EMA  
For EMA and regulatory authorities who reference EMA, the primary efficacy varia ble will be 
the 75% responder rate in observable focal -onset seizures during the Maintenance Period and 
will be analyzed using logistic regression with factors for treatment group, Baseline seizure 
frequency, Region, and Baseline SV2A use. If there are iss ues with convergence, Baseline SV2A 
use will be dropped.  
The same methodology carried out in Section  [IP_ADDRESS]  will be applied to the pairwise analy ses. 
13.3.2  Secondary efficacy analysis  
[IP_ADDRESS]  Secondary efficacy variables for the US FDA, PMDA, and other 
regulatory authorities not specified in Section [IP_ADDRESS]  
The 75% responder rate in observable focal -onset seizures during the Maintenance Period is a 
secondary eff icacy variable for the FDA. It is the primary efficacy variable for EMA. The 
analyses are described in Section  [IP_ADDRESS] .  
In addition, the 50% respon der rate in observable focal -onset seizures during the Maintenance 
Period will be analyzed using logistic regression as described in Section  [IP_ADDRESS] . Analyses of 
the percent change in seizure reduction endpoints will be performed using the Wilcoxon -Mann -
Whitney test. The Hodges -Lehmann nonparametric estimator will be used to estimate the median 
percent reduction in seizures between groups and its corr esponding 95%  confidence interval (CI) 
will be provided.  
[IP_ADDRESS]  Secondary efficacy variables for EMA and regulatory authorities who 
reference EMA  
The change in log -transformed observable focal -onset seizure frequency from Baseline, over the 
12-week Maintenance Pe riod is a secondary efficacy variable for EMA. It is the primary efficacy 
variable for the FDA. The analyses are described in Section  [IP_ADDRESS] .  
In addition, the 50% responder rate in observable focal -onset seizures during the Maintenance 
Period will be analyzed using logistic regression as described in Section  [IP_ADDRESS] .   
Analyses of the percent change in seizure reduction endpoints will be performed using the 
Wilcoxon -Mann -Whitney test. The Hodges -Lehmann nonparametric estimator will be used to 
estimate the median percent reduction in seizures b etween groups and its corresponding 95%  CI 
will be provided.  
13.3.3  Other efficacy analyses  
All other analyses of the 75% and 50% responder rate endpoints will be analyzed using the same 
logistic regression model as specified in Section  [IP_ADDRESS] . Analyses of 90% responder rate and 
seizure freedom will use the same methodology. In addition to observable focal -onset seizures 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172689] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 88 of 152 and focal -onset seizures, analyses will also be carried out on all seizures (seizure -free status and 
seizure -free days) during the 12 -week Maintenance Period and the 16 -week Treatment Period.  
All other analyses o f the change from Baseline in seizure frequency will be analyzed using the 
ANCOVA model on the log -transformed data, as specified in Section  [IP_ADDRESS] . 
The time  to return to baseline 28-day observable focal -onset seizure count during the 12 -week 
Maintenance Period  will be analyzed using Kaplan -Meier methodology. Additional details of the 
analysis will be captured in the SAP.  
The QOLIE -31-P and SSG assessments will be summarized using descriptive statistics by [CONTACT_843843].  
13.4 Planned safety and other analyses  
13.4.1  Safety analyses  
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA®). Ad verse events will be summarized by [CONTACT_184768]. The incidence of SAEs, AEs leading to premature discontinuation or dose tapering, and 
related AEs, and the incidence of AEs by [CONTACT_11196], will also be summarized.  
Labo ratory values, ECG data (ventricular rate, PR, QTcB, QTcF, and QRS) and arrhythmias, 
vital signs, weight, and changes from Baseline in these measures will be summarized by [CONTACT_6278], 
visit, and treatment group. Possibly clinically significant treatment emerge nt abnormalities for 
laboratory values, vital signs, and weight will be listed and summarized by [CONTACT_843844].  
Electrocardiogram abnormalities as well as physical and neurological abnormalities will also be 
listed by [CONTACT_843845]. Quantitative safety parameters will be summarized descriptively by 
[CONTACT_432633]. Categorical safety summaries will provide the number and 
percentage of subjects within each summarized category.  
Doppler echocardiogram results at Ba seline and during and after treatment, and changes from 
Baseline, will be listed and descriptively summarized.  
All C -SSRS data obtained at Baseline and subsequent visits will be reported as a listing ordered 
by [CONTACT_3598]. Psychiatric and Mental Sta tus assessment and  CIWA -B data will also be 
included using listings.  
13.4.2  Pharmacokinetic analyses  
Blood concentrations of PSL and metabolites will be determined from blood samples obtained in 
the study, during the Titration and Maintenance Periods in order to  investigate the PK of PSL 
and metabolites . 
The PK parameters calculated include, AUC (0-τ), AUC, C max, tmax, t½, Ctrough, and C max ss. 
The PK variables will be derived from population PK modeling.  
The PK parameters of PSL and metabolites will be listed and  summarized using the following 
descriptive statistics: number of observations, geometric mean, lower and upper 95%  CI, 
geometric coefficient of variation, arithmetic mean, SD, median, and minimum and maximum 
values. Graphical outputs over time will be pro duced on the trough plasma PSL concentrations.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172690] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 89 of 152 Plasma concentration data for concomitantly administered AEDs will be assessed by [CONTACT_843846] (pre -PSL) levels.  
An exploratory comparison of PS L blood levels derived from the MITRA samples with 
conventional venous sampling may be made.  An exploratory evaluation of PSL metabolites may 
be undertaken.  
13.4.3  Entry and exit personal outcomes interview and caregiver survey  
The data from the qualitative perso nal outcomes interviews/surveys are considered exploratory, 
will be maintained separate from the clinical database, and results made available only after 
database lock of the primary study. The subject/caregiver’s interviews/surveys will be analyzed 
by a t hird party not involved in the clinical conduct of the study and will be reported outside the 
clinical study report.  
13.[ADDRESS_1172691] been verified/entered into a database and prior to database lock, a data 
evaluation mee ting will take place. The purpose of the data evaluation will be to examine all 
protocol deviations, define the PPS, and to verify the quality of the data. The data evaluation will 
also help in guiding decisions on how to manage data issues on a case -by-case basis 
(eg, withdrawals, dropouts, and protocol deviations).  
Accepted deviations from theoretical time points will be described in the appropriate documents 
and included in the Study Master File. After the data review, resolution of all issues, and 
docum entation of all decisions, the database will be locked.  
13.[ADDRESS_1172692] (LOCF) 
method will be applied to obtain a seizure frequency estimate for the Maintenance Period:  
 Subjects discontinued during the Titration and Stabilization Period: seizure frequency will be 
calculated using all available data in the Titration and Stabilization Period and carry forward 
for the Maintenance Period.  
 Subjects discontinued during the Maintenance Period: seizure frequency will be calculated 
using all available data in the Maintenance Period.  
Additional details and sensitivity analyses  for missing data will be described in the SAP.  
13.[ADDRESS_1172693] of 
members independent from UCB. Study enrollment will not be halted during DMC review o f the 
safety data. The DMC may also be asked to provide a review of final study results, as deemed 
appropriate. The detailed role, scope, composition, responsibilities, and operation of the DMC, as 
well as the identity of the DMC members will be defined in  a separate DMC Charter.  
Safety and tolerability data will be made available to the DMC at each meeting as described in 
the DMC Charter. The data will be provided in a semi -unblinded fashion (data will be visualized 
by [CONTACT_271366], but the treatm ent/dose assigned to each group will remain blinded) and 
the full unblinding can be requested by [CONTACT_13156], if appropriate. Pharmacokinetic data 
may be provided to the DMC at their request. These safety, tolerability, and PK data will be 
presented by  [CONTACT_843847]. The deliberations 
and decisions of the DMC will be formally documented.  
Ad hoc DMC meetings can be held for other reasons if deemed appropriate by [CONTACT_843848].  
In addition to ongoing review of safety data and safety signal detection within UCB, the 
occurrence of AEs of interest including cardiac and behavioral adverse events, in particular, will 
be monitored by [CONTACT_843849]. Statistical modeling may be used to provide estimates for quantification of the level of 
risk in the study based on the risk in the epi[INVESTIGATOR_843771] (see Inclusion and Exclusion Criteria in Section  6). This analysis may 
inform any decisions regarding changes in study conduct and/or study termination.  
The DMC pro cedures will ensure that the data remain blinded to the study team and 
Investigators at all times throughout the conduct of the study until the data have been unblinded. 
Only DMC members and an independent statistical group will have access to unblinded sa fety 
data emerging from the study. DMC members will also have access to unblinded efficacy data 
when required. It is understood that maintaining validity and integrity of the study is of 
paramount importance to ensure its acceptability to the Sponsor, the scientific community and 
health authorities.  
13.8 Determination of sample size  
The sample size was calculated  based on achieving 90% power to observe a statistically 
significant result for either the 400mg bid and 200mg bid or 200mg  bid and 100mg bid doses 
when compared to placebo, for a change from Baseline of the log -transformed (ln x +1) 28 -day 
adjusted seizure frequency. Multiplicity is controlled for using the Hochberg step up procedure.  
The log -reduction from Baseline in seizure frequency was ass umed to be 0.195 for placebo and 
0.492, 0.670, 0.754, and 0.780 for the 50mg bid, 100mg bid, 200mg bid, and 400mg bid doses of  
PSL, respectively . A common SD of 0.985 was assumed. These estimates are based on prior 
experience in epi[INVESTIGATOR_843772]0069 study results.  
With power of 90%, a 2 -sided Type -1 error of 5%, and all dose groups of the same size, 
[ADDRESS_1172694] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 91 of 152 Assuming a screening failure rate of approximately 20%, it is anticipated to enro ll around 
500 subjects and randomize 400 subjects in this study.  
The study is also powered to give over 80% power to observe a statistically significant result for 
the 75% response rate. For the 75% responder rate, assumptions were a 0.[ADDRESS_1172695]’s informed consent must be obtaine d and documented in accordance with local 
regulations, ICH -GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.  
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject in both oral and written form by [CONTACT_737] (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with 
the Investigator.  
Prior to participation in th e study, the ICF should be signed and personally dated by [CONTACT_423], 
or his/her legal representative, and by [CONTACT_28490] 
(Investigator or designee). The subject or his/her legal representative must receive a c opy of the 
signed and dated ICF. As part of the consent process, each subject must consent to direct access 
to his/her medical records for study -related monitoring, auditing, IRB/IEC review, and 
regulatory inspection.  
If the ICF is amended during the study , the Investigator (or the Sponsor, if applicable) must 
follow all applicable regulatory requirements pertaining to the approval of the amended ICF by 
[CONTACT_1201]/IEC and use of the amended form.  
All studies conducted at centers in the [LOCATION_002] must inclu de the use of a Health Insurance 
Portability and Accountability Act Authorization form.  
The subject may withdraw his/her consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the ICF. An eC RF must not be 
started, nor may any study specific procedure be performed for a given subject, without having 
obtained his/her written consent to participate in the study.  
14.[ADDRESS_1172696] identification cards  
Upon signing the Informed Consent and Assent form (as a pplicable), the subject or legal 
representative will be provided with a subject identification card in the language of the subject. 
The Investigator will fill in the subject identifying information and medical emergency contact 
[CONTACT_3031]. The Investigato r will instruct the subject to keep the card with him/her at all times.  
14.3 Institutional Review Boards and Independent Ethics 
Committees  
The study will be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172697] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 92 of 152 The Investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH -GCP version or applicable country -specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the Investigator/UCB will forward copi[INVESTIGATOR_18280], ICF, IB, 
Investigator’s curriculum vitae (if applicable), advertisement (if applicable), and all other 
subject -related documents to be used for the study to the IRB/IEC for its review and approval.  
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IRB/IEC f or the protocol.  
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.  
The Invest igator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by [CONTACT_313620], it may be possible for the Investigator to obtain an expedited review by [CONTACT_1201]/IEC, 
as allowed.  
As part of the IRB/IEC requirements for continuing review of approved studies, the Investigator 
will be responsible for submitting periodic p rogress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study 
completion.  
UCB ( or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be informed by [CONTACT_843850] e Sponsor, as specified 
by [CONTACT_59002]. Where applicable, 
Investigators are to provide the Sponsor (or its representative) with evidence of such IRB/IEC 
notification.  
14.[ADDRESS_1172698] privacy  
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by [CONTACT_18427].  
The Investigator agrees that representatives of UCB, its des ignee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that directly concerns this study (including, but not limited to, 
laboratory test r esult reports, ECG reports, admission/discharge summaries for hospi[INVESTIGATOR_18281] a subject’s study participation, and autopsy reports for deaths 
occurring during the study).  
14.[ADDRESS_1172699] 
be app roved by [CONTACT_18338], the IRB/IEC, and the regulatory authorities (if required), prior to being 
implemented.  
[ADDRESS_1172700] essed in the Investigator and/or CRO 
agreements, as applicable.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172701] of dichotomising continuous variables. BMJ. 
2006;332:1080.  
Azuma H, Akechi T. Effects of psychosocial functioning, depression, seizu re frequency, and 
employment on quality of life in patients with epi[INVESTIGATOR_002]. Epi[INVESTIGATOR_41744]. 2014;41C:18 -20. 
Baker GA, Jacoby A, Buck D, Stalgis C, Monnet D . Quality of life of people with epi[INVESTIGATOR_002]: a 
European study. Epi[INVESTIGATOR_8330]. 1997;38(3):353 -62. 
Beyenburg S, Stavem K, Schmidt D. Placebo -corrected efficacy of modern nonenzyme -inducing 
AEDs for refractory focal epi[INVESTIGATOR_002]: systematic review and meta -analysis. Epi[INVESTIGATOR_8330]. 
2012;53(3):512 -20. 
Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatmen t response in 
newly diagnosed epi[INVESTIGATOR_002]. Neurology. 2012;78(20):1548 -54. 
Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepi[INVESTIGATOR_188560]. 
J Clin Psychopharmacol. 1989;9(6):412 -6. 
Choi H, Hamberger MJ, Munger Clary H, Loeb R, Onchiri FM,  Baker G, et al. Seizure frequency 
and patient -centered outcome assessment in epi[INVESTIGATOR_002]. Epi[INVESTIGATOR_8330]. 2014;55(8):1205 -12. 
Chung S, Ben -Menachem E, Sperling MR, Rosenfeld W, Fountain NB, Benbadis S, et  al. 
Examining the clinical utility of lacosamide: pooled an alyses of three phase II/III clinical trials. 
CNS Drugs. 2010a;24(12):1041 -54. 
Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, Doty P; SP754 Study Group. 
Lacosamide as adjunctive therapy for partial -onset seizures: a randomized controlled trial . 
Epi[INVESTIGATOR_8330]. 2010b;51(6):[ADDRESS_1172702] Epi[INVESTIGATOR_002]. 
Proposal for revised clinical and electroencephalographic classification of epi[INVESTIGATOR_122174]. 
Epi[INVESTIGATOR_8330]. 1981;22:489 -501. 
CHMP/EWP /566/98 Rev.2/Corr. Guidance on clinical investigation of medicinal products in the 
treatment of epi[INVESTIGATOR_67552]. July 2010.  
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.  
Cramer JA, Van Hammee G, N132 Study Group. Mainten ance of improvement in health -related 
quality of life during long -term treatment with levitiracetam. Epi[INVESTIGATOR_41744].  2003;4:118 -23. 
Cramer JA, Perrine K, Devinsky O, Bryant -Comstock L, Meador K, Hermann B. Development 
and cross -cultural translations of a 3 1-item quality of life in epi[INVESTIGATOR_261424]. Epi[INVESTIGATOR_8330]. 
1998;39(1):81 -8. 
de Oliveira GN, Lessa JM, Goncalves AP, Portela EJ, Sander JW, Teixeira AL. Screening for 
depression in people with epi[INVESTIGATOR_002]: comparative study among neurological disorders depressio n 
inventory for epi[INVESTIGATOR_002] (NDDI -E), hospi[INVESTIGATOR_843773] 
(HADS -D), and Beck depression inventory (BDI). Epi[INVESTIGATOR_41744]. 2014;34:[ADDRESS_1172703] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 95 of 152 de Tisi J, Bell GS, Peacock JL, McEvoy AW, Harkness WF, Sander JW, et al. The long -term 
outcome of adult epi[INVESTIGATOR_58741], patterns of seizure remission, and relapse: a cohort study. 
Lancet. 2011;378:1388 -95. 
Devinsky O. Sudden, unexpected death in epi[INVESTIGATOR_002]. N Engl J Med. 2011;365:1801 -11. 
Elger C, Halász P, Maia J, Almeida L, Soares -da-Silva P; BIA -2093 -301 Investigators Study 
Group. Efficacy and safety of eslicarbazepi[INVESTIGATOR_843774] -onset seizures: a randomized, double -blind, placebo -controlled, parallel -group 
phase  III study. Epi[INVESTIGATOR_8330] . 2009;50(3):[ADDRESS_1172704]: Oxford University Press; 2013:Chapter 6 page 6  
Fazel S, Wolf A, Långström N, Newton CR, Lichtenstein P. Premature mortality in epi[INVESTIGATOR_843775]: a total population study. Lancet. 2013;382:1646 -54. 
Food and Drug Administration. Development Resources. Drug development and drug 
interactions: Table  of substrates, inhibitor and inducers. Accessed Sep 2017. 
https://www.fda.gov/drugs/developmentapprovalprocess/de velopmentresources/druginteractionsl
abeling/ucm093664.htm  
Food and Drug Administration. Guidance for Industry. Guidelines for the clinical evaluation of 
antiepi[INVESTIGATOR_006] (adults and children). US Department of Health and Human Services. Center 
for Drug  Evaluation and Research, 81 -3110, 01/1981.  
Giussani G, Canelli V, Bianchi E, Erba G, Franchi C, Nobili A, et al. Long -term prognosis of 
epi[INVESTIGATOR_002], prognostic patterns and drug resistance: a population -based study. Eur J Neurol. 
2016;23(7):1218 -27. 
Hesdorff er DC, Tomson T. Sudden unexpected death in epi[INVESTIGATOR_002]: Potential role of antiepi[INVESTIGATOR_132385]. CNS Drugs. 2013;27(2):[ADDRESS_1172705] B, Nielsen JB, Rasmussen PV, HaunsøS, et al. Epi[INVESTIGATOR_843776]: a nationwide study. Epi[INVESTIGATOR_8330]. 
2013;54(9):1613 -20. 
Iung B, Vahanian A. Epi[INVESTIGATOR_843777]. Nat Rev Cardiol. 
2011;8(3):162 -72. 
Jehi L. Neurology's Silent Killer: Drug -Resistant Epi[INVESTIGATOR_002]. Epi[INVESTIGATOR_80337]. 2016;16:232 -3. 
Jones DJ, Stehling LC, Zauder HL. Cardiovascular responses to diazepam and midazolam 
maleate in the dog. Anesthesiology. 1979;51:[ADDRESS_1172706] H. Benefit of combination therapy in 
epi[INVESTIGATOR_002]: a review of the precl inical evidence with levetiracetam. Epi[INVESTIGATOR_8330]. 
2009  Mar;50(3):387 -97. 
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. Definition of 
drug resistant epi[INVESTIGATOR_002]: Consensus proposal by [CONTACT_843851]. Epi[INVESTIGATOR_8330]. 2010;51(6):1069 -77.  
Kwan P, Sander JW. The natural history of epi[INVESTIGATOR_002]: an epi[INVESTIGATOR_843778]. J Neurol 
Neurosurg Psychiatry. 2004;75(10):[ADDRESS_1172707] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 96 of 152 Laxer KD, Trinka E, Hirsch LJ, Cendes F, Langfitt J, Delanty N, et al. The consequences of 
refractory epi[INVESTIGATOR_458600]. Epi[INVESTIGATOR_41744]. 2014;37:59 -70. 
Lin CY, Pakpour AH. Using Hospi[INVESTIGATOR_5620] (HADS) on patients with 
epi[INVESTIGATOR_002]: Confirmatory factor analysis and Rasch models. Seizure. 2017;45:42 -6. 
Mohanraj R, Brodie MJ. Diagnosing refractory epi[INVESTIGATOR_002]: response to sequential treatment 
schedules. Eur J Neurol. 2006;13(3):277 -82. 
Moseley BD, Sperling MR, Asadi -Pooya AA, Diaz A, Elmouft S, Schiemann J, Whitesides  J. 
Efficacy, safety, and tolerability of a djunctive brivaracetam for secondarily generalized 
tonic -clonic seizures: Pooled results from three Phase III studies. Epi[INVESTIGATOR_5612]. 
2016;127:179 -85. 
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA,  et al, The 
Columbia -Suicide Severity Rat ing Scale: initial validity and internal consistency findings from 
three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266 -77. 
Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epi[INVESTIGATOR_843779]: a meta -analysis of placebo -controlled 
randomised trials. Lancet Neurol. 2011;10:961 –68. 
Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L. ILAE Classification 
of the epi[INVESTIGATOR_843780]: Position paper of the ILAE Commission for Classification Terminology. 
Epi[INVESTIGATOR_8330]. 2017;58(4):512 -21.  
Schiller Y, Najjar Y. Quantifying the response to antiepi[INVESTIGATOR_006]: effect of past treatment 
history. Neurology. 2008;70(1):54 -65. 
Sperling MR. The consequences of uncontrolled epi[INVESTIGATOR_002]. CNS Spectr. 2004;9(2):98 -109. 
Semah F, Pi[INVESTIGATOR_843781], Adam C, Broglin D, Arzimanoglou A, Bazin B, et al. Is the underlying 
cause of epi[INVESTIGATOR_002] a major prognostic factor for recurrence? Neurology. 1998;51(5):1256 -62. 
Steinhof f BJ. Efficacy of perampanel: a review of pooled data. Epi[INVESTIGATOR_8330]. 2014;[ADDRESS_1172708]  1:9-12. 
Taylor DC, McMackin D, Staunton H, Delanty N, Phillips  J. Patients' aims for epi[INVESTIGATOR_58741]: 
desires beyond seizure freedom. Epi[INVESTIGATOR_8330]. 2001;42(5):629 -33. 
Wiglusz MS,  Landowski J, Michalak L, Cubala WJ. Validation of the Hospi[INVESTIGATOR_843782]. Epi[INVESTIGATOR_41744]. 2016;58:97 -101. 
Zack MM, Kobau R. National and state of the numbers of adults and children with active 
epi[INVESTIGATOR_002] -United S tates, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:821 -5. 
Zhoghbi WA, Adams D, Bonow RO, Enriquwz -Sarano M, Foster E, Grayburn PA, et  al. 
Recommendations for noninvasive evaluation of native valvular regurgitation: A report from the 
American Society of Echoca rdiography developed in collaboration with the society for 
cardiovascular magnetic resonance. JASE. 2017;30:303 -71. 
Zigmond RP, Snaith AS. The Hospi[INVESTIGATOR_5620]. Acta Psychiatr Scand. 
1983;67(6):[ADDRESS_1172709] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 97 of 152 17 APPENDICES  
17.1 Protocol Amendment 1  
Rationale for the amendment  
The protocol has been amended primarily to increase the potential for the study to be 1 of 2 
adequate and well -controlled studies that supports registration. This requires an increase in the 
sample size to allow for pairwise com parisons and the use of the 75% responder rate status as the 
primary endpoint for EMA (CHMP/EWP/566/98  Rev.2/Corr,  2010).  
Per EMA guidance, the primary endpoint in add -on epi[INVESTIGATOR_843783]/non -responders, where re sponders are patients who obtained at least a certain 
pre-defined percentage reduction of seizure frequency. An improvement of >75% is regarded as 
clinically more meaningful than >50% and seems feasible given the premise of greater efficacy 
of PSL based up on nonclinical animal data and EP0069 results. Therefore, the 75% responder 
rate has been selected as the primary endpoint, rather than the more commonly used 50% 
responder rate.  
Another important addition to the protocol is that the DMC may stop enrollmen t into a 
padsevonil dose arm for safety and tolerability reasons and allocate remaining patients to 
remaining padsevonil dose or placebo arms. This addition does not reflect a change in intent. 
Rather, the plan had been to describe this possibility in the DMC Charter, but it is now also being 
included in the protocol to avoid disruption to the trial via a subsequent amendment in the 
unlikely event that a dose arm is dropped from the trial for safety/tolerability reasons.  
Modifications and changes  
Specific c hanges  
Change #[ADDRESS_1172710] OF ABBREVIATIONS (deletion bolded)  
ANCOVA = analysis of variance  
ICH = International Council on Harmonization  
Has been changed to (revisions bolded):  
ANCOVA = analysis of covariance  
ICH = International Council for Harmonization  
The following abbreviations have been added :  
EMA = European Medicines Agency  
PMDA = Pharmaceuticals and Medical Devices Agency  
PRN = (pro re nata) as needed  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172711] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 98 of 152 Change #2  
Section 1  Summary, Paragraph 2 (deletion bolded)  
EP0091 is a multicenter, randomized, double -blind, placebo -controlled, parallel -group, 
dose-finding study in adults (≥18  years of age) with drug -resistant epi[INVESTIGATOR_843784] -onset seizures despi[INVESTIGATOR_843712] 4  prior antiepi[INVESTIGATOR_32551] (AED) regimens  
including past and current treatment.  
Has been changed to (revisions bolded):  
EP0091 is a multicenter, randomized, double -blind, placebo -controlled, parallel -group, 
dose-finding study in adults (≥18  years of age) with drug -resistant epi[INVESTIGATOR_843785] -onset seizures despi[INVESTIGATOR_843712]  4 tolerated, appropriately 
chosen and used prior antiepi[INVESTIGATOR_32551] s (AEDs),  including current AEDs (Kwan et al, 
2010) . 
Change #3  
Section 1  Summary, Paragraph 3 (key deletions bolded ) 
The primary objective of this study is to characterize the dose -response relationship with respect 
to efficacy of PSL administered concomitantly with up to 3 AEDs for treatment of observable 
focal -onset seizures in patients  with drug -resistant epi[INVESTIGATOR_002]. The secondary objective s are to 
assess safety and tolerability of PSL and efficacy  of the 4  selected dose regimens (100mg/day, 
200mg/day, 400mg/day, and 800mg/day)  compared with placebo.  
Has been changed to (revisions bolded):  
The primary objectives of this study are to characterize the dose -response relationship with 
respect to efficacy of PSL administered concomitantly with up to 3 AEDs for treatment of 
observable focal -onset seizures in subjects with drug -resistant epi[INVESTIGATOR_843786] 4 selected dose regimens of PSL  compared with placebo. The secondary 
objective is to assess the safety and tolerability of all doses of PSL in relation to placebo . 
Change #[ADDRESS_1172712] of 1  Safety Follow -up (SFU) 
Visit after the last IMP intake (including echocardiogram) and a 6 -month follow -up 
echocardiog ram, depending on the duration of exposure to IMP.  
Has been changed to (revisions bolded):  
Subjects who withdraw from the study or decide not to participate in the OLE study will be 
progressively tapered off the IMP. Safety follow up for these subjects will consist of 1  Safety 
Follow -up (SFU) Visit [ADDRESS_1172713] IMP intake (including an echocardiogram) and a 
6-month follow -up echocardiogram, depending on the duration of exposure to IMP.  
Change #[ADDRESS_1172714] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 99 of 152 The assessment of eff icacy is based on seizure frequency. The primary efficacy variable is the 
change from Baseline in log -transformed observable focal -onset seizure frequency (for the 
purpose of this protocol defined as Types IA1, IB, and IC, according to the International Le ague 
Against Epi[INVESTIGATOR_002] [ILAE] classification [ ILAE  Classification  of Epi[INVESTIGATOR_843714],  1981 ]) over 
the 12 -week Maintenance Period.  
Has been changed to (revisions bolded):  
The assessment of efficacy is based on seizure frequency. For the US Food and Drug 
Administration (FDA), Pharmaceuticals and Medical Devices Agency (PMDA), and other 
regulatory authorities not specified in Section [IP_ADDRESS], the  primary efficacy variable is the 
change from Baseline in log -transformed observable focal -onset seizure frequency  (for the 
purpose of this protocol defined as Types IA1, IB, and IC, according to the International League 
Against Epi[INVESTIGATOR_002] [ILAE] classification [ ILAE  Classification  of Epi[INVESTIGATOR_843714],  1981 ]) over 
the 12 -week Maintenance Period. For the European Medic ines Agency (EMA) and 
regulatory authorities who reference EMA, the primary efficacy variable is the 75% 
responder rate status, defined as a ≥75% reduction in observable focal -onset seizure 
frequency from Baseline, over the 12 -week Maintenance Period . 
Chan ge #6  
Section 1  Summary, Paragraph 7 (deletions bolded)  
The total duration of study per subject will be up to 24 weeks with a maximum of 20  weeks 
exposure to PSL. It is estimated that approximately 300 subjects will be included at 
approximately 140 sites w orldwide; 250 subjects are expected to be randomized.  
Has been changed to (revisions are bolded):  
The total duration of study per subject will be up to 27 weeks with a maximum of 20  weeks 
exposure to PSL. It is estimated that approximately 500 subjects wil l be included at 
approximately 200 sites worldwide; 400 subjects are expected to be randomized.  
Change #[ADDRESS_1172715] the option of providing additional informed consent for 
exploratory deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) analyses to understand the 
cause, progression, and appropriate treatment of drug -resistant epi[INVESTIGATOR_002]. Participation in this 
additional portion of the study is optional and does not preclude participatio n in the main study. 
The additional genomic samples must not be collected if the subject has not consented to 
participate in this exploratory genomic substudy.  
Has been changed to (revision bolded):  
During this study, subjects will also have the option of providing additional informed consent for 
exploratory deoxyribonucleic acid (DNA), ribonucleic acid  (RNA) , and 
lipi[INVESTIGATOR_1800]/proteomics/additional blood biomarker  analyses to understand the cause, 
progression, and appropriate treatment of drug -resistant epi[INVESTIGATOR_31631]. Participation in this additional 
portion of the study is optional and does not preclude participation in the main study. The 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172716] has not consented to participate 
in this exploratory genomic s ubstudy.  
Change #[ADDRESS_1172717] sentence (deletion bolded)  
The ILAE defines drug resistance as failure of adequate trials of 2 tolerated and appropriately 
chosen AEDs either as monotherapy or in combination to ach ieve sustained seizure freedom 
(ILAE  Classification  of Epi[INVESTIGATOR_843714],  1981 ). 
Has been changed to (revision bolded):  
The ILAE defines drug resistance as failure of adequate trials of 2 tolerated and appropriately 
chosen AEDs either as monotherapy or in  combination to achieve sustained seizure freedom 
(Kwan et al, 2010 ). 
Change #9  
Section 2.1  Drug -resistant epi[INVESTIGATOR_002], Paragraph 2, (deletion bolded)  
An estimated 12%  of patients diagnosed with drug -resistant epi[INVESTIGATOR_843718] 
(Jehi, 2016 ). 
Has been changed to (revision bolded):  
An estimated 1% of patients diagnosed with drug -resistant epi[INVESTIGATOR_843718] 
(Jehi, 2016).  
Change #10  
Section 2.3  Clinical studies, Paragraph 1 (deletions bolded)  
To date, PSL has been administered in t he following 7 completed human pharmacology 
studies : N01360 —a single, ascending dose safety, pharmacokinetic (PK), and pharmacodynamic 
(PD) study; N01386 —a multiple, ascending dose safety, PK, and PD study; UP0010 —a single -
dose absorption, distribution, me tabolism, and elimination study; UP0001 —a single - and 
multiple -dose comparative PK and food effect study; UP0013 —a multiple -dose, 2 -part 
drug-drug interaction (DDI) study; N01383 —a positron -emission tomography (PET) study 
evaluating the brain GABA -A recept or occupancy following multiple dosing of PSL; and 
UP0002 —a multiple -dose study in subjects with epi[INVESTIGATOR_843787], safety, and tolerability of PSL in the presence of 
concomitant AEDs. The 2 ongoing clinical pharmacology studies with PSL include UP0036 
and UP0039.  
Has been changed to (revisions bolded):  
To date, PSL has been administered in the following 9 completed human pharmacology 
studies : 
 N01360 —a single, ascending dose safety, pharma cokinetic (PK), and pharmacodynamic 
(PD) study  
 N01386 —a multiple, ascending dose safety, PK, and PD study  
 UP0010 —a single -dose absorption, distribution, metabolism, and elimination study  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172718] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 101 of 152  UP0001 —a single - and multiple -dose comparative PK and food effect study  
 UP0013 —a multiple -dose, 2 -part drug -drug interaction (DDI) study  
 N01383 —a positron -emission tomography (PET) study evaluating the brain GABA -A 
receptor occupancy following multiple dosing of PSL  
 UP0002 —a multipl e-dose study in subjects with epi[INVESTIGATOR_843725], safety, and tolerability of PSL in the presence 
of concomitant AEDs  
 UP0036 —an adaptive, open -label, single -dose PET study evaluating SV2A  occupancy  
 UP0039 — a single - and multiple -dose safety and PK study in healthy Japanese and 
Caucasian subjects  
Change #11  
Section 3.1  Primary objective (deletions bolded)  
The primary objective  of this study is to characterize the dose -response relationship with respect 
to efficacy of PSL administered concomitantly with up to 3 AEDs for treatment of observable 
focal -onset seizures in subjects with drug -resistant epi[INVESTIGATOR_002].  
Has been changed to (revisions bolded):  
The primary objectives  of this study are to char acterize the dose -response relationship with 
respect to efficacy of PSL administered concomitantly with up to 3 AEDs for treatment of 
observable focal -onset seizures in subjects with drug -resistant epi[INVESTIGATOR_843713] 4 selected do se regimens of PSL compared with placebo.  
Change #12  
Section 3.2  Secondary objectives (deletions bolded)  
The secondary objectives are  to:  
 Assess the safety and tolerability of PSL  
 Evaluate the efficacy of the 4 selected dose regimens of PSL compared with placebo  
 Assess the safety and tolerability of all doses of PSL in relation to placebo   
Has been changed to:  
Section 3.2  Secondary objective  
The secondary objective is  to assess the safety and tolerability of all doses of PSL in relation to 
placebo.  
Change #13  
Section 3.3.2  Pharamcokinetic objectives  
The PK objectives are to:  
 Evaluate the steady -state PK profiles of PSL and the exposure -response relationship  
 Evaluate the impact of enzyme -inducing concomitant AEDs on PSL exposure  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172719] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 102 of 152 Has been changed to ( revision bolded):  
The PK objectives are to:  
 Evaluate the steady -state PK profiles of PSL and the exposure -response relationship  
 Evaluate the impact of enzyme -inducing concomitant AEDs on PSL exposure  
 Evaluate concomitant AED (and/or relevant metabolites) plasma levels  
Change #14  
Section 4.1.1  Primary efficacy variable  
The key change is that the original primary efficacy variable now will apply only to the US FDA, 
PMDA, and other regulatory authorities not specified in Section [IP_ADDRESS], and the primary effic acy 
variable for EMA and regulatory authorities who reference EMA will be the 75% responder rate, 
consistent with European guidance. The primary efficacy variable for FDA/PMDA/other 
regulatory authorities not specified in Section [IP_ADDRESS] will be a secondar y efficacy variable for 
EMA and regulatory authorities who reference EMA. The 75% responder rate remains a 
secondary efficacy variable for FDA/PMDA/other regulatory authorities not specified in Section 
[IP_ADDRESS].  
Old text:  
The primary efficacy variable is t he change in log -transformed observable focal onset seizure 
frequency from Baseline, over the 12 -week Maintenance Period.  
Has been changed to (revisions bolded):  
[IP_ADDRESS]   Primary efficacy variable for the US FDA, PMDA, and other regulatory 
authorities not specified in Section [IP_ADDRESS]  
The primary efficacy variable is the change in log -transformed observable focal onset seizure 
frequency from Baseline, over the 12 -week Maintenance Period.  
[IP_ADDRESS]   Primary efficacy variable for EMA and regulatory authorities w ho reference 
EMA  
The primary efficacy variable is the 75% responder rate status, defined as a ≥75% reduction in 
observable focal -onset seizure frequency from Baseline, over the 12 -week Maintenance Period.  
Change #15  
Section 4.1.2  Secondary efficacy variabl es 
Old text:  
 The 75% responder rate status, defined as a ≥75% reduction in observable focal -onset seizure 
frequency from Baseline, over the 12 -week Maintenance Period  
 The 50% responder rate status, defined as a ≥50% reduction in observable focal -onset seizure 
frequency from Baseline, over the 12 -week Maintenance Period  
 Percent reduction in observable focal -onset seizure frequency from Baseline, over the 
12-week Maintenance Period  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172720] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 103 of 152 Has been changed to (revisions bolded):  
[IP_ADDRESS]   Secondary efficacy variab les for the US FDA, PMDA, and other regulatory 
authorities not specified in Section [IP_ADDRESS]  
The secondary efficacy variables are as follows:  
 The 75% responder rate status, defined as a ≥75% reduction in observable focal -onset seizure 
frequency from Baseli ne, over the 12 -week Maintenance Period  
 The 50% responder rate status, defined as a ≥50% reduction in observable focal -onset seizure 
frequency from Baseline, over the 12 -week Maintenance Period  
 Percent reduction in observable focal -onset seizure frequency from Baseline, over the 
12-week Maintenance Period  
[IP_ADDRESS]   Secondary efficacy variables for EMA and regulatory authorities who reference 
EMA  
The secondary efficacy variables are as follows:  
 The change in log -transformed observable focal onset seizure fr equency from Baseline, over 
the 12 -week Maintenance Period  
 The 50% responder rate status, defined as a ≥50% reduction in observable focal -onset seizure 
frequency from Baseline, over the 12 -week Maintenance Period  
 Percent reduction in observable focal -onset  seizure frequency from Baseline, over the 
12-week Maintenance Period  
Change #16  
Section 4.1.3  Other efficacy variables  
Old heading: Other efficacy variables  
Has been changed to (revision bolded):  
Heading has been changed to: Other efficacy variables (This  list applies for all regulatory 
authorities)  
Change #17  
Section 4.1.3  Other efficacy variables, Bullet 18 (deletions bolded)  
 Time to loss of efficacy (defined as  return to Baseline observable focal -onset seizure 
frequency ) during the 12 -week Maintenance Period  
Has been changed to (revisions bolded):  
 Time to return to  baseline observable focal -onset seizure frequency during the 12 -week 
Maintenance Period  
Change #18  
Section 4.2.1  Other safety variables, Bullet 10 (deletions bolded)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172721] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 104 of 152 Occurrence of a clinicall y-significan t valvular or pericardial effusion change  or other clinically -
significant abnormalities as identified by 2 -dimensional Doppler echocardiogram at each 
assessment by [CONTACT_843852] (revisions bolded):  
Occurrence of valvular abnormalities  or pericardial effusion changes  or other significant 
abnormalities as identified by 2 -dimensional Doppler echocardiogram at each assessment by 
[CONTACT_843853] #19  
Section 4.3.3  Exploratory pharmacogenetic variables  
Additional blood samples will be collected at specific time points ( Table  5-1) from subjects who 
consent to participate in the pharmacogenetic substudy to measure DNA bi omarkers in order to 
assess:  
 Pharmacogenetic variants associated with drug -resistant epi[INVESTIGATOR_843735] -resistant epi[INVESTIGATOR_002], 
AED  resistance, and PK.  
Has been c hanged to (revision bolded):  
Additional blood samples will be collected at specific time points (Table 5 -1) from subjects who 
consent to participate in the pharmacogenetic substudy to measure DNA biomarkers in order to 
assess:  
 Pharmacogenetic variants asso ciated with drug -resistant epi[INVESTIGATOR_843735] -resistant epi[INVESTIGATOR_002], 
AED  resistance, and PK. The samples will be stored up to 20 years for the research purposes 
stated in this protocol.  
Change #20  
Section 4.3.4  Exploratory pharmacokinetic evaluation, Paragraph 2 (deletion bolded)  
Additionally, evaluation of PSL and major metabolites in plasma will be undertaken from trough 
samples collected by a subset of qualifie d sites . 
Has been changed to (revision bolded):  
Additionally, evaluation of PSL and major metabolites in plasma will be undertaken from trough 
samples. The collection of plasma samples for this comparison may cease during the course 
of the study based on periodic review of the data.  
Change #21  
Section 5.1  Study description, Paragraph 1 (deletion bolded)  
EP0091 is a multicenter, randomized, double -blind, placebo -controlled, parallel -group 
dose-finding study in adults (≥18 years of age) with drug -resistant e pi[INVESTIGATOR_843788]. 
UCB   [ADDRESS_1172722] 1  to 3 AEDs with or 
without neurostimulation devices.  
Has been changed to (revisions bolded):  
EP0091 is a multicenter, randomized, double -blind, placebo -controlled, parallel -group 
dose-finding study in adults (≥18 years  of age) with drug -resistant epi[INVESTIGATOR_843711] -onset seizures despi[INVESTIGATOR_843712]  4 tolerated, appropriately 
chosen and used prior AEDs , including current AEDs  (Kwan et al, 2010) . All eligible subjects 
will have a n epi[INVESTIGATOR_843736] [ADDRESS_1172723] 1  to 3 AEDs with or without neurostimulation devices.  
Change #22  
Section 5.1  Study description, Treatment Period, Paragraph 7 (minor rearrangeme nt of 
first sentence for improved clarity)  
Subjects who complete the Maintenance Period or who discontinue early from the study 
will return for an End -of-Treatment Visit or Early Discontinuation Visit (EDV), 
respectively.  Subjects completing the Maintenanc e Period will have the opportunity to enroll 
into the OLE study, EP0093. They will be converted to the entry dose of the EP0093 study, 
400mg/day. Subjects withdrawing from the study or deciding not to participate in the OLE study 
(EP0093) will be progressi vely tapered off the IMP.  
Has been changed to (revision bolded):  
Subjects who complete the Maintenance Period will return for an End of Treatment Visit. 
Subjects who discontinue early from the study will return for an Early Discontinuation 
Visit (EDV).  Subjects completing the Maintenance Period will have the opportunity to enroll 
into the OLE study, EP0093. They will be converted to the entry dose of the EP0093 study, 
400mg/day. Subjects withdrawing from the study or deciding not to participate in the OLE s tudy 
(EP0093) will be progressively tapered off the IMP.  
Change #[ADDRESS_1172724] IMP intake (Week  23) incl uding an echocardiogram. An additional follow -up 
echocardiogram will be performed at 6 months (±1  month) after the last IMP intake only for 
subjects exposed to IMP for more than 3  weeks.  
Has been changed to (revision bolded):  
Safety follow up for subjects not entering the OLE will consist of [ADDRESS_1172725] IMP intake (Week  23 or sooner in case of early discontinuation ) including an 
echocardiogram. An additional follow -up echocardiogram will be performe d at 6 months 
(±1 month) after the last IMP intake only for subjects exposed to IMP for more than [ADDRESS_1172726] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 106 of 152 Change #[ADDRESS_1172727] the option of providing additional informed consent for 
exploratory genetic (DNA) analyses. Participation in this additional portion of the study is 
optional and does not preclude participation in the main study. The additional pharmacogenetic 
sample must not be collected if the subject has not consented to par ticipate in this exploratory 
genetic substudy. A volume of 6mL of whole blood samples will be collected at Baseline 
(Visit  2). 
Has been changed to (revision bolded):  
During this study, subjects will have the option of providing additional informed consent for 
exploratory DNA , RNA, and lipi[INVESTIGATOR_1800]/proteomics/additional blood biomarker analyses. 
Participation in this additional portion of the study is optional and does not preclude participation 
in the main study. The additional pharmacogenetic sample must not  be collected if the subject 
has not consented to participate in this exploratory genetic substudy. A volume of 6mL of whole 
blood samples will be collected at Baseline (Visit  2). 
Change #[ADDRESS_1172728], Paragraph 1 (deletion b olded)  
The total duration of study per subject will be up to 24 weeks  with a maximum of 20  weeks 
exposure to PSL. An additional follow -up echocardiogram will be performed at 6  months 
(±1 month) after the last IMP intake only for subjects exposed to IMP for  more than 3  weeks and 
either discontinuing the study or not entering the OLE.  
Has been changed to (revision bolded):  
The total duration of study per subject will be up to 27 weeks  with a maximum of 20  weeks 
exposure to PSL. An additional follow -up echoca rdiogram will be performed at 6  months 
(±1 month) after the last IMP intake only for subjects exposed to IMP for more than 3  weeks and 
either discontinuing the study or not entering the OLE.  
Change #26  
Section 5.1.3  Planned number of subjects and sites (d eletions bolded)  
It is estimated that approximately 300 subjects will be included at approximately 140 sites 
worldwide; 250 subjects are expected to be randomized.  
Has been changed to (revisions bolded):  
It is estimated that approximately 500 subjects will  be included at approximately 200 sites 
worldwide; 400 subjects are expected to be randomized.  
Change #27  
Section 5.2  Schedule of study assessments, footnote l  
AED samples will ideally be taken immediately prior to dose of concomitant medication on each 
occasion. If this is not possible, then the sample may be taken at any time after dose and the 
timing of sample in relation to dose should be kept the same (±1 hour) on each occasion for each 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172729] when AED  samples are collected should 
be scheduled approximately at the same time whenever possible. Assay of parent PSL and 
metabolites may be included in the AED panel of tests.  
Has been changed to (revision bolded):  
AED samples will ideally be taken immediately  prior to dose of concomitant medication on each 
occasion. If this is not possible, then the sample may be taken at any time after dose and the 
timing of sample in relation to dose should be kept the same (±1 hour) on each occasion for each 
subject. Theref ore, the timing of visits for each subject when AED samples are collected should 
be scheduled approximately at the same time whenever possible. Assay of parent PSL and 
metabolites may be included in the AED panel of tests at Visits 6 and 7.  
Change #28  
Section 5.4.1  Choice of study design and endpoints, Paragraph 1 (deletion bolded)  
The target indication for PSL is as adjunctive therapy in the treatment of focal -onset seizures in 
adult patients with drug -resistant epi[INVESTIGATOR_002]. The key inclusion criteria are aim ed at selecting a 
sample of study subjects from this target population. The criterion for drug resistance or failure 
to achieve control of seizures, with ≥[ADDRESS_1172730] not been 
able to control their seizures despi[INVESTIGATOR_12847] 4 or more AED regimens, the likelihood of 
achieving complete seizure control with another AED regimen is further reduced to 1% to 4% 
(Schiller  and Najjar, 2008; Mohanraj and Brodie, 2006). Study subjects also will be required to 
have on average at least 4 spontaneous and observable focal -onset seizures (IA1, IB, or IC) per 
28 days during each 4 -week interval of the 8 -week retrospective Baseline Period prior to entry 
and during the 4 -week Baseline Period. This minimum seizure frequency was selected to provide 
assurance that a meaningful change in percent reduction in seizure frequency over 28  days and 
50%, 75%, and 90% responder rates could be demonstrat ed during the 12 -week Maintenance 
Period.  
Has been changed to (revision bolded):  
The target indication for PSL is as adjunctive therapy in the treatment of focal -onset seizures in 
adult patients with drug -resistant epi[INVESTIGATOR_002]. The key inclusion criteria are  aimed at selecting a 
sample of study subjects from this target population. The criterion for drug resistance or failure 
to achieve control of seizures, with ≥[ADDRESS_1172731] not been able to 
control their seizures despi[INVESTIGATOR_12847] 4 or more AED regimens, the likelihood of 
achieving complete seizure control with another AED regimen is further reduced to 1% to 4% 
(Schiller  and Najjar , 2008; Mohanraj and Brodie, 2006). Study subjects also will be required to 
have on average at least 4 spontaneous and observable focal -onset seizures (IA1, IB, or IC) per 
28 days during each 4 -week interval of the 8 -week retrospective Baseline Period prio r to entry 
and during the 4 -week Baseline Period. This minimum seizure frequency was selected to provide 
assurance that a meaningful change in percent reduction in seizure frequency over 28  days and 
50%, 75%, and 90% responder rates could be demonstrated d uring the [ADDRESS_1172732] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 108 of 152 Change #29  
Section 5.4.3  Justification for genomic and biomarker strategy  
The biomarker samples will be collected to understand the molecular characteristics of epi[INVESTIGATOR_843739] (including safety, efficacy, and tolerability of PSL and concomitant therapi[INVESTIGATOR_014]), 
which may enable potential molecular stratification in future clinical studies. A broad range of 
molecular data may be generated from each individual sample. The exact format of these 
analyses will be spe cified at a later time.  
Has been changed to (revision bolded):  
The biomarker samples will be collected to understand the molecular characteristics of epi[INVESTIGATOR_843739] (including safety, efficacy, and tolerability of PSL and concomitant therapi[INVESTIGATOR_014]), 
which may enable potential molecular stratification in future  clinical studies. A broad range of 
molecular data may be generated from each individual sample. The exact format of these 
analyses will be specified at a later time. The samples will be stored at -80°C at the Central 
Laboratory facilities for up to 20 yea rs or according to local laws .  
Change #30  
Section 6.1  Inclusion criteria, Inclusion Criterion 1 (deletion bolded)  
An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written ICF 
is signed and dated by [CONTACT_843854](s) or by [CONTACT_80518], where 
applicable. The ICF or a specific Assent form, where required, will be signed and dated by 
[CONTACT_122256], according to country -specific regulations. A separate ICF should be signed and dated by 
[CONTACT_843806], mRNA , and lipi[INVESTIGATOR_1800]/proteomics/additional blood 
biomarker samples.  
Has been changed to (revision bolded):  
An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written ICF 
is signed and dated by [CONTACT_28246] b y the parent(s) or by [CONTACT_80518], where 
applicable. The ICF or a specific Assent form, where required, will be signed and dated by 
[CONTACT_122256], according to country -specific regulations. A separate ICF should be signed and dated by 
[CONTACT_843806], RNA , and lipi[INVESTIGATOR_1800]/proteomics/additional blood 
biomarker samples.  
Change #31  
Section 6.1  Inclusion criteria, Inclusion Criterion 7 (deletion bolded)  
Subject has failed to achieve seizure control with ≥[ADDRESS_1172733] and ongoing treatment. Prior 
discontinued AED treatment would need to be assessed by [CONTACT_843855]/or caregiver interview . "Prior AED" is defined as all past 
and ongoing AED treatments with a start date before the Screening Visit (Visit  1). 
Has been changed to (revsions bolded):  
Subject has failed to achieve seizure control with ≥[ADDRESS_1172734] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 109 of 152 dose and duration. Prior discontinued AED treatment would need to be assessed by [CONTACT_843807]/or caregiver i nterview. 
"Prior AED" is defined as all past and ongoing AED treatments with a start date before the 
Screening Visit (Visit  1 
Change #[ADDRESS_1172735] 1 and  up to 3 AEDs for the 8  weeks 
prior to the Screening Visit (Visit  1) with or without additional concurrent vagus nerve 
stimulation (VNS) or other neurostimulation treatments. The latter will not be counted as AEDs 
for the purpose of eligibility.  
Has been c hanged to (revision bolded):  
Subject is currently treated with an individually optimized and  stable dose of at least 1 and up 
to 3 AEDs for the 8  weeks prior to the Screening Visit (Visit  1) with or without additional 
concurrent vagus nerve stimulation (VN S) or other neurostimulation treatments. The latter will 
not be counted as AEDs for the purpose of eligibility.  
Change #33  
Section 6.1  Inclusion criteria, Inclusion Criterion 10, Paragraph 1 (deletion bolded)  
Female subjects of child bearing potential mus t have a negative serum pregnancy test at the 
Screening Visit (Visit  1), which is confirmed to be negative by [CONTACT_843856]  1 (Visit  2) and prior to further dispensing at each study visit thereafter. Subjects 
will be withdrawn from the study as soon as pregnancy is known.  
Has been changed to (revision bolded):  
Female subjects of child bearing potential must have a negative serum pregnancy test at the 
Screening Visit (Visit  1), which is confirmed to be negative by [CONTACT_843857] 1 (Visit  2) and prior to further dispensing at each study visit thereafter. Subjects 
will be withdrawn from the study as soon as pregnancy is known.  
Change #[ADDRESS_1172736] be of nonchildbearing potential, defined as being 
postmenopausal (for at least 2 years before the Screening Visit [Visit  1]), verified by [CONTACT_843858] > 40mIU/mL at the Screening Visit (Visit  1), or permanently 
sterilized (eg, bilateral tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656]), or congenitally 
sterile.  
Has been changed to (revision bolded):  
Women not agreeing to use birth control must be abstinent (as described in the preceding 
bullet) or be of nonchildbearing potential, defined as being postmenopausal (for at least 2 years 
before the Screening Visit [Visit  1]), verified by [CONTACT_843834] 
>40mIU/mL at the Scree ning Visit (Visit  1), or permanently sterilized (eg, bilateral tubal 
occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656]), or congenitally sterile.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172737] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 110 of 152 Change #35  
Section 6.2  Exclusion criterion 13, Line 2  
>2.0 upper limit of normal (ULN) of any of the following:  
Has been changed to (revision bolded):  
>2.0x upper limit of normal (ULN) of any of the following:  
Change #36  
Section 6.2  Exclusion criterion 14 (deletion bolded)  
Subject has an abnormality on echocardiogram at Screening Visit (Visit  1) as assessed by [CONTACT_843859] (eg, shortness of breath, palpi[INVESTIGATOR_814], and 
murmur) or a Grade  2* (or higher) /moderate severity abnormality or a history of rheumatic 
heart disease or other known valvular abnormalities (* according to th e ASE Guidelines, 
Zoghbi  et al, 2017).  
Subjects whose echocardiograms are not interpretable at Screening Visit (Visit  1) by 
[CONTACT_462612] (TTE), eg, due to technical difficulties or position of the 
heart will be excluded from the study.  
Has been changed to (revisions are bolded):  
Subject has an abnormality on echocardiogram at Screening Visit (Visit  1) as assessed by [CONTACT_843860] (eg, shortness of breath, palpi[INVESTIGATOR_814], and 
murmur) or a ≥Grade  2*/mode rate severity abnormality or a history of rheumatic heart disease 
or other known valvular abnormalities (*according to the ASE Guidelines, Zoghbi  et al, 2017).  
Subjects whose echocardiograms are not interpretable at Screening Visit (Visit  1) by 
[CONTACT_843861] (TTE), eg, due to technical difficulties or position of the heart 
will be excluded from the study.  
Change #37  
Section 6.2  Exclusion criterion 15 (deletions bolded)  
Subject has a history of or signs for idiopathic  generalized (genetic)  epi[INVESTIGATOR_002].  
Has been changed to (revisions bolded):  
Subject has a history of or signs of generalized (formerly referred to as ‘idiopathic 
generalized’) or combined generalized and focal (formerly referred to as ‘symptomatic 
generalized’) epi[INVESTIGATOR_002] (Scheffer IE e t al, 2017) . 
Change #38  
Section 6.2  Exclusion criterion 22 (deletion bolded)  
Subject has VNS, deep brain stimulation, Responsive Neurostimulator System, or other 
neurostimulation for epi[INVESTIGATOR_843749]   
 implanted or activated <1 year prior to enrollment, or  
 with stimulation parameters that have been stable for <[ADDRESS_1172738] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 111 of 152  with battery life of unit not anticipated to extend for duration of trial.  
Has been changed to (revisions bolded):  
Subject has VNS, deep brain stimulation, Responsive Neurostimulator Syste m, or other 
neurostimulation for epi[INVESTIGATOR_843749]   
 implanted and activated <1 year prior to enrollment, or  
 with stimulation parameters that have been stable for <3 months, or  
 with battery life of unit not anticipated to extend for duration of trial.  
Change  #[ADDRESS_1172739] is taking GABA -A-ergic drugs (agonists [ie, barbiturates] or receptor positive allosteric 
modulators [ie, BZDs or non -BZDs]) excluding GABA -A-ergic AEDs >2  times per week for any 
indication.  
Has been changed to (revisions bolded):  
Subject is taking GABA -A-ergic drugs regularly  (agonists [ie, barbiturates] or receptor positive 
allosteric modulators [ie, BZDs or non -BZDs]), excluding as needed (PRN) intake of  
GABA -A-ergic AEDs <3 times per week for emergencies . 
Change #[ADDRESS_1172740] with an echocardiogram showing a Grade  2 finding (moderate regurgitation) if 
accompanied with moderate to severe signs/symptoms or a Grade 3 finding (severe 
regurgitation) will be discontinued from the study regardless of accompanying clinical 
symptoms, and should begin discontinuation of the IMP. Additionally, a jump of 2  grades, from 
Grade  0 to Grade  2 (moderate regurgitation) accompanied with moderate to severe symptoms or 
from Grade  1 to Grade 3 (sev ere regurgitation) will result in subject discontinuation (see Section 
6.3.2).  
Has been changed to (revisions bolded):  
Subject with an echocardiogram showing a Grade  2 finding (moderate regurgitation/stenosis) if 
accompanied with moderate to severe signs/ symptoms or a Grade 3 finding (severe 
regurgitation/stenosis) will be discontinued from the study regardless of accompanying clinical 
symptoms, and should begin discontinuation of the IMP. Additionally, a jump of 2  grades, from 
Grade  0 to Grade  2 (moderate  regurgitation/stenosis) accompanied with moderate to severe 
symptoms or from Grade  1 to Grade 3 (severe regurgitation/ stenosis ) will result in subject 
discontinuation (see Section 6.3.2) . 
Change #[ADDRESS_1172741] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 112 of 152 Table 6 -1:   Valvular abnormality grading criteria  
Echocardiogram 
Valvular 
Abnormality  Severity / Description  Potential 
Cardiovascular 
Signs/Symptoms  Action  
Grade  0 Absent: no regurgitation, 
no stenosis  None reported  None  
Grade  1 Mild: trace or barely 
detected regurgitation  Minimal to none  None; continued observation  
Grade  2 Moderate: regurgitation 
with intermediate values  Symptomsa: 
Shortness of breath on 
exertion or at rest; 
palpi[INVESTIGATOR_226367] n; syncope; 
anginal or pericarditic 
chest pain; fatigue or 
weakness  
 
Signs:  
Pulmonary arterial 
pressure >40mm Hg and 
rise of >10mmHg; 
pulmonary edema; 
peripheral edema or 
ascites; atrial fibrillation 
or malignant arrhythmia; 
hypotension  For a Grade  2/mod erate severity, a 
decision to discontinue is based on 
severity of clinical signs/symptoms; 
if accompanied with moderate to 
severe signs/symptoms this results 
in subject discontinuation.  
Grade 3  Severe: regurgitation in 
the extreme range, often 
accompanied  by [CONTACT_190218] 
(eg, pulmonary 
congestion)  Discontinuation of subject.  
For a Grade [ADDRESS_1172742] 
should be discontinued regardless of 
accompanying clinical symptoms.  
Grade increase by 
2 levels  Increasing from:  
Grade  0 to 2 or  
Grade  1 to 3  Rapid onset of above 
signs/symptoms  A jump of 2 grades to 
Grade  2/moderate accompanied with 
moderate to severe signs/symptoms 
results in subject discontinuation.  
A jump of 2 grades to 
Grade  3/severe (with/without 
symptoms) will result in subject 
discontinuation.  
a [LOCATION_001] Heart Association Classification of symptoms; for other echocardiogram measurements, see the 
Echocardiogram Manual.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172743] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 113 of 152 Has been changed to (revision bolded):  
Table 6 -1:   Valvular abnormality grading criteria  
Echocardiogram 
Valvular 
Abnormality  Severity / Description  Potential 
Cardiovascular 
Signs/Symptoms  Action  
Grade  0 Absent: no regurgitation, 
no stenosis  None reported  None  
Grade  1 Mild: trace or barely 
detected 
regurgitation/ stenosis  Minimal to none  None; continued observation  
Grade  2 Moderate: 
regurgitation/ stenosis  
with intermediate values  Symptomsa: 
Shortness of breath on 
exertion or at rest; 
palpi[INVESTIGATOR_332]; syncope; 
anginal or pericarditic 
chest pain; fatigue or 
weakness  
 
Signs:  
Pulmonary arterial 
pressure >40mm Hg and 
rise of >10mmHg; 
pulmonary edema; 
peripheral edema or 
ascites; atrial fibrillation 
or malignant arrhythmia; 
hypotension  For a Grade  2/moderate severity, a 
decision to discontinue is based on 
severity of clinical signs/symptoms; 
if accompanied with moderate to 
severe signs/symptoms this results 
in subject discontinuation.  
Grade 3  Severe: 
regurgitation/ stenosis  in 
the extreme range, often 
accompan ied by [CONTACT_190218] 
(eg, pulmonary 
congestion)  Discontinuation of subject.  
For a Grade [ADDRESS_1172744] 
should be discontinued regardless of 
accompanying clinical symptoms.  
Grade increase by 
2 levels  Increasing from:  
Grade  0 to 2 or  
Grade  1 to 3  Rapid onset of above 
signs/symptoms  A jump of 2 grades to 
Grade  2/moderate accompanied with 
moderate to severe signs/symptoms 
results in subject discontinuation.  
A jump of 2 grades to 
Grade  3/severe (with/without 
symptoms) will result in subject 
discontinu ation.  
a [LOCATION_001] Heart Association Classification of symptoms; for other echocardiogram measurements, see the 
Echocardiogram Manual.  
Change #42  
Section 6.3.2  Echocardiogram valvular abnormalities assessments, Paragraphs 4 and 5  
Subjects with an echocardiogram showing a Grade  2 finding (moderate regurgitation) will 
undergo a repeat echocardiogram within 1 month (unscheduled visit) to confirm the finding. For 
a Grade  2 echocardiogram of  moderate severity, a decision to discontinue will be based on the 
severity of clinical signs/symptoms; if accompanied with moderate to severe signs/symptoms 
this would result in subject discontinuation. Investigators may contact [CONTACT_843815]’s clinical signs/symptoms.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172745] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 114 of 152 Subjects with an echocardiogram showing a Grade 3 finding (severe regurgitation) will undergo 
a repeat echocardiogram within 2 weeks (unscheduled visit) to confirm the finding. For a 
Grade  [ADDRESS_1172746] should be discontinued from the 
study regardless of accompanying clinical signs/symptoms and should begin discontinuation of 
the IMP.  
Has been changed to (revisions bolded):  
Subjects with an echocardiogram showing  a Grade  2 finding (moderate regurgitation/ stenosis ) 
will undergo a repeat echocardiogram within 1 month (unscheduled visit) to confirm the finding. 
For a Grade  2 echocardiogram of moderate severity, a decision to discontinue will be based on 
the severity of clinical signs/symptoms; if accompanied with moderate to severe signs/symptoms 
this would result in subject discontinuation. Investigators may contact [CONTACT_843815]’s clinical signs/symptoms.  
Subjects with an ec hocardiogram showing a Grade 3 finding (severe regurgitation/ stenosis ) will 
undergo a repeat echocardiogram within 2 weeks (unscheduled visit) to confirm the finding. For 
a Grade  [ADDRESS_1172747] should be discontinued f rom the 
study regardless of accompanying clinical signs/symptoms and should begin discontinuation of 
the IMP.  
Change #43  
Section 6.3.2  Echocardiogram valvular abnormalities assessments, final paragraph 
(deletion bolded)  
Regulatory authorities will be notif ied of any discontinuations . 
Has been changed to (revision bolded):  
Regulatory authorities will be notified of any subject who is discontinued due to an abnormal 
echocardiogram . 
Change #44  
Section 7.2.2  Taper Period, Table 7 -3  
Has been changed to:  
The following footnote has been added:  
Taper Period for subjects who choose an early discontinuation may occur before Week 16.  
Change #45  
Section 7.8.2  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014]) (deletions 
bolded)  
The following concomit ant medications are prohibited during the study:  
 Benzodiazepi[INVESTIGATOR_1651] ( GABA -A-ergic drugs : including agonists [ie, barbiturates] or 
receptor -positive allosteric modulators [ie, BZDs or non -BZDs like zolpi[INVESTIGATOR_6730]] taken >2  times 
per week). Benzodiazepi[INVESTIGATOR_843789].  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172748] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 115 of 152 Strong CYP3A4 inhibitors/inducers: AEDs including carbamazepi[INVESTIGATOR_050], phenytoin, 
phenobarbital, primidone (for more details refer to Table  3-2 and Table  3-3 in FDA  Drug 
Development Resources, Drug development and drug interactions: Table  of substrates, 
inhibitor and inducers).  
Non-AED strong CYP3A4 enzyme inducers/inhibitors (ie, prescription drugs, 
nonprescription drugs, medical cannabis, cannabidiol, dietary [eg, grapefruit or passion fruit].  
 Strong CYP2C19 strong  sensitive substrates/inhibitors/inducers including S -mephenytoin, 
omeprazole, fluconazole, fluoxetine, fluvoxamine, ticlopi[INVESTIGATOR_5325], rifampin, ritonavir ( for more 
details refer to Table  3-1, Table  3-2, and Ta ble 3-3 in FDA Drug Development Resources, 
Drug development and drug interactions: Table  of substrates, inhibitor and inducers).  
Has been changed to (revisions bolded):  
The following concomitant medications are prohibited during the study:  
 GABA -A-ergic dru gs including agonists (ie, barbiturates) or receptor -positive allosteric 
modulators (ie, BZDs or non -BZDs like zolpi[INVESTIGATOR_6730]) taken >2  times per week. Regular intake 
of benzodiazepi[INVESTIGATOR_843790] d. However, PRN intake of GABA -A drugs <3 times per week is allowed, ie, for 
emergencies .  
 Strong CYP3A4 inhibitors/inducers  
 AEDs including carbamazepi[INVESTIGATOR_050], phenytoin, phenobarbital, primidone  
 Non-AED strong CYP3A4 enzyme inducers/inhibitors (ie, prescription drugs, 
nonprescription drugs, medical cannabis, cannabidiol, dietary [eg, grapefruit or passion 
fruit]. For more details refer to Table  3-2 and Table  3-3 in FDA Drug Development 
Resources, Drug development and drug interactions: Table  of subst rates, inhibitor and 
inducers.  
 Strong CYP2C19 sensitive substrates/inhibitors/inducers including S -mephenytoin, 
omeprazole, fluconazole, fluoxetine, fluvoxamine, ticlopi[INVESTIGATOR_5325], rifampin, ritonavir ( for more 
details refer to Table  3-1, Table  3-2, and Table  3-3 in FDA Drug Development Resources, 
Drug development and drug interactions: Table  of substrates, inhibitor and inducers).  
Change #46  
Section 7.10  Randomization and numbering of subjects, Paragraph 1 (deletion bolded)  
An IRT will be used for assigning eligible subjects to a treatment regimen (as applicable) based 
on a predetermined production randomization and/or packaging schedule provided by [CONTACT_843820]. The randomization schedule will be produced by [CONTACT_352240] . The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule.  
Has been changed to:  
An IRT will be used for assigning eligible subjects to a treatment regimen (as applicable) based 
on a predetermine d production randomization and/or packaging schedule provided by [CONTACT_843862]. 
UCB   [ADDRESS_1172749] kits of IMP, as appropriate, 
according to the visit schedule.  
Change #47  
Section [IP_ADDRESS]  Visit 7 (Week 16±1  week, End -of-Treatment or Early Discontinuation 
Visit)  
Has been changed to:  
The heading has been changed to (revisions bolded):  
Visit  7 (Week  16±1  week for End-of-Treatment or earlier for  Early  Discontinuation Visit)  
Change #48  
Section 8.4  Safety Follow -Up (Visit  9 [Week 23, approximately [ADDRESS_1172750] IMP 
intake])  
Has been changed to:  
The heading has been changed to (revision bolded):  
Safety Follow -Up (Visit  9 [Week [ADDRESS_1172751] IMP 
intake])  
Change #49  
Section 9.2  Seizure Severity Global Item, Paragraph 1 (deletion bolded)  
The SSG consists of [ADDRESS_1172752] 4 weeks and/or since the Baseline (in 
EP0091). The subjects should describe their most common type  of seizure when answering the 
questions.  
Has been changed to (revision bolded):  
The SSG consists of [ADDRESS_1172753] 4 weeks and/or since the Baseline (in 
EP0091). The subjects should describe all types  of seizure s when answering the questions.  
Change #50  
Section [IP_ADDRESS]  Concomitant AED assay  
Has been changed to (revision bolded):  
The headin g has been change to: Concomitant AED and exploratory pharmacokinetic 
evaluation  
Change #51  
Section [IP_ADDRESS]  Concomitant AED and exploratory pharmacokinetic evaluation, final 
paragraph (deletion bolded)  
Assay of PSL metabolites will be included in the concomitant AED assay screen.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172754] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 117 of 152 Has been changed to (revision bolded):  
Assay of PSL metabolites may be included in the concomitant AED assay screen.  
Change #52  
Section 10.2  Exploratory variables, Paragraph 2 (deletion bolded)  
Results for the exploratory parameters obtained from DNA, mRNA , lipi[INVESTIGATOR_1800], and proteomics 
analysis, and serum biomarkers will be described in a separate report.  
Has been changed to (revision bolded):  
Results for the exploratory parameters obtained from DNA, RNA , lipi[INVESTIGATOR_1800], and proteomics 
analysis, and serum biomarkers will be described in a separate report.  
Change #53  
Section [IP_ADDRESS].[ADDRESS_1172755]  
This is a new section. The text was moved from another location, but was not revised.  
Has been changed to:  
Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total bilirubin in 
the absence of ≥2xULN ALP, with no alternative explanation for the biochemical abnormality, 
must ALWAYS be reported to UCB as an AE of special int erest (ie, without waiting for any 
additional etiologic investigations to have been concluded). Follow -up information should then 
be reported if an alternative etiology is identified during investigation and monitoring of the 
subject.  
Change #54  
Section 11 .1.7  Safety signal detection, Paragraph 4  
In addition, an unblinded DMC will oversee safety data approximately every 6 months (subject 
to DMC recommendation) during the course of the study during which the safety of PSL will be 
assessed. The safety variab les and the decision rules to be used will be specified in the DMC 
charter. This analysis will inform any decisions regarding changes in study conduct and/or study 
termination. The precise membership, scope, and responsibilities of the DMC are described in  
the DMC charter.  
Has been changed to (revison bolded):  
In addition, an unblinded independent  DMC will oversee safety data approximately every 6 
months (subject to DMC recommendation) during the course of the study during which the 
safety of PSL will be a ssessed. The safety variables and the decision rules to be used will be 
specified in the DMC charter. This analysis will inform any decisions regarding changes in study 
conduct and/or study termination. The precise membership, scope, and responsibilities o f the 
DMC are described in the DMC charter.  
Change #55  
Section 11.2  Laboratory measurements, Paragraph 2 (deletion bolded)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172756] will be a maximum 
of 31.5mL  by [CONTACT_141420], which includes 2mL for hematology, 5mL for blood chemistry, 5mL 
and 20µL for AED and PSL plasma level (including back -up samples for AED assay), 6mL for 
genetic substudy, 13.5mL for genomic assessments,  and 80µL for PK measurements.  
Has been changed to (revision bolded) : 
The total blood volume drawn for clinical laboratory assessments per subject will be a maximum 
of 31.6mL  by [CONTACT_141420], which includes 2mL for hematology, 5mL for blood chemistry, 5mL 
and 20µL for AED and PSL plasma level (including back -up samples for AED  assay), 6mL for 
genetic substudy, 13.5mL for genomic assessments,  and 80µL for PK measurements.  
Change #56  
Section 11.2  Laboratory measurements, Table 11 -2 
Has been changed to:  
FSH test has been added to the table and to the list of abbreviations for the  table.  
Change #57  
Section 11.2  Laboratory measurements, a second paragraph below Table 11 -2 has been 
added.  
Has been added:  
Women not agreeing to use birth control must be abstinent or be of nonchildbearing potential, 
defined as being postmenopausal (for  at least 2 years before the Screening Visit [Visit 1]), 
verified by [CONTACT_843834] >40mIU/mL at the Screening Visit (Visit 1), 
or permanently sterilized (eg, bilateral tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656]), 
or congenitally sterile.  
Change #58  
Section 11.3.3   Echocardiograms, Paragraph 2  
Two-dimensional Doppler echocardiography will be performed with:  
 Diastolic measurements (mitral forward flow E and A waves and deceleration time)  
 Tissue Doppler on medial and late ral mitral valve annulus (S, E, and A waves)  
 Standardized views for left atrial volume measurements  
Has been changed to:  
Two-dimensional Doppler echocardiography will include the following 
measurements/observations:  
 Epi[INVESTIGATOR_843766]  
 Functional meas urements  
 Diastology (ie, Mitral Valve E/A waves, etc.)  
 Systolic (ie, Left Ventricular Ejection Fraction, LVEF, etc. ) 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172757] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 119 of 152  Epi[INVESTIGATOR_843791]  
 Amount of effusion  
 Pericardial thickness  
 Valvular Abnormalities  
 Measurement of valve regurgitation/stenosis  
 Measurement  of left atrial volume  
Change #[ADDRESS_1172758] should return for an EDV and SFU Visit (Visit  9) 
including an echocardiogram within approximately [ADDRESS_1172759] to follow -up. 
Has been changed to (revision bolded):  
In case of discontinuation, the subject should return for an EDV and SFU Visit (Visit  9) 
including an echocardiogram within approximately [ADDRESS_1172760] to follow -up 
Change #[ADDRESS_1172761](s), the minimum requirements for source 
documents used in clinical studies are that they  should contain the identity of the subject and 
study -related identifiers (such as randomization/treatment number, or similar), they should 
mention the subject’s participation in the study and identification of that study (study title or 
number), they shou ld record the obtaining of consent (date of consent), the exposure to 
investigational product, the subject’s medical history, the concomitant medication treatments and 
dates (including contraceptive treatment), AEs and SAEs, and the of the visits. The sour ce 
documents should provide evidence that inclusion/exclusion criteria have been met.  
Has been changed to (revision bolded):  
For subjects randomized to investigational product(s), the minimum requirements for source 
documents used in clinical studies are t hat they should contain the identity of the subject and 
study -related identifiers (such as randomization/treatment number, or similar), they should 
mention the subject’s participation in the study and identification of that study (study title or 
number), t hey should record the obtaining of consent (date of consent), the exposure to 
investigational product, the subject’s medical history, the concomitant medication treatments and 
dates (including contraceptive treatment), AEs and SAEs, and the date of the visits. The source 
documents should provide evidence that inclusion/exclusion criteria have been met  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172762] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 120 of 152 Change #61  
Section 13.3.1   Analysis of the primary efficacy variable  
Subsections [IP_ADDRESS] and [IP_ADDRESS] have been added to account for the analysis of different 
primary efficacy variables for FDA/PMDA/other regulatory authorities not specified in Section 
[IP_ADDRESS] and for EMA and regulatory authorities who reference EMA.  
Old text (deletions bolded):  
The primary efficacy variable is the change from Base line in observable focal -onset seizure 
frequency per [ADDRESS_1172763]-Baseline (maintenance) seizure frequency will be transformed with the natural logarithm, 
specifically ln(x+1), where x represent s the 28 -day seizure frequency. The transformed seizure 
frequency data will be analyzed using analysis of covariance (ANCOVA) with treatment group 
as the main factor, Baseline log -adjusted seizure frequency as a continuous covariate, and 
Baseline SV2A use as a categorical factor . Linear contrasts will be constructed to compare 
the dose -response trend and  pairwise contrasts will be constructed to compute estimated effects 
of each dose from placebo.  
The ANCOVA model on the log -transformed, change from Baselin e in observable focal -onset 
seizure frequency will be used to assess the doses, corresponding responses, and final dose.  
The dose -response relationship for change from Baseline in observable focal -onset seizure 
frequency across 4 doses of PSL and placebo w ill be evaluated using the MCP -Mod 
methodology. Monotonic dose -response trends will be tested using the appropriate contrasts as 
determined by [CONTACT_271416] -Mod methodology such that the overall Type 1 error rate is controlled at 
0.05 (2 -sided testing). Four dif ferent dose -response models (“candidate models”) were identified: 
sigmoidal E max, Emax, log-linear, and logistic, and the MCP -Mod methodology controls for 
multiplicity.  
The SAP will describe additional features and detail around the MCP -Mod methodology as well 
as handling of missing data.  
All aforementioned analyses  of the primary efficacy variable will be repeated on the PPS.  
Assuming at least 1 statistically significant result is obtained from the primary MCP -Mod 
analysis each of the 4 dose groups will be  compared with placebo using the above analysis 
model . Type 1 error will be controlled by [CONTACT_843842] -up procedure within SAS® Proc 
Multtest. Full details will be provided in the SAP.  
Has been changed to (revisions bolded):  
[IP_ADDRESS]  Analysis of the p rimary efficacy variable for the US FDA, PMDA, and other 
regulatory authorities not specified in Section [IP_ADDRESS]  
Prior to the primary analysis, the dose -response relationship for  change from Baseline in 
observable focal -onset seizure frequency across 4 dos es of PSL and placebo will be evaluated 
using the MCP -Mod methodology. Monotonic dose -response trends will be tested using the 
appropriate contrasts as determined by [CONTACT_271416] -Mod methodology such that the overall Type 1 
error rate is controlled at 0.05 (2si ded testing). Four different dose -response models (“candidate 
models”) were identified: sigmoidal E max, Emax, log-linear, and logistic, and the MCP -Mod 
methodology controls for multiplicity.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172764] 1 statistically significant result is obtained from the primary MCP -Mod 
analysis , then pairwise comparisons of 400mg, 200mg and 100mg dose groups versus 
placebo will be carried out u sing the analysis model below. Type 1 error will be controlled by 
[CONTACT_843842] -up procedure within SAS® Proc Multtest.  If all the results of the pairwise 
comparisons are statistically significant then the 50mg dose group will be compared to 
placebo.  
For the US FDA, PMDA, and other regulatory authorities not specified in Section [IP_ADDRESS] 
the primary efficacy variable is the change in log-transformed  observable focal -onset seizure 
frequency from Baseline , over the [ADDRESS_1172765]-Baseline (maintenance) seizure frequency will be transformed with the natural logarithm, 
specifically ln(x+1), where x represents the 28 -day seizure frequency. The transformed seizure 
frequency data will be analyzed using analysis of covari ance (ANCOVA) with treatment group 
as the main factor, Baseline log -adjusted seizure frequency as a continuous covariate, and 
Baseline SV2A use and Region  as categorical factor s. Pairwise contrasts will be constructed to 
compute estimated effects of each d ose from placebo.  
All pairwise analyses  of the primary efficacy variable will be repeated on the PPS.  
A sensitivity analysis of the primary efficacy continuous variable will be carried out using a 
Mixed Model Repeated Measures analysis. Full details will be provided in the SAP.  
[IP_ADDRESS]  Analysis of the primary efficacy variable for EMA and regulatory authorities 
who reference EMA  
For EMA and regulatory authorities who reference EMA, the primary efficacy variable 
will be the 75% responder rate status and wi ll be analyzed using logistic regression with 
factors for treatment group, Baseline seizure frequency, Region, and Baseline SV2A use. If 
there are issues with convergence, Baseline SV2A use will be dropped. The responder rates 
are defined as a ≥75% reducti on in the observable focal -onset seizure frequency from 
Baseline over the 12 -week Maintenance Period.  
The same methodology carried out in Section [IP_ADDRESS] will be applied to MCP -Mod and the 
pairwise analyses.  
Change #62  
Section [IP_ADDRESS]  Sensitivity analysi s of the primary efficacy variable  
This section has been deleted.  
Change #63  
Section 13.3.2   Secondary efficacy analysis  
Subsections [IP_ADDRESS] and [IP_ADDRESS] have been added to account for differences in secondary 
efficacy variables for FDA/PMDA/other regulatory authorities not specified in Section [IP_ADDRESS] 
and for EMA and regulatory authorities who reference EMA.  
Old text (del etions bolded):  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172766] 1 of t he dose -response models. Pairwise testing will 
then be conducted using the appropriate multiplicity adjusted methods (eg, sequential 
testing, Hochberg, etc) to control for Type I error inflation, due to multiple pairwise dose 
comparison hypothesis. Details  of the multiplicity adjustments will be pre -specified and 
captured in the study SAP.  
The 75% responder rate status and 50% responder rate will be analyzed using logistic regression 
with factors for treatment group, Baseline seizure frequency, and Baseline  SV2A use. If there are 
issues with convergence, Baseline SV2A use will be dropped. The responder rates are defined as 
follows:  
 75% responder rate status: a ≥75% reduction in the observable focal -onset seizure frequency 
from Baseline over the 12 -week Maint enance Period  
 50% Responder rate: a ≥50% reduction in observable focal -onset seizure frequency from 
Baseline over the [ADDRESS_1172767]. The Hodges -Lehmann nonparametric estimator will be used to 
estimate the median percent reduction in seizures between groups and its corresponding 95% 
confidence interval (CI) will be provided.  
Has been changed to (revisions bolded):  
[IP_ADDRESS]  Second ary efficacy variables for the US FDA, PMDA, and other regulatory 
authorities not specified in Section [IP_ADDRESS]  
The 75% responder rate status and 50% responder rate will be analyzed using logistic regression 
with factors for treatment group, Baseline seizur e frequency, Region , and Baseline SV2A use. If 
there are issues with convergence, Baseline SV2A use will be dropped. The responder rates are 
defined as follows:  
 75% responder rate status: a ≥75% reduction in the observable focal -onset seizure frequency 
from Baseline over the 12 -week Maintenance Period  
 50% Responder rate status: a ≥50% reduction in observable focal -onset seizure frequency 
from Baseline over the [ADDRESS_1172768]. The Hodges -Lehmann nonparametric estimator will be used to 
estimate the median percent reduction in seizures between groups and its corresponding 95% 
confidence interval (CI) will be provided.  
[IP_ADDRESS]  Second ary efficacy variables for EMA and regulatory authorities who reference 
EMA  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172769] as for the primary 
analys is used for the FDA ie, pairwise comparisons of 400mg, 200mg and 100 mg dose 
groups versus placebo will be carried out using the analysis model described inSection 
[IP_ADDRESS]. Type 1 error will be controlled by [CONTACT_843842] -up procedure within SAS® 
Proc  Multtest. If the results of all pairwise comparisons are statistically significant, then 
the 50mg dose group will be compared to placebo.  
In addition, the 50% responder rate will be analyzed using logistic regression with factors 
for treatment group, Base line seizure frequency, Region, and Baseline SV2A use. If there 
are issues with convergence, Baseline SV2A use will be dropped. The responder rates are 
defined as follows:  
 50% Responder rate status: a ≥50% reduction in observable focal -onset seizure 
freque ncy from Baseline over the [ADDRESS_1172770]. The Hodges -Lehmann nonparametric estimator will be used 
to estimate the median perce nt reduction in seizures between groups and its corresponding 
95% (CI will be provided.  
Change #64  
Section 13.3.3   Other efficacy analyses, Paragraph 3 (deletion bolded)  
The time -to-loss of efficacy  will be analyzed using Kaplan -Meier methodology. Addition al 
details of the analysis will be captured in the SAP.  
Has been changed to (revision bolded):  
The time -to-return to baseline observable focal -onset seizure frequency  will be analyzed 
using Kaplan -Meier methodology. Additional details of the analysis will be captured in the SAP.  
Change #65  
Section 13.7  Planned interim analysis and data monitoring (deletions bolded)  
A DMC will be formed to monitor the ongoing safety of the study. The DMC will consist of at 
least [ADDRESS_1172771] 
care physicians. The duration of membership for the DMC will be inclusive of planned 
analyses for EP0091.  The DMC will periodically  review study data and evaluate the treatments 
for excess ad verse effects and other potential safety issues. The DMC may also be asked to 
provide a review of final study results, as deemed appropriate. The detailed role, scope, 
composition, responsibilities, and operation of the DMC, as well as the identity of the DMC 
members, will be defined in a separate DMC Charter.  
Safety and tolerability data will be made available to the DMC at each meeting as described in 
the DMC Charter. The data will be provided in a semi -unblinded fashion (data will be visualized 
by [CONTACT_5203] t reatment groups, but the treatment/dose assigned to each group will remain blinded) and 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172772] including cardiac and behavioral adverse events, in particular, will 
be monitored by [CONTACT_843863]. Statistical modeling will be used to provide estimates for quantification of the level of 
risk in the study based on the risk in the epi[INVESTIGATOR_843771] (see Inclusion and Exclusion Criteria in Section  6). This analysis will 
inform any decisions regarding changes in study conduct and/or study termination.  
The DMC procedures will ensure that the data remain blinded to the study team and 
Investigators at all times throughout the conduct of the study until the data have been unblinded.  
Has been changed to (revisions bolded):  
An independent  DMC will be formed to monitor the ongoing safety of the study. The DMC will 
consist of at least [ADDRESS_1172773] of members independent from UCB. Study enrollment will no t be halted during 
DMC review of the safety data. The DMC may also be asked to provide a review of final study 
results, as deemed appropriate. The detailed role, scope, composition, responsibilities, and 
operation of the DMC, as well as the identity of the  DMC members will be defined in a separate 
DMC Charter.  
Safety and tolerability data will be made available to the DMC at each meeting as described in 
the DMC Charter. The data will be provided in a semi -unblinded fashion (data will be visualized 
by [CONTACT_5203] t reatment groups, but the treatment/dose assigned to each group will remain blinded) and 
the full unblinding can be requested by [CONTACT_13156], if appropriate. Pharmacokinetic data 
may be provided to the DMC at their request. These safety, tolerability, a nd PK data will be 
presented by [CONTACT_843847]. The deliberations 
and decisions of the DMC will be formally documented.  
Ad hoc DMC meetings can be held for other reasons if deemed appropriate by [CONTACT_1034] o r the 
DMC members.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172774] udy (see Inclusion and Exclusion Criteria in Section 6). This analysis may 
inform any decisions regarding changes in study conduct and/or study termination.  
The DMC procedures will ensure that the data remain blinded to the study team and 
Investigators at all times throughout the conduct of the study until the data have been unblinded. 
Only DMC members and an independent statistical group will have access to unblinded 
safety data emerging from the study. DMC members will also have access to unblinded 
effica cy data when required. It is understood that maintaining validity and integrity of the 
study is of paramount importance to ensure its acceptability to the Sponsor, the scientific 
community and health authorities.  
Change #66  
Section 13.8  Determination of sa mple size (deletions bolded)  
The size of this study is governed by [CONTACT_663985] a dose -response 
relationship across the [ADDRESS_1172775] udy is change from Baseline of the 
log-transformed (ln  x +1) 28 -day adjusted seizure frequency . Four different dose -response 
models (“candidate models”) were identified: sigmoidal E max, Emax, log-linear, and logistic, 
and the MCP -Mod methodology controls f or multiplicity.  
The sample size assessment was estimated using the “Dose Finding” library in the R 
statistical package (Bretz  et al, 2005). This software library implements design and analysis 
aspects of the MCP -Mod method. The sample size requirement was  obtained for each 
candidate model in turn and the maximum value was taken, thus maintaining the power 
requirement.  
The log -reduction from Baseline in seizure frequency was assumed to be 0.195 for placebo and 
0.780 for PSL. A common SD of 0.985 was assumed . These estimates are based on prior 
experience in epi[INVESTIGATOR_843772]0069 study results.  
With power of 90%, a 2 -sided Type -1 error of 5%, and all dose groups of the same size, 
50 subjects are required per arm, for a total of 250 subjects.  
Assumi ng a screening failure rate of approximately 20%, it is anticipated to enroll around 
300 subjects and randomize 250 subjects in this study.  
Has been changed to (revisions bolded):  
The sample size is based on achieving 90% power to observe a statistically s ignificant result 
for either the 400mg and 200mg or 200mg and 100mg doses when compared to placebo , a 
primary endpoint of change from Baseline of the log -transformed (ln x +1) [ADDRESS_1172776] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 126 of 152 The log -reduction from Baseline in seizure frequency was assumed to be 0.195 for placebo and 
0.780 for PSL. A common SD of 0.985 was assumed. These estimates are based on prior 
experience in epi[INVESTIGATOR_843792] t he EP0069 study results.  
With power of 90%, a 2 -sided Type -1 error of 5%, and all dose groups of the same size, 
80 subjects are required per arm, giving a total of 400 subjects.  
Assuming a screening failure rate of approximately 20%, it is anticipated to e nroll around 
500 subjects and randomize 400 subjects in this study.  
The study is also powered to give over 80% power to observe a statistically significant 
result for either the 400mg and 200mg or 200mg and 100mg doses when compared to 
placebo for the 75% response rate endpoint, the primary endpoint specified for EMA.  
Change #67  
Section 16   References  
Has been added:  
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. Definition of 
drug resistant epi[INVESTIGATOR_002]: Consensus proposal by [CONTACT_843864]. Epi[INVESTIGATOR_8330]. 2010;51(6):1069 -77.  
Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L. ILAE Classification 
of the epi[INVESTIGATOR_31629]: Position paper of the ILAE Commission for Class ification Terminology. 
Epi[INVESTIGATOR_8330]. 2017;58(4):512 -21.  
Has been deleted:  
Bretz F, Pi[INVESTIGATOR_144676], Branson M. Combining multiple comparisons and modeling techniques in 
dose-response studies. Biometrics. 2005;61(3):[ADDRESS_1172777] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 127 of 152 17.2 Protocol Amendment 2  
Rationale for the amendment  
The main reason the protocol has been amended is to clarify that the primary efficacy analysis is 
comparing each padsevonil dose to placebo with Type I error controlled for all comparisons. 
MCP -Mod analysis has been removed since it will no l onger contribute to the overall study 
conclusion and dose selection for future studies.  
Other changes include the following:  
 Updates to study contact [CONTACT_3031] . 
 Minor refinements to the wording describing responder rate variables.  
 Correction of the ma ximum duration of exposure to PSL from 20 to 19 weeks.  
 Clarification of the rationale for the study to state that dose -response relationship will be 
evaluated with respect to safety as well as efficacy . 
 Revised other efficacy variable, number of seizure -free days to percentage of seizure -free 
days.  
 Revised other efficacy variable, time to return to baseline observable focal -onset seizure 
frequency to time to return to baseline 28 -day observable seizure count.  
 Revision of designation of TEAEs, TEAEs leadi ng to withdrawal, and SAEs from “safety 
variables” to “primary safety variables.” A heading was added for these primary variables.  
 Clarification  of a Schedule of Assessments footnote  that questionnaires should be completed 
prior to other study procedures, when possible. Previously it was mandated that these be 
completed prior to other procedures.  
 Removal of efficiencies of the MCP -Mod model based design and analysis as one of the 
drivers for EP0091 dose selection. In addition, the rationale for selection o f intermediate 
doses was revised due to the elimination of MCP -Mod analysis.  
 Revision of Inclusion Criterion [ADDRESS_1172778] that use of legal 
representative/caregiver may not be legally permitted in some countries.  
 Modification of Inclusion Cr iterion 5 to facilitate the acceptance of ambulatory EEGs which 
are used more frequently in some regions, to require (must versus should) consultation with 
the UCB Study Physician or representative when determining subject eligibility based on 
eye-witness seizure report, home video documentation, or other proof, and to allow 
substitution of head CT for MRI if MRI is contraindicated.  
 Modification of Exclusion Criterion 1 to allow re -screening of subjects under certain 
circumstances.  
 Clarification of t he description of the interpretation o f echocardiograms   
 The original description stated that the echocardiograms would be interpreted at the sites 
by [CONTACT_843865] s and then provided to a central reader where they would be 
interpreted. Given that all echoc ardiograms are to be centrally read and a report provided 
within [ADDRESS_1172779].  
 Clarification of the Titration Period Dosing Table 7 -1 to indicate that this period consists of 
Week 1, Week 2, and Week 3 (versus previous unclear designations of Day 1, Week 1 and 
Week 2).  
 Clarifications regarding administration of the Seizure Severity Global Item, Quality of Life 
Inventory inEpi[INVESTIGATOR_002] -31-P, and Hospi[INVESTIGATOR_5620].  
 Other modifications to the Statistics section (in addition to those related to the removal of 
MCP -Mod analysis), such as inclusion of information on handlin g of dropouts and missing 
data and further details about the determination of sample size.  
Modifications and changes  
Specific changes  
Change # [ADDRESS_1172780] Information  
Sponsor Study Physician  
Name:   
[CONTACT_2761]:  UCB Biosciences GmbH  
Alfred Nobel Strasse, 10  
[ZIP_CODE] Monheim am Rhein,  
[LOCATION_013]  
Phone:   
Clinical Project Manager  
Name:   
[CONTACT_2761]:  UCB Biopharma SPRL  
Allée de la Recherche 60  
1070 Brussels  
Belgium  
Phone:  +  
REDACTED COPY 
This document cannot be used to su ort an rketing authorization application and any extensions or variations thereof. 

UCB   [ADDRESS_1172781] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 129 of 152 Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  UCB Biosciences GmbH  
Alfred Nobel Strasse, 10  
[ZIP_CODE] Monheim am Rhein,  
[LOCATION_013]  
Phone:   
Has been changed to  (bolded text added or revised) : 
Sponsor Study Physician  
Name:   [CONTACT_843877]:  UCB Biosciences GmbH  
Alfred Nobel Strasse, 10  
[ZIP_CODE] Monheim am Rhein,  
[LOCATION_013]  
Phone:   
Clinical Project Manager  
Name:   
[CONTACT_2761]:  UCB Biosciences GmbH  
Alfred Nobel Strasse, 10  
[ZIP_CODE] Monheim am Rhein,  
[LOCATION_013]  
Phone:   
Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  UCB Pharma Ltd  
[ADDRESS_1172782]  
Berkshire SL 13WE Slough,  
[LOCATION_006] 
Phone:   
Change # [ADDRESS_1172783] of Abbreviations  
Has been added:  
LOCF=last observation carried forward  
REDAC ED COPY 
This document cannot be used to su ort an arketing authorization application and any extensions or variations thereof. 

UCB   [ADDRESS_1172784] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 130 of 152 Change # 3 
Section 1: Summary, Paragraph 5 (bolded text deleted)  
The assessment of efficacy is based on seizure frequency. For the US Food and Drug 
Administration (FDA), Pharmaceuticals and Medical Devices Agency (PMDA), and other 
regulatory authorities not specified in Section  [IP_ADDRESS] , the primary efficacy variable is the change 
from Baseline in log -transformed observable focal -onset seizure frequency (for the purpose of 
this protocol defined as Types IA1, IB, and IC, according to the International League Against 
Epi[INVESTIGATOR_002] [ILAE ] classification [ ILAE  Classification  of Epi[INVESTIGATOR_843714],  1981 ]) over  the 
12-week Maintenance Period. For the European Medicines Agency (EMA) and regulatory 
authorities who reference EMA, the primary efficacy variable is the 75% responder rate status , 
defined as  a ≥75% reduction in observable focal -onset seizure frequency from Baseline, over the 
12-week Maintenance Period.  
Has been changed to (bolded text added):  
The assessment of efficacy is based on seizure frequency. For the US Food and Drug 
Administ ration (FDA), Pharmaceuticals and Medical Devices Agency (PMDA), and other 
regulatory authorities not specified in Section  [IP_ADDRESS], the primary efficacy variable is the change 
from Baseline in log -transformed observable focal -onset seizure frequency (for t he purpose of 
this protocol defined as Types IA1, IB, and IC, according to the International League Against 
Epi[INVESTIGATOR_002] [ILAE] classification [ILAE  Classification  of Epi[INVESTIGATOR_843714],  1981]) over the 
12-week Maintenance Period. For the European Medicines Ag ency (EMA) and regulatory 
authorities who reference EMA, the primary efficacy variable is the 75% responder rate, where 
a responder is a subject experiencing a  ≥75% reduction in observable focal -onset seizure 
frequency from Baseline, over the 12 -week Maint enance Period.  
Change # 4 
Section 1: Summary, Paragraph 7 (bolded text deleted)  
The total duration of study per subject will be up to 2 7 weeks with a maximum of 20 weeks 
exposure to PSL. It is estimated that approximately 500 subjects will be included at 
approximately 200 sites worldwide; 400  subjects are expected to be randomized.  
Has been changed to (bolded text added):  
The total duration of study per subject will be up to 27  weeks with a maximum of 19 weeks 
exposure to PSL. It is estimated that approximat ely 500  subjects will be included at 
approximately 200  sites worldwide; 400  subjects are expected to be randomized.  
Change # 5 
Section 2.4: Rationale for this study, Paragraph [ADDRESS_1172785] to efficacy of PSL administered 
concomitantly with up to 3 AEDs for treatment of observable focal -onset seizures.   
Has been changed to (bolded text added):  
Padsevonil is an AED with a dual mechanism of action, specifica lly synthesized and designed 
for an increased anticonvulsant activity and hence for the treatment of seizures in patients with 
epi[INVESTIGATOR_843730]. Based on the evidence of unprecedented 
superiority of seizure control c ompared with other marketed AEDs across several preclinical 
models of epi[INVESTIGATOR_843731], EP0069, treatment with PSL has 
the potential to benefit an underserved epi[INVESTIGATOR_843732], 
namely th ose who have drug -resistant epi[INVESTIGATOR_843733] -onset seizures 
constitute a substantial threat to their health and well -being. The current study, EP0091, will 
characterize the dose -response relationship with respect to efficacy and safety  of PSL 
administered concomitantly with up to 3 AEDs for treatment of observable focal -onset seizures.  
Change # 6  
Section [IP_ADDRESS]:  Primary efficacy variable for EMA and regulatory authorities who 
reference EMA (bolded text deleted)  
The primary efficacy variab le is the 75% responder rate status , defined as  a ≥75% reduction in 
observable focal -onset seizure frequency from Baseline, over the 12 -week Maintenance Period . 
Has been changed to (bolded text added):  
The primary efficacy variable is  the 75% responder rat e, where a responder is a subject 
experiencing  a ≥75% reduction in observable focal -onset seizure frequency from Baseline, over 
the 12 -week Maintenance Period.  
Change # 7  
Section [IP_ADDRESS]: Secondary efficacy variables for the US FDA, PMDA, and other regulatory 
authorities not specified in Section [IP_ADDRESS] (bolded text deleted)  
The secondary efficacy variables are as follows:  
 The 75% responder rate status , defined as  a ≥75% reduction in observable focal -onset 
seizure frequency from Baseline, over the 1 2-week Maintenance Period  
 The 50% responder rate status , defined as  a ≥50% reduction in observable focal -onset 
seizure frequency from Baseline, over the 12 -week Maintenance Period  
 Percent reduction in observable focal -onset seizure frequency from Baseline,  over the 
12-week Maintenance Period  
Has been changed to (bolded text added):  
The secondary efficacy variables are as follows:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172786] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 132 of 152  The 75% responder rate, where a responder is a subject experiencing  a ≥75% reduction in 
observable focal -onset seizure frequency from Baseline, over the 12 -week Maintenance 
Period  
 The 50% responder rate, where a responder is a subject experiencing  a ≥50% reduction in 
observable focal -onset seizure frequency from Baseline,  over the 12 -week Maintenance 
Period  
 Percent reduction in observable focal -onset seizure frequency from Baseline, over the 
12-week Maintenance Period  
Change # 8  
Section [IP_ADDRESS]: Secondary efficacy variables for EMA and regulatory authorities who 
reference  EMA (bolded text deleted)  
The secondary efficacy variables are as follows:  
 The change in log -transformed observable focal -onset seizure frequency from Baseline, over 
the 12 -week Maintenance Period  
 The 50% responder rate status , defined as  a ≥50% reductio n in observable focal -onset 
seizure frequency from Baseline, over the 12 -week Maintenance Period  
 Percent reduction in observable focal -onset seizure frequency from Baseline, over the 
12-week Maintenance Period  
Has been changed to (bolded text added):  
The secondary efficacy variables are as follows:  
 The change in log -transformed observable focal -onset seizure frequency from Baseline, over 
the 12 -week Maintenance Period  
 The 50% responder rate, where a responder is a subject experiencing  a ≥50% reduction in 
observable focal -onset seizure frequency from Baseline, over the 12 -week Maintenance 
Period  
 Percent reduction in observable focal -onset seizure frequency from Baseline, over the 
12-week Maintenance Period  
Change # 9  
Section 4.1.3: Other efficacy variables  (This list applies for all regulatory authorities) 
(bolded text deleted)  
The other efficacy variables are as follows:  
 Change from Baseline in log -transformed observable focal -onset seizure frequency over the 
first [ADDRESS_1172787] 4 wee ks of the 12 -week Maintenance Period  
 Change from Baseline in log -transformed observable focal -onset seizure frequency over the 
16-week Treatment Period  
 The 50% responder rate status , defined as  a ≥50% reduction in observable focal -onset 
seizure frequency from Baseline, over the [ADDRESS_1172788] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 133 of 152  The 75% responder rate status , defined as  a ≥75% reduction in observable focal -onset 
seizure frequency from Baseline, over the 16 -week Treatment Period  
 The 90% responder rate status , defined as  a ≥90% reduction in observable focal -onset 
seizure frequency from Baseline, over the 12 -week Maintenance Period  
 Percent reduction in observable focal -onset seizure frequency from Baseline, over the 
16-week Treatment Period  
 Change from Baseline in log -transformed focal -onset (Type I) seizure frequency over the 
12-week Maintenance Period  
 The 50% responder rate status , defined as  a ≥50% reduction in focal -onset (Type I) seizure 
frequency from Baseline, over the  12-week Maintenance Period  
 The 75% responder rate status , defined as  a ≥75% reduction in focal -onset (Type I) seizure 
frequency from Baseline, over the 12 -week Maintenance Period  
 The 90% responder rate status , defined as  a ≥90% reduction in focal -onset (Type I) seizure 
frequency from Baseline, over the 12 -week Maintenance Period  
 Percent reduction in focal -onset (Type I) seizure frequency from Baseline, over the 12 -week 
Maintenance Period and the 16 -week Treatment Period  
 Seizure -freedom status (yes/no) du ring the 12 -week Maintenance and the 16 -week Treatment 
Period  
 Number  of seizure -free days during the 12 -week Maintenance Period and the 16 -week 
Treatment Period  
 Cumulative responder rate during the 16 -week Treatment Period  
 Change in the Seizure Severity Gl obal Item (SSG) scores from Baseline to Week  4 during 
the Maintenance Period (Visit  4) and the end of the 16 -week Treatment Period (Visit  7) 
 Change in Quality of Life Inventory in Epi[INVESTIGATOR_002] -31-P (QOLIE -31-P) scores from Baseline to 
Week  4 during the Mainten ance Period (Visit  4) and the end of the 16 -week Treatment 
Period (Visit  7) 
 Change in HADS scores from Baseline to Week 4 during the Maintenance Period (Visit  4) 
and to the end of the 16 -week Treatment Period (Visit  7) 
 Time to return to baseline observable  focal -onset seizure frequency  during the 12 -week 
Maintenance Period  
 Use of health -related outcomes and HRU, including healthcare provider consultations not 
foreseen by [CONTACT_990], caregiver support, concurrent medical procedures, concomitant 
medications and  hospi[INVESTIGATOR_843793] (bolded text added):  
The other efficacy variables are as follows:  
 Change from Baseline in log -transformed observable focal -onset seizure frequency over the 
first [ADDRESS_1172789] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 134 of 152  Change from Baseline in log -transformed observable focal -onset seizure frequency over the 
16-week Treatment Period  
 The 50% responder rate, where a responder is a subject experiencing  a ≥50% reduction in 
observable focal -onset seizur e frequency from Baseline, over the 16 -week Treatment Period  
 The 75% responder rate, where a responder is a subject experiencing  a ≥75% reduction in 
observable focal -onset seizure frequency from Baseline, over the 16 -week Treatment Period  
 The 90% responde r rate, where a responder is a subject experiencing  a ≥90% reduction in 
observable focal -onset seizure frequency from Baseline, over the 12 -week Maintenance 
Period  
 Percent reduction in observable focal -onset seizure frequency from Baseline, over the 
16-week Treatment Period  
 Change from Baseline in log -transformed focal -onset (Type I) seizure frequency over the 
12-week Maintenance Period  
 The 50% responder rate, where a responder is a subject experiencing  a ≥50% reduction in 
focal -onset (Type I) seizure frequ ency from Baseline, over the 12 -week Maintenance Period  
 The 75% responder rate, where a responder is a subject experiencing  as a ≥75% reduction 
in focal -onset (Type I) seizure frequency from Baseline, over the 12 -week Maintenance 
Period  
 The 90% responder r ate, where a responder is a subject experiencing  a ≥90% reduction in 
focal -onset (Type I) seizure frequency from Baseline, over the 12 -week Maintenance Period  
 Percent reduction in focal -onset (Type I) seizure frequency from Baseline, over the 12 -week 
Maint enance Period and the 16 -week Treatment Period  
 Seizure -freedom status (yes/no) during the 12 -week Maintenance and the 16 -week Treatment 
Period  
 Percentage  of seizure -free days during the 12 -week Maintenance Period and the 16 -week 
Treatment Period  
 Cumulative  responder rate during the 16 -week Treatment Period  
 Change in the Seizure Severity Global Item (SSG) scores from Baseline to Week  4 during 
the Maintenance Period (Visit  4) and the end of the 16 -week Treatment Period (Visit  7) 
 Change in Quality of Life Inve ntory in Epi[INVESTIGATOR_002] -31-P (QOLIE -31-P) scores from Baseline to 
Week  4 during the Maintenance Period (Visit  4) and the end of the 16 -week Treatment 
Period (Visit  7) 
 Change in HADS scores from Baseline to Week 4 during the Maintenance Period (Visit  4) 
and to the end of the 16 -week Treatment Period (Visit  7) 
 Time to return to baseline 28-day observable focal -onset seizure count  during the [ADDRESS_1172790] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 135 of 152  Use of health -related outcomes and HRU, including healthcare provider consultations not 
foreseen by [CONTACT_990], caregiver support, concurrent medical procedures, concomitant 
medications and hospi[INVESTIGATOR_843794] # 10  
Section 4.2: Safety variables  
The safety variables are as follows:  
 Incidence of TEAEs reported by [CONTACT_3184]/or caregiver or observed by [CONTACT_843866]  
 Incidence of TEAEs leading to study withdrawal  
 Incidence of treatment -emergent serious adverse events (SAEs) during the entire  study  
4.2.1 Other safety variables  
Other safety variables are as follows:  
 Incidence of TEAEs reported by [CONTACT_3184]/or caregiver or observed by [CONTACT_843801]: 16 -week Treatment Period, 12 -week Maintenance Period, 
4-week Titration/Stabilization Period, and 3 -week Taper Period  
 Number of and reaso n for subjects requiring premature tapering due to TEAEs  
 Number of and reason for subjects requiring a dose reduction during the Stabilization Period 
due to TEAEs  
 Incidence of treatment -emergent SAEs during the following periods: 16 -week Treatment 
Period, 12-week Maintenance Period, 4 -week Titration/Stabilization Period  
 Changes in clinical laboratory test parameters (including hematology, blood chemistry, and 
urinalysis)  
 Changes in vital sign parameters (including pulse rate, systolic BP, diastolic BP, and 
respi[INVESTIGATOR_697])  
 Changes in 12 -lead ECG parameters  
 Physical examination (including body weight) and neurological examination findings  
 Changes in Psychiatric and Mental Status  
 Occurrence of valvular abnormalities or pericardial effusion changes or other si gnificant 
abnormalities as identified by 2 -dimensional Doppler echocardiogram at each assessment by 
[CONTACT_39582]  
 Changes in withdrawal symptoms using Clinical Institute Withdrawal 
Assessment -Benzodiazepi[INVESTIGATOR_1651] (CIWA -B) from the End of Treatment Visit (Visi t 7) to end of 
the Taper Period (Visit  8) and end of the SFU Period (Visit  9 [[ADDRESS_1172791] IMP 
intake]).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172792] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 136 of 152 Has been changed to (added a level 3 heading for the safety variables and 
designated them as primary safety variables):  
4.2.1  Primary safety variables  
The safety variables are as follows:  
 Incidence of TEAEs reported by [CONTACT_3184]/or caregiver or observed by [CONTACT_843866]  
 Incidence of TEAEs leading to study withdrawal  
 Incidence of treatment -emergent serious adverse events (SAEs) during the entire  study  
4.2.2  Other safety variables  
Other safety variables are as follows:  
 Incidence of TEAEs reported by [CONTACT_3184]/or caregiver or observed by [CONTACT_843801]: 16 -week Treatment Pe riod, 12 -week Maintenance Period, 
4-week Titration/Stabilization Period, and 3 -week Taper Period  
 Number of and reason for subjects requiring premature tapering due to TEAEs  
 Number of and reason for subjects requiring a dose reduction during the Stabilizati on Period 
due to TEAEs  
 Incidence of treatment -emergent SAEs during the following periods: 16 -week Treatment 
Period, 12 -week Maintenance Period, 4 -week Titration/Stabilization Period  
 Changes in clinical laboratory test parameters (including hematology, bloo d chemistry, and 
urinalysis)  
 Changes in vital sign parameters (including pulse rate, systolic BP, diastolic BP, and 
respi[INVESTIGATOR_697])  
 Changes in 12 -lead ECG parameters  
 Physical examination (including body weight) and neurological examination findings  
 Chang es in Psychiatric and Mental Status  
 Occurrence of valvular abnormalities or pericardial effusion changes or other significant 
abnormalities as identified by 2 -dimensional Doppler echocardiogram at each assessment by 
[CONTACT_39582]  
 Changes in withdrawal sy mptoms using Clinical Institute Withdrawal 
Assessment -Benzodiazepi[INVESTIGATOR_1651] (CIWA -B) from the End of Treatment Visit (Visit  7) to end of 
the Taper Period (Visit  8) and end of the SFU Period (Visit  9 [[ADDRESS_1172793] IMP 
intake]).  
Change # 11  
Section 5.1.2 : Study duration per subject, Paragraph 1 (bolded text deleted)  
The total duration of study per subject will be up to [ADDRESS_1172794] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 137 of 152 (±1 month ) after the last IMP intake  only for subjects exposed to IMP for  more than 3  weeks  and 
either discontinuing the study or not entering the OLE .  
Has been changed to (bolded text added):  
The total duration of study per subject will be up to 27 weeks with a maximum of 19 weeks 
exposure to PSL. An additional follow -up echocardiogram will be performed at 6  months 
(±1 month) after the last IMP intake only for subjects exposed to IMP for more t han 3  weeks and 
either discontinuing the study or not entering the OLE.  
Change # 12  
Section 5.2: Schedule of study assessments, Table 5 -1, footnote c  
Questionnaires to be completed by [CONTACT_843867].  
Has been  changed to (bolded text added):  
Questionnaires to be completed by [CONTACT_843867] , 
when possible . 
Change # 13  
Section 5.4.2: Rationale for dose selection (bolded text deleted)  
Dose selection for EP0091 was informed by [CONTACT_843804]:  
1. Efficiencies of the MCP -Mod model -based design and analysis  
2. UP0036: PET -derived human SV2A receptor occupancy vs exposure relationship  
3. N01383: PET -derived human GABA -A receptor occupancy  
4. The maximum tolerated dose (MTD) of 400mg bid in Phase 1  
5. EP0069: efficacy -exposure analysis  
6. Preclinical pharmacological exposure -response data  
Four dose levels of PSL (equally spaced on the logarithmic scale), 100mg/day, 200mg/day, 
400mg/day, and 800mg/day, administered bid hav e been selected to fully explore the 
dose-response curve for PSL in patients with drug -resistant epi[INVESTIGATOR_002].  
Two PET studies, UP0036: PET -derived human SV2A receptor occupancy and 
N01383:  PET-derived human GABA -A receptor occupancy, were performed to inform dose 
selection for the clinical studies. Using population -PK modeling of the PK and PET data with a 
SV2A ligand in UP0036, simulations projected SV2A receptor occupancy in human brain 
regions to be greater than 90% over the whole dosing interval for 90% of  a population treated 
with the 400 and 300mg bid dosing, and greater than 90% for 75% of a population at 100mg bid 
dosing. In N01383, modeling of the receptor occupancy of PSL at brain GABA -A receptors 
measured using the PET ligand, flumazenil, demonstrate d that subjects treated with PSL 200mg 
bid had maximal GABA -A receptor occupancy ranging from lower limit quantification (5%) to 
9.7%. Subjects treated with PSL 400mg bid had maximal GABA -A receptor occupancy ranging 
from 7.6% to 16.8%.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172795] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 138 of 152 The rationale for t he selection of the maximum dose, 400mg bid (800mg/day), is based on the 
MTD seen in Phase 1 single dose and multiple dose clinical studies, and is in line with receptor 
occupancy at the SV2A receptor and the nonclinical data described above. Furthermore, 
800mg/day has demonstrated clinically meaningful efficacy (EP0069 primary outcome analysis) 
with acceptable tolerability. The maximum dose is supported further by [CONTACT_843868]2A receptor occupancy are required fo r efficacy in the primary 
model of resistant epi[INVESTIGATOR_002] (amygdala kindling, mean effective dose [ED 50]=95%). Conversely, 
receptor occupancy at the GABA site associated with efficacy was relatively low (ED 50=9%). 
Therefore, it is reasonable to conclude that t he high dose level should be associated with 
occupancy consistent with these levels observed at SV2A and GABA -A receptors and 
maintained for SV2A.  
However, for brivaracetam, an AED with SV2A mode of action, a dose with demonstrated 
therapeutic efficacy (20 0mg), had an observed SV2A receptor occupancy below 90% 
(UCB  internal data, EP0074). In this context, the lowest dose for PSL in EP0091 has been set at 
100mg/day (50mg bid) based on preliminary simulations that indicate that a dose around 
50mg  bid will hav e an SV2A occupancy roughly equivalent to that associated with a therapeutic 
dose of brivaracetam. Of note, data from N01383 indicates that, at this lower dose level, 
GABA -A receptor occupancy may be below quantifiable levels, but even very low levels of 
occupancy may provide some synergy with SV2 mechanisms.  
Finally, the 2 intermediate doses, in the ascending part of the dose -response curve, were 
selected to increase the efficiencies of the MCP -Mod model -based design and analysis of 
EP0091 for dose finding : 
 100mg bid (200mg/day) which represent an SV2A receptor occupancy >90% with no 
quantifiable GABA -A occupancy  
 200mg bid (400mg/day) which represent an SV2A receptor occupancy >90% with 
quantifiable GABA -A occupancy  
Subjects completing the Maintenance Perio d in EP0091 will be offered the option to enter the 
OLE study EP0093 with open -label treatment with PSL. This will be achieved through a 
Conversion Period to ensure blinding of the parent study. All subjects who choose to transition to 
EP0093 will enter th e study after the 3 -week Conversion Period at an intermediate dose of 
400mg/day PSL before further individual dose adjustment can be made. This dose level was 
selected considering the benefit/risk balance and is based on clinical pharmacology and PET data 
in healthy human subjects suggesting that it will provide full occupancy at the SV2A binding site 
while maintaining some minimal binding to the GABA -A binding site. For subjects previously 
on placebo in EP0091, a full SV2A occupancy is desirable to obtain a meaningful anticonvulsive 
effect while minimal BZD binding will result in fewer GABA -related CNS AEs. On the other 
hand, for subjects exposed to high doses of PSL in EP0091 maintenance (800mg/day), the target 
transition dose of 400mg/day will likely main tain the full SV2A -related effect while not entirely 
eliminating GABA -binding related effects. Once subjects enter EP0093, further individual dose 
adjustments can be made, as needed as per the OLE protocol.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172796] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 139 of 152 Has been changed to:  
Dose selection for EP0091 wa s informed by [CONTACT_843804]:  
1. UP0036: PET -derived human SV2A receptor occupancy vs exposure relationship  
2. N01383: PET -derived human GABA -A receptor occupancy  
3. The maximum tolerated dose (MTD) of 400mg bid in Phase 1  
4. EP0069: efficacy -exposur e analysis  
5. Preclinical pharmacological exposure -response data  
Four dose levels of PSL (equally spaced on the logarithmic scale), 100mg/day, 200mg/day, 
400mg/day, and 800mg/day, administered bid have been selected to fully explore the 
dose-response curve for PSL in patients with drug -resistant epi[INVESTIGATOR_002].  
Two PET studies, UP0036: PET -derived human SV2A receptor occupancy and 
N01383:  PET-derived human GABA -A receptor occupancy, were performed to inform dose 
selection for the clinical studies. Using population -PK modeling of the PK and PET data with a 
SV2A ligand in UP0036, simulations projected SV2A receptor occupancy in human brain 
regions to be greater than 90% over the whole dosing interval for 90% of a population treated 
with the 400 and 300mg bid dosing, and greater than 90% for 75% of a population at 100mg bid 
dosing. In N01383, modeling of the receptor occupancy of PSL at brain GABA -A receptors 
measured using the PET ligand, flumazenil, demonstrated that subjects treated with PSL 200mg 
bid had maximal GA BA-A receptor occupancy ranging from lower limit quantification (5%) to 
9.7%. Subjects treated with PSL 400mg bid had maximal GABA -A receptor occupancy ranging 
from 7.6% to 16.8%.  
The rationale for the selection of the maximum dose, 400mg bid (800mg/day), is based on the 
MTD seen in Phase 1 single dose and multiple dose clinical studies, and is in line with receptor 
occupancy at the SV2A receptor and the nonclinical data described above. Furthermore, 
800mg/day has demonstrated clinically meaningful efficacy  (EP0069 primary outcome analysis) 
with acceptable tolerability. The maximum dose is supported further by [CONTACT_843868]2A receptor occupancy are required for efficacy in the primary 
model of resistant epi[INVESTIGATOR_002] (am ygdala kindling, mean effective dose [ED 50]=95%). Conversely, 
receptor occupancy at the GABA site associated with efficacy was relatively low (ED 50=9%). 
Therefore, it is reasonable to conclude that the high dose level should be associated with 
occupancy co nsistent with these levels observed at SV2A and GABA -A receptors and 
maintained for SV2A.  
However, for brivaracetam, an AED with SV2A mode of action, a dose with demonstrated 
therapeutic efficacy (200mg), had an observed SV2A receptor occupancy below 90% 
(UCB  internal data, EP0074). In this context, the lowest dose for PSL in EP0091 has been set at 
100mg/day (50mg bid) based on preliminary simulations that indicate that a dose around 
50mg  bid will have an SV2A occupancy roughly equivalent to that associated  with a therapeutic 
dose of brivaracetam. Of note, data from N01383 indicates that, at this lower dose level, 
GABA -A receptor occupancy may be below quantifiable levels, but even very low levels of 
occupancy may provide some synergy with SV2 mechanisms.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172797] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 140 of 152 Finally, the 2 intermediate doses were selected based on equal spacing between the high 
and low doses on log -scale and SV2A and GABA -A receptor occupancy:  
 100mg bid (200mg/day) which represent an SV2A receptor occupancy >90% with no 
quantifiable GABA -A occ upancy  
 200mg bid (400mg/day) which represent an SV2A receptor occupancy >90% with 
quantifiable GABA -A occupancy  
Subjects completing the Maintenance Period in EP0091 will be offered the option to enter the 
OLE study EP0093 with open -label treatment with PSL . This will be achieved through a 
Conversion Period to ensure blinding of the parent study. All subjects who choose to transition to 
EP0093 will enter the study after the 3 -week Conversion Period at an intermediate dose of 
400mg/day PSL before further indi vidual dose adjustment can be made. This dose level was 
selected considering the benefit/risk balance and is based on clinical pharmacology and PET data 
in healthy human subjects suggesting that it will provide full occupancy at the SV2A binding site 
while  maintaining some minimal binding to the GABA -A binding site. For subjects previously 
on placebo in EP0091, a full SV2A occupancy is desirable to obtain a meaningful anticonvulsive 
effect while minimal BZD binding will result in fewer GABA -related CNS AEs.  On the other 
hand, for subjects exposed to high doses of PSL in EP0091 maintenance (800mg/day), the target 
transition dose of 400mg/day will likely maintain the full SV2A -related effect while not entirely 
eliminating GABA -binding related effects. Once sub jects enter EP0093, further individual dose 
adjustments can be made, as needed as per the OLE protocol.  
Change # 14  
Section 6.1: Inclusion criterion [ADDRESS_1172798]/legal representative/caregiver is considered reliable and capable of adhering to the 
protocol ( eg, able to understand and complete diaries), visit schedule, or medication intake 
according to the judgment of the Investigator . 
Has been changed to (bolded text added):  
[ADDRESS_1172799]/legal representative/caregiver (where legally permitted)  is considered reli able and 
capable of adhering to the protocol (eg, able to understand and complete diaries), visit 
schedule, or medication intake according to the judgment of the Investigator.  
Change # 15  
Section 6.1: Inclusion criterion 5 (bolded text deleted)  
[ADDRESS_1172800] f ulfills diagnostic criteria for epi[INVESTIGATOR_843740] -onset ( 1A1, 1B, and 
1C) seizures for at least 3 years at the time of enrolment (according to the 
ILAE  Classification  of Epi[INVESTIGATOR_843714],  1981 ): 
 Epi[INVESTIGATOR_843741] -EEG recordings in the past 
(description or report is available). The Investigator must consult with the UCB Study 
Physician or representative for confirmation of eligibility as per instructions in th e 
Study  Manual.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172801] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 141 of 152 If no video -EEG report is available and, in the opi[INVESTIGATOR_689], epi[INVESTIGATOR_843742] (ie,  eye-witnessed seizure report, ictal EEG evidence during 
clinical event , home video documentation of habitual events), the Investigator should  
consult with the UCB Study Physician or representative for a case review  
 A brain magnetic resonance imaging (MRI) to be performed before randomization, if no 
such scan was performed in  the last [ADDRESS_1172802] scan, a new scan should be obtained.  
Has been changed to (bolded text added):  
[ADDRESS_1172803] fulfills diagnostic criteria for epi[INVESTIGATOR_843740] -onset ( IA1, IB, and 
IC) seizures for at least 3 years at the time of enrolment (according to the 
ILAE  Classification  of Epi[INVESTIGATOR_843714],  1981):  
 Epi[INVESTIGATOR_843795] -EEG recordings or ictal -EEG 
(+/- simultaneous video)  in the past (description or report is available). The Investigator 
must consult with the UCB Study Physician or representative for confirmation of 
eligibility as per instructions in t he Study  Manual.  
 If no video -EEG report is available and, in the opi[INVESTIGATOR_689], epi[INVESTIGATOR_843742] (ie,  eye-witnessed seizure report, home video documentation of 
habitual events, or other proof ), the Investigator must  consult wit h the UCB Study 
Physician or representative for a case review  
 A brain magnetic resonance imaging (MRI) to be performed before randomization, if no 
such scan was performed in the last [ADDRESS_1172804] 3 years before randomization will suffice.  
Change # 16  
Section 6.2: Exclusion  criterion 1 (bolded text deleted)  
1. Subject has previously participated  in this study or subject has previously been assigned 
to treatment in  a study of the medication under investigation in this study  
Has been changed to (bolded text added):  
1. Subject has previously been randomized  in this study or a study of the medication under 
investigation in this study. Re-screening of a subject may be permitted but requires prior 
medical monitor approval, and is not permitted in case of screen failure due to seizure 
count.  
Change # 17  
Section 6.3.2: Echocardiogram valvular abnormalities assessments, Paragraph immediately 
below Table 6 -1. (bolded text deleted)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172805] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 142 of 152 Echocardiograms will be obtained every 3 months and will be repeated sooner if new or 
worsening abn ormalities are present (detailed below). Echocardiograms will be interpreted  at 
the site by [CONTACT_843869]. When local reads warrant, cen tral reads 
will be expedited. An expedited review of an echocardiogram should be performed if the 
following conditions are met: (1) a Grade  2 of moderate severity, accompanied by [CONTACT_843870]/symptoms; (2) a Grade 3 finding of severe severity ( with or without accompanying 
symptoms; or (3) an increase (or jump) in 2 grades (0 to 2 or 1 to 3) between echocardiograms. 
When any of these findings are observed, the Investigator/site should initiate an expedited review 
from the central reader.  
Has been  changed to (bolded text added):  
Echocardiograms will be obtained every 3 months and will be repeated sooner if new or 
worsening abnormalities are present (detailed below). Echocardiograms will be examined  at the 
site by [CONTACT_843871] a cardiologist . When local reads 
warrant, central reads will be expedited. An expedited review of an echocardiogram should be 
performed if the following cond itions are met: (1) a Grade  2 finding  of moderate severity, 
accompanied by [CONTACT_843814]/symptoms; (2) a Grade 3 finding of severe severity 
(with or without accompanying symptoms; or (3) an increase (or jump) in 2 grades (0 to 2 or 1 to 
3) betwe en echocardiograms. When any of these findings are observed, the Investigator/site 
should initiate an expedited review from the central reader.  
Change # 18  
Section 7.2.1: Titration Period, Table 7 -1 (bolded text deleted)  
Table 7 -1:  Titration Period dosing  
Dose Arm  Dose in mg per intake (morning -evening) during titration  
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
Day/Week  Day 1 Week  1 Week  2 
PSL 800mg/day  
50-50 100-100 150-150 200-200 300-300 
PSL 400mg/day  200-200 
PSL 200mg/day  100-100 
PSL 100mg/day  50-50 
Placebo  1-1 
PSL=padsevonil  
On Day 22, the target dose will be administered.  
Has been changed to (bolded text added, footnote added):  
Table 7 -1:  Titration Period dosing  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172806] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 143 of 152 Dose Arm  Dose in mg per intake (morning -evening) during  titration  
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
Week  Week  1 Week  2 Week  3 
PSL 800mg/day  
50-50 100-100 150-150 200-200 300-300a 
PSL 400mg/day  200-200 
PSL 200mg/day  100-100 
PSL 100mg/day  50-50 
Placebo  1-1 
PSL=padsevonil  
a On Day 22, the target dose will be administered.  
Change # 19  
Section 9.2: Seizure Severity Global Item, Paragraph 2 (bolded text deleted)  
The SSG will be completed according to the tabular schedule of study procedures,  Table [ADDRESS_1172807] will be 
asked to  complete the questionnaire on his/her own. Once completed, the subject will return the 
completed questionnaire to the Investigator or designee, who  will verify that all questions have 
been answered. Further details about the SSG  will be covered in the Study Manual.  
Has been changed to (bolded text added):  
The SSG will be completed according to the tabular schedule of study procedures, Table [ADDRESS_1172808] complete the questionnaire on his/her own ; however, assistance may be provided by 
[CONTACT_843826].  Once completed, the subject will return the 
completed questionnaire to the Investigator or designee, who will verify that all questions have 
been answered. Further details about the SSG will be covered in the Study Manual.  
Change # 20  
Section 9.3: Quality of Life Inventory in  Epi[INVESTIGATOR_002] -31-P, Paragraph 4 (bolded text deleted)  
The QOLIE -31-P will be completed according to the tabular schedule of study procedures  in 
Table  5-1. At the very beginning of the visit, the QOLIE -31-P will be provided to all subjects. 
The subject will be asked to complete the questionnaire on his/her own in a quiet place . Once 
completed, the subject will return the completed questionnaire to the Investigator or designee, 
who will verify that all questions have been answered. Further details about the QOLIE -31-P 
will be covered in the Study Manual.  
Has been changed to (bolded text added):  
The QOLIE -31-P will be completed according to the tabular schedule of study procedures in  
Table [ADDRESS_1172809] will be asked to complete the questionnaire on his/her own; 
however, assistance may be provided by [CONTACT_843827] . Once 
completed, the subject will return the completed questionnaire to the Investigator or designee, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172810] been answered. Further details about the QOLIE -31-P 
will be covered in the Study Manual.  
Change # 21  
Section 9.4: Hospi[INVESTIGATOR_580657] -established psychometric properties both in general 
population and more recently in patients with epi[INVESTIGATOR_002]  (Lin and Pakpour, 2017 ; 
Wiglusz  et al, 2016 ; de Oliviera  et al, 2014 ). The HA DS scores for anxiety and for depression 
range from 0 -21 with higher scores indicating worse state. A score below 8 is considered to be 
normal ( Zigmond  and Snaith,  1983 ). 
Has been changed to (bolded text added):  
The HADS was chosen for its well -established  psychometric properties both in general 
population and more recently in patients with epi[INVESTIGATOR_002] (Lin and Pakpour, 2017; 
Wiglusz  et al, 2016; de  Oliviera  et al, 2014). The HADS scores for anxiety and for depression 
range from 0 -21 with higher scores indicat ing worse state. A score below 8 is considered to be 
normal (Zigmond  and Snaith,  1983). It is preferred that the subject complete the 
questionnaire on his/her own; however, assistance may be provided by [CONTACT_843872].  
Change  #22  
Section 11.2: Laboratory measurements, Table 11 -2 
Has been changed to (a footnote b applicable to measurement of FSH has 
been added):  
b Only applicable to postmenopausal women  
Change # 23  
Section 11.3.3: Echocardiograms , second paragraph below numbered list (bolded text 
deleted)  
Echocardiograms should be acquired by a qualified technician . The echocardiograms will be 
interpreted locally by a qualified cardiologist  who should also determine the clinical 
significance of any a bnormality . Echocardiograms will also be sent to a central reader for 
review as detailed in the Echocardiogram Manual.  
Has been changed to (bolded text added):  
Echocardiograms should be acquired by a qualified technician . The echocardiograms will be 
examin ed by [CONTACT_843873] . Echocardiograms will also be sent to a central cardiologist  
for review as detailed in the Echocardiogram Manual.  
Change # 24  
Section 11.3.3: Echocardiograms, fourth  paragraph below numbered list  
Subjects with an echocardiogram showing an abnormality meeting the withdrawal criteria (see  
Section  6.3) are to be discontinued from the study. An expedited review of an echocardiogram 
(at the central reader) should be requested if the following conditions are met: (1) a Grade  [ADDRESS_1172811] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 145 of 152 moder ate severity, accompanied by [CONTACT_843814]/symptoms; (2) a Grade  3 finding of 
severe severity (with or without accompanying symptoms); or (3) an increase (or jump) in 
2 grades (0  to 2 or 1 to 3) between echocardiograms. When any of these conditi ons are met, the 
Investigator/site should initiate an expedited review from the central reader (see 
Echocardiography Manual). Regulatory authorities will be notified of any discontinuations.  
Has been changed to (bolded text added):  
Subjects with an echocar diogram showing an abnormality meeting the withdrawal criteria (see  
Section  6.3) are to be discontinued from the study. An expedited review of an echocardiogram 
(at the central reader) should be requested if the following conditions are met: (1) a Grade  2 
finding  of moderate severity, accompanied by [CONTACT_843814]/symptoms; (2) a Grade  3 
finding of severe severity (with or without accompanying symptoms); or (3) an increase (or 
jump) in 2  grades (0  to 2 or 1 to 3) between echocardiograms. When any of these conditions are 
met, the Investigator/site should initiate an expedited review from the central reader (see 
Echocardiography Manual). Regulatory authorities will be notified of any discontinuations.  
Change # 25  
Section 13.1.4: Full Analysis Set (bo lded text deleted)  
The Full Analysis Set (FAS) consists of all subjects in the RS who were administered at least 
[ADDRESS_1172812] -Baseline visit during the Treatment 
Period. In case of dosing administration error, or change in treatment dose, summaries and 
analyses using the FAS will be conducted according to randomized treatment. The FAS will be 
the primary analysis set for all efficacy summaries  and analyses.  
Has been changed to (bolded text added):  
The Full Analysis Set (FAS) consists of all subjects in the RS who were administered at least 
[ADDRESS_1172813] -Baseline seizure 
frequency data  during the Treatment Period. In case of dosing administration error, or change in 
treatment dose, summaries and analyses using the FAS will be conducted according to 
randomized treatment. The FAS will be the primary analysis set for all efficacy summaries and 
analyses.  
Change # 26  
Section [IP_ADDRESS]: Analysis of the primary efficacy variable for the US FDA, PMDA, and 
other regulatory authorities not specified in Section 4.1.12 (bolded text deleted)  
Prior to the primary analysis, the dose -response relationship for  change from Baseline in 
observable focal -onset seizure frequency across 4 doses of PSL and placebo will be 
evaluated using the MCP -Mod methodology. Monotonic dose -response trends will be tested 
using the appropriate contrasts as determined by [CONTACT_271416] -Mod methodology such that the 
overall Type 1 error rate is controlled at 0.05 (2sided testing). Four different dose -response 
models (“candidate models”) were identified: sigmoidal E max, Emax, log-linear, and logistic, 
and the MCP -Mod methodology controls for m ultiplicity.  
The SAP will describe additional features and detail around the MCP -Mod methodology as 
well as handling of missing data.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172814] 1 statistically significant result is obtained from the primary MCP -Mod 
analysis, then  pairwise comparis ons of 400mg, 200mg and 100mg dose groups versus placebo 
will be carried out using the analysis model below. Type 1 error will be controlled by [CONTACT_843874] -up procedure within SAS® Proc Multtest. If all the results of the pairwise 
comparisons are sta tistically significant then the 50mg dose group will be compared to placebo.  
For the US FDA, PMDA, and other regulatory authorities not specified in Section  [IP_ADDRESS], the 
primary efficacy variable is the change in log -transformed observable focal -onset seiz ure 
frequency from Baseline, over the [ADDRESS_1172815]-Baseline (maintenance) seizure frequency will be transformed with the natural logarithm, 
specifically ln(x+1), where x represents the 28 -day seizure frequency. T he transformed seizure 
frequency data will be analyzed using analysis of covariance (ANCOVA) with treatment group 
as the main factor, Baseline log -adjusted seizure frequency as a continuous covariate, and 
Baseline SV2A use and Region as categorical factors . Pairwise contrasts will be constructed to 
compute estimated effects of each dose from placebo.  
All pairwise analyses of the primary efficacy variable will be repeated on the PPS.  
A sensitivity analysis of the primary efficacy continuous variable will be carried out using a 
Mixed Model Repeated Measures analysis. Full details will be provided in the SAP.  
Has been changed to:  
Pairwise comparisons of 400mg, 200mg and 100mg dose groups versus placebo will be carried 
out using the analysis model below. Type 1 error will be controlled by [CONTACT_843842] -up 
procedure within SAS® Proc Multtest. If all the results of the pairwise comparisons are 
statistically significant then the 50mg dose group will be compared to placebo.  
For the US FDA, PMDA, and other regulat ory authorities not specified in Section  [IP_ADDRESS], the 
primary efficacy variable is the change in log -transformed observable focal -onset seizure 
frequency from Baseline, over the [ADDRESS_1172816]-Baseline (maintenance ) seizure frequency will be transformed with the natural logarithm, 
specifically ln(x+1), where x represents the 28 -day seizure frequency. The transformed seizure 
frequency data will be analyzed using analysis of covariance (ANCOVA) with treatment group 
as the main factor, Baseline log -adjusted seizure frequency as a continuous covariate, and 
Baseline SV2A use and Region as categorical factors. Pairwise contrasts will be constructed to 
compute estimated effects of each dose from placebo.  
All pairwise analys es of the primary efficacy variable will be repeated on the PPS.  
Change # 27  
Section [IP_ADDRESS]: Analysis of the primary efficacy variable for EMA and regulatory 
authorities who reference EMA (bolded text deleted)  
For EMA and regulatory authorities who refer ence EMA, the primary efficacy variable will be 
the 75% responder rate status  and will be analyzed using logistic regression with factors for 
treatment group, Baseline seizure frequency, Region, and Baseline SV2A use. If there are issues 
with convergence, Baseline SV2A use will be dropped. The responder rates are defined as a 
≥75% reduction in the observable focal -onset seizure frequency from Baseline over the 
12-week Maintenance Period.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172817] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 147 of 152 The same methodology carried out in Section  [IP_ADDRESS] will be applied t o MCP -Mod and the 
pairwise analyses.  
Has been changed to (bolded text added):  
For EMA and regulatory authorities who reference EMA, the primary efficacy variable will be 
the 75% responder rate in observable focal -onset seizures during the Maintenance Perio d and 
will be analyzed using logistic regression with factors for treatment group, Baseline seizure 
frequency, Region, and Baseline SV2A use. If there are issues with convergence, Baseline SV2A 
use will be dropped.  
The same methodology carried out in Sect ion [IP_ADDRESS] will be applied to the pairwise analyses.  
Change # 28  
Section [IP_ADDRESS]: Secondary efficacy variables for the US FDA, PMDA, and other 
regulatory authorities not specified in Section [IP_ADDRESS] (bolded text deleted)  
The 75% responder rate status an d 50% responder rate will be analyzed using logistic 
regression with factors for treatment group, Baseline seizure frequency, Region, and 
Baseline SV2A use. If there are issues with convergence, Baseline SV2A use will be 
dropped. The responder rates are de fined as follows:  
 75% responder rate status: a ≥75% reduction in the observable focal -onset seizure 
frequency from Baseline over the 12 -week Maintenance Period  
 50% Responder rate status: a ≥50% reduction in observable focal -onset seizure 
frequency from Ba seline over the [ADDRESS_1172818]. The Hodges -Lehmann nonparametric estimator will be used to 
estimate the median percent reductio n in seizures between groups and its corresponding 
95% confidence interval (CI) will be provided.  
Has been changed to (bolded text added):  
The 75% responder rate in observable focal -onset seizures during the Maintenance Period 
is a secondary efficacy variable for the FDA. It is the primary efficacy variable for EMA. 
The analyses are described in Section  [IP_ADDRESS].  
In addition, the 50% responder rate in observable focal -onset seizures during the 
Maintenance Period will be analyzed using logistic regression as described in 
Section  [IP_ADDRESS].  Analyses of the percent change in seizure reduction endpoints will be 
performed using the Wilcoxon -Mann -Whitney test. The Hodges -Lehmann nonparametric 
estimator will be used to estimate the median percent reduction in seizures between groups and 
its corresponding 95%  confidence interval (CI) will be provided.  
Change # 29  
Section [IP_ADDRESS]: Secondary effi cacy variables for EMA and regulatory authorities who 
reference EMA (bolded text deleted)  
The change in log -transformed observable focal -onset seizure frequency from Baseline, over the 
12-week Maintenance Period will be analyzed in the same way as for the primary analysis 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172819] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 148 of 152 used for the FDA ie, pairwise comparisons of 400mg, 200mg and 100 mg dose groups 
versus placebo will be carried out using the analysis model described in Section  [IP_ADDRESS]. 
Type 1 error will be controlled by [CONTACT_843842] -up procedure w ithin SAS® Proc 
Multtest. If the results of all pairwise comparisons are statistically significant, then the 
50mg dose group will be compared to placebo.  
In addition, the 50% responder rate will be analyzed using logistic regression with factors for 
treatm ent group, Baseline seizure frequency, Region, and Baseline SV2A use. If there are 
issues with convergence, Baseline SV2A use will be dropped. The responder rates are 
defined as follows:  
 50% Responder rate status: a ≥50% reduction in observable focal -onset  seizure 
frequency from Baseline over the [ADDRESS_1172820]. The Hodges -Lehmann nonparametric estimator will be used to 
estimate t he median percent reduction in seizures between groups and its corresponding 95%   CI 
will be provided.  
Has been changed to (bolded text added):  
The change in log -transformed observable focal -onset seizure frequency from Baseline, over the 
12-week Maintenan ce Period is a secondary efficacy variable for EMA. It is the primary 
efficacy variable for the FDA. The analyses are described in Section  [IP_ADDRESS].   
In addition, the 50% responder rate in observable focal -onset seizures during the 
Maintenance Period  will be analyzed using logistic regression as described in 
Section  [IP_ADDRESS].   
Analyses of the percent change in seizure reduction endpoints will be performed using the 
Wilcoxon -Mann -Whitney test. The Hodges -Lehmann nonparametric estimator will be used to 
estima te the median percent reduction in seizures between groups and its corresponding 95%  CI 
will be provided.  
Change # 30  
Section 13.3.3: Other efficacy analyses (bolded text deleted)  
All other analyses of the 75% and 50% responder rate and seizure freedom  endpoints will be 
analyzed using the same logistic regression model as specified for the secondary efficacy 
analysis for the 75% responder rate . Analyses of 90% responder rate and seizure freedom will 
use the same methodology. In addition to observable focal -onset seizures and focal -onset 
seizures, analyses will also be carried out on all seizures (seizure -free status and seizure -free 
days) during the [ADDRESS_1172821] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 149 of 152 The QOLIE -31-P and SSG assessments will be summarized using descriptive statistics by [CONTACT_843843].  
Has been changed to (bolded text added):  
All other analyses of the 75% and 50% responder rate endpoints will be analyzed using the same 
logistic regression model as specified in Section [IP_ADDRESS].  Analyses of 90% responder rate and 
seizure freedom will use the same methodology . In addition to observable focal -onset seizures 
and focal -onset seizures, analyses will also be carried out on all seizures (seizure -free status and 
seizure -free days) during the 12 -week Maintenance Period and the 16 -week Treatment Period.  
All other analy ses of the change from Baseline in seizure frequency  will be analyzed using the 
ANCOVA model on the log -transformed data, as specified in Section  [IP_ADDRESS].  
The time  to return to baseline 28-day observable focal -onset seizure count during the 12 -week 
Mainte nance Period  will be analyzed using Kaplan -Meier methodology. Additional details of 
the analysis will be captured in the SAP.  
The QOLIE -31-P and SSG assessments will be summarized using descriptive statistics by [CONTACT_843843].  
Change # 31  
Section 1 3.4.2: Pharmacokinetic analyses, Paragraphs 6 and 7 (bolded text deleted)  
An exploratory comparison of PSL blood levels derived from the MITRA sampler  with 
conventional venous sampling will be made.  
An exploratory evaluation of PSL metabolites will be undertaken.  
Has been changed to (bolded text added):  
An exploratory comparison of PSL blood levels derived from the MITRA samples  with 
conventional venous sampling may be made.  An exploratory evaluation of PSL metabolites may 
be undertaken.  
Change # 32  
Section 13.6: Handing of dropouts or missing data (bolded text deleted)  
The methods for handling dropouts will be described in the SAP.  
Has been changed to:  
Seizure frequency will be computed over non -missing diary days. Unless noted otherwise, for 
subjec ts who prematurely discontinued the study, last observation carried forward (LOCF) 
method will be applied to obtain a seizure frequency estimate for the Maintenance Period:  
 Subjects discontinued during the Titration and Stabilization Period: seizure freque ncy will be 
calculated using all available data in the Titration and Stabilization Period and carry forward 
for the Maintenance Period.  
 Subjects discontinued during the Maintenance Period: seizure frequency will be calculated 
using all available data in th e Maintenance Period.  
Additional details and sensitivity analyses for missing data will be described in the SAP.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   [ADDRESS_1172822] 2018  
Clinical Study Protocol  Padsevonil  EP0091  
   
Confidential  Page 150 of 152 Change # 33  
Section 13.8: Determination of sample size (bolded text deleted)  
The sample size is based on achieving 90% power to observe a statistically significant result for 
either the 400mg and 200mg or 200mg and 100mg doses when compared to placebo , a primary 
endpoint of change from Baseline of the log -transformed (ln x +1) [ADDRESS_1172823].  
The log -reduction from Baseline in seizure frequency was assumed to be 0.195 for placebo and 
0.780 for  PSL. A common SD of 0.985 was assumed. These estimates  are based on prior 
experience in epi[INVESTIGATOR_843772]0069 study results.  
With power of 90%, a 2 -sided Type -1 error of 5%, and all dose groups of the same size, 
80 subjects are required per arm, giving a total of 400 subjects.  
Assuming a screening  failure rate of approximately 20%, it is anticipated to enroll around 
500 subjects and randomize 400 subjects in this study.  
The study is also powered t o give over 80% power to observe a statistically significant result for 
either the 400mg and 200mg or 2 00mg and 100mg doses when compared to placebo for the 
75% response rate endpoint, the primary endpoint specified for EMA .  
Has been changed to (bolded text added):  
The sample size was calculated  based on achieving 90% power to observe a statistically 
signi ficant result for either the 400mg bid and 200mg bid or 200mg  bid and 100mg bid doses 
when compared to placebo, for a  change from Baseline of the log -transformed (ln x +1) 28 -day 
adjusted seizure frequency. Multiplicity is controlled for using the Hochberg  step up procedure.  
The log -reduction from Baseline in seizure frequency was assumed to be 0.195 for placebo and 
0.492, 0.670, 0.754, and 0.780 for the 50mg bid, 100mg bid, 200mg bid, and 400mg bid 
doses of  PSL, respectively . A common SD of 0.985 was assum ed. These estimates are based on 
prior experience in epi[INVESTIGATOR_843772]0069 study results.  
With power of 90%, a 2 -sided Type -1 error of 5%, and all dose groups of the same size, 
80 subjects are required per arm, giving a total of 400 subjects.  
Assuming a screening failure rate of approximately 20%, it is anticipated to enroll around 
500 subjects and randomize 400 subjects in this study.  
The study is also powered to give over 80% power to observe a statistically significant result for 
the 75% resp onse rate. For the 75% responder rate, assumptions were a 0.[ADDRESS_1172824].  
Investigator:  
 
   
Printe d name   [CONTACT_1782]/Signature  
 
[CONTACT_207346]. 
UCB   [ADDRESS_1172825] this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
Approval Signatures
Name: [CONTACT_261559]0091-protocol-amend-2
Version: 1 . 0
Document Number: CLIN-000125670
Title: EP0091 Protocol Amendment 2
Approved Date: [ADDRESS_1172826]: ApprovedName: 
[CONTACT_18469]: Clinical
Date of Signature: 12-Oct-2018 18:48:23 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Clinical
Date of Signature: 14-Oct-2018 20:04:02 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Clinical
Date of Signature: 15-Oct-2018 07:14:41 GMT[PHONE_006]
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
